2024-03-29T00:39:45Z
http://www.ijcto.org/index.php/IJCTO/oai
oai:ojs.ijcto.org:article/7
2013-11-03T16:25:16Z
IJCTO:ORIGINAL
cam 3u
"130918 2013 eng "
dc
Dose prediction accuracy of collapsed cone convolution superposition algorithm in a multi-layer inhomogenous phantom
Oyewale, Stephen; Cancer Centers of Southwest Oklahoma
Medical Physics; Radiation Oncology
Collapsed Cone Convolution Superposition, Heterogeneity Correction, PDD, Pinnacle
<p><strong>Purpose: </strong>Dose prediction accuracy of dose calculation algorithms is important in external beam radiation therapy.<strong> </strong>This study investigated the effect of air gaps on depth dose calculations computed by collapsed cone convolution superposition (CCCS) algorithm. <strong></strong></p><p><strong>Methods</strong>: A computed tomography (CT) scan of inhomogenous phantom (30 × 30 × 30 cm<sup>3</sup>) containing rectangular solid-water blocks and two 5 cm air gaps was used for central axis dose calculations computed by CCCS in Pinnacle treatment planning system. Depth dose measurements were taken using a cylindrical ionization chamber for identical beam parameters and monitor units as in the depth dose computations. The calculated and the measured percent depth dose (PDDs) were then compared. The data presented in this study included 6 MV photon beam and field sizes of 3 × 3 cm<sup>2</sup>, 5 × 5 cm<sup>2</sup>, 10 × 10 cm<sup>2</sup>, and 15 × 15 cm<sup>2</sup>.</p><p><strong>Results: </strong>The results of CCCS were within ±1.4% in the first water medium. However, upon traversing the first air gap and re-entering the water medium, in comparison to the measurements, the CCCS under-predicted the dose, with difference ranged from -1.6% to -3.3% for 3 × 3 cm<sup>2</sup>, from -2.4% to -4.2% for 5 × 5 cm<sup>2</sup>, from -2.4% to -6.7% for 10 × 10 cm<sup>2</sup>, and from -1.6% to -6.3% for 15 × 15 cm<sup>2</sup>. After the second air gap, the CCCS continued to under-predict the dose, and the difference ranged from -3.2% to -3.9% for 3× 3cm<sup>2</sup>, from -2.4% to -5.6% for 5 × 5 cm<sup>2</sup>, from -2.3% to -6.0% for 10 × 10 cm<sup>2</sup>, and from -1.5% to -5.6% for 15 × 15 cm<sup>2</sup>. <strong></strong></p><p><strong>Conclusion</strong>: The CCCS under-predicted the dose in water medium after the photon beam traversed the air gap. Special attention must be given during the patient set-up since large air gap between the patient body and immobilization devices may lead to unacceptable dose prediction errors.</p><p>----------------------------------------------</p><p><strong>Cite this article as:</strong><br />Oyewale S. Dose prediction accuracy of collapsed cone convolution superposition algorithm in a multi-layer inhomogenous phantom. <em>Int J Cancer Ther Oncol</em> 2013; <strong>1</strong>(1):01016.<br /><br /></p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0101.6" target="_blank">http://dx.doi.org/10.14319/ijcto.0101.6</a></p>
International Journal of Cancer Therapy and Oncology
2013-10-10 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Oyewale
International Journal of Cancer Therapy and Oncology; Vol 1, No 1 (2013): September - October
en
http://www.ijcto.org/index.php/IJCTO/article/download/7/21
http://www.ijcto.org/index.php/IJCTO/article/download/7/22
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/39
2014-04-12T11:23:47Z
IJCTO:CONF
cam 3u
"131221 2013 eng "
dc
Water-light interaction: A novel pathway for multi hallmark therapy in cancer
Santana-Blank, Luis; Fundalas’ Cancer, Immunology and Neuroscience Programs, Venezuela.
Rodriguez-Santana, Elizabeth; Foundation for Interdisciplinary Research and Development Fundalas, Caracas 1020, Venezuela.
Reyes, Heberto; Clinica Avila, Radiology Department, Urbanizacion Altamira Caracas 1060, Venezuela.
J.M. Vargas Hospital, Radiology Department, Parroquia San Jose, Caracas 1010, Venezuela.
Santana-Rodriguez, Jesus; Foundation for Interdisciplinary Research and Development Fundalas, Caracas 1020, Venezuela.
Santana-Rodriguez, Karin; Foundation for Interdisciplinary Research and Development Fundalas, Caracas 1020, Venezuela.
Photobiomodulation
Laser photobiomodulation; Fourth phase of water; Cancer, Light-water interaction
<p class="Default">Laser photobiomodulation (LPBM) has been proposed as a multi-target (multi-hallmark) therapy for cancer and other complex diseases based on an approach that aims to substitute and/or complement metabolic energy pathways through oxygen-dependent (e.g., cytochrome c oxidase (CcO)) and/or oxygen-independent (e.g., light-water interactions (e.g., F0-F1 motors)) mechanisms with critical signaling pathways in primarily aqueous media. Cellular and molecular bases for water-mediated, long-range, energy supplementation aimed at inducing and modulating physiologically reparative processes, including apoptosis, have been previously presented through a mechanism termed Photo Infrared Pulsed Biomodulation (PIPBM). Water’s role as an oscillator in LPBM has also been documented. These ideas were recently complemented by integrating the role of the quasi-crystalline exclusion zone (EZ) described by Pollack as the fourth phase of water. This is retrospective analysis of experimental and clinical data using an infrared pulsed laser device (IPLD). It found photo-induced effects over the water dynamics of burned rat tissue monitored by <sup>1</sup>H-NMR transverse relaxation times (1/T2), indicating significantly greater structuring of water. In addition, a microdensitometry study of T2 weighted tumor heterogeneities from a phase I clinical trial of the IPLD in patients with advanced neoplasias and an algorithm for tumor characterization indicated significantly increased structuring of water, possibly proving a photobiomodulation effect over the EZ associated with histologically-confirmed selective photo-induced tumor cell death. To the best of our knowledge, this is the first clinical demonstration of light-induced effects over the EZ. It supports our premise that LPBM can increase potential energy in the EZ, which then acts as a rechargeable electrolytic bio-battery for the external selective supplementation of the energy demand required for cellular work, signaling pathways and gene expression in the presence of injury-induced redox potentials. It further suggests that EZ structuring may be used as a predicator of anticancer response before measurable tumor volume reduction.</p><p class="Default">------------------------------------------------</p><p class="Default"><strong>Cite this article as</strong>: Santana-Blank L, Rodriguez-Santana E, Reyes H, Santana- Rodriguez J, Santana- Rodriguez K. Water-light interaction: A novel pathway for multi hallmark therapy in cancer. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):02012.</p><p class="Default"><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.2" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.2</a></p>
International Journal of Cancer Therapy and Oncology
2014-02-23 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Santana-Blank1
International Journal of Cancer Therapy and Oncology; Vol 2, No 1 (2014): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/49
2014-05-14T17:01:18Z
IJCTO:CASE
cam 3u
"140325 2014 eng "
dc
Multiple adenomatoid tumours in the Epididymis and Tunica vaginalis: Case report
Abroaf, Ahmed; Urology Department, Freeman Hospital
Newcastle Upon Tyne
Veeratterapillay, Rajan; Urology Department, Freeman Hospital
Newcastle Upon Tyne
Vasdev, Nikhil; Urology Department, Freeman Hospital
Newcastle Upon Tyne
Majo, Joaquim; Department of Pathology, Royal Victoria Infirmary, Newcastle Upon Tyne
El-Sherif, Amira; Department of Pathology, Royal Victoria Infirmary, Newcastle Upon Tyne
Paez, Edgar; Urology Department, Freeman Hospital
Newcastle Upon Tyne
Medical Oncology
Tumour; Adenomatoid: Tunica; Epididymis
<p>We describe the case of a 65 year-old male presenting with a tender right testicular mass, confirmed to be a tumour on ultrasound. The patient underwent a radical inguinal orchidectomy and histology revealed multiple adenomatoid tumours in epididymis and tunica vaginalis. This is an infrequent benign tumour of mesothelial origin that has rarely been reported as multiple lesions in the literature. Immunohistochemistry demonstrates that adenomatoid tumour and mesotheliomas share the expression of podoplanin (D2-40) which is helpful to differentiate them from carcinomas. On the other hand adenomatoid tumour is differentiated from mesothelioma on morphological grounds since the former does not exhibit cellular atypia, mitotic activity or bland focal tumour necrosis. Although testis preserving surgery can be an option for benign adenomatoid tumours, most patients (as in our case) proceed to orchidectomy as diagnosing them confidently can be difficult.</p><p>---------------------------</p><p><strong>Cite this article as:</strong> Abroaf A, Veeratterapillay R, Vasdev N, Majo J, Sherif AE, Paez E. Multiple adenomatoid tumours in the Epididymis and Tunica vaginalis : Case Report. Int J Cancer Ther Oncol 2014; <strong>2</strong>(1):02021.</p><p><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0202.1" target="_blank">http://dx.doi.org/10.14319/ijcto.0202.1</a></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Abroaf
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/49/414
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/109
2014-05-14T17:01:17Z
IJCTO:CONF
cam 3u
"140409 2014 eng "
dc
Mathematical analysis of approximate biological effective dose (BED) calculation for multi-phase radiotherapy treatment plans
Kauweloa, Kevin I; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Cancer Therapy and Research Center, San Antonio, TX, USA.
Gutierrez, Alonso N; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Cancer Therapy and Research Center, San Antonio, TX, USA.
Bergamo, Angelo; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Cancer Therapy and Research Center, San Antonio, TX, USA.
Stathakis, Sotirios; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Cancer Therapy and Research Center, San Antonio, TX, USA.
Papanikolaou, Niko; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Cancer Therapy and Research Center, San Antonio, TX, USA.
Mavroidis, Panayiotis; Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Cancer Therapy and Research Center, San Antonio, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>There is growing interest about biological effective dose (BED) and its application in treatment plan evaluation due to its stronger correlation with treatment outcome. An approximate biological effective dose (BED<sub>A</sub>) equation was introduced in order to simplify BED calculations by treatment planning systems in multi-phase treatments. The purpose of this work is to reveal its mathematical properties relative to the true, multi-phase BED (BED<sub>T</sub>) equation.</p><p><strong>Methods</strong>: The BED<sub>T</sub> equation was derived and used to reveal the mathematical properties of BED<sub>A</sub>. MATLAB (MathWorks, Natick, MA) was used to simulate and analyze common and extreme clinical multi-phase cases. In those cases, percent error and Bland-Altman analysis were used to study the significance of the inaccuracies of BED<sub>A</sub> for different combinations of total doses, numbers of fractions, doses per fractions and α/β values. All the calculations were performed on a voxel-basis in order to study how dose distributions would affect the accuracy of BED<sub>A</sub>.</p><p><strong>Results: </strong>When the voxel dose-per-fractions (DPF) delivered by both phases are equal, BED<sub>A</sub> and BED<sub>T</sub> are equal (0% error). In heterogeneous dose distributions, which significantly vary between the phases, there are fewer occurrences of equal DPFs and hence the imprecision of BED<sub>A</sub> is greater. It was shown that as the α/β ratio increased the accuracy of BED<sub>A</sub> would improve. Examining twenty-four cases, it was shown that the range of DPF ratios for 3% P<sub>error</sub> varied from 0.32 to 7.50Gy, whereas for P<sub>error</sub> of 1% the range varied from 0.50 to 2.96Gy.</p><p><strong>Conclusion</strong>: The DPF between the different phases should be equal in order to render BED<sub>A</sub> accurate. OARs typically receive heterogeneous dose distributions hence the probability of equal DPFs is low. Consequently, the BED<sub>A</sub> equation should only be used for targets or OARs that receive uniform or very similar dose distributions by the different treatment phases.</p><p><strong>---------------------------</strong></p><p><strong>Cite this article as</strong>: Kauweloa KI, Gutierrez AN, Bergamo A, Stathakis S, Papaniko-laou N, Mavroidis P. Mathematical analysis of approximate biological effective dose (BED) calculation for multi-phase radiotherapy treatment plans. Int J Cancer Ther Oncol 2014; 2(2):020226. <strong>DOI: 10.14319/ijcto.0202.26</strong></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Kauweloa
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/126
2014-05-14T17:01:18Z
IJCTO:CONF
cam 3u
"140409 2014 eng "
dc
SPECT deadtime count loss correction using monitor source method
Siman, Wendy; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Kappadath, Cheenu S; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>Deadtime-count-loss (DTloss) correction using monitor source (MS) requires: 1) uniform fractional DTloss across FOV, 2) high statistics MS images both with & without the object. The aims are validating condition 1 and developing a practical protocol that satisfies conditions 2 with minimal additional study duration.</p><p><strong>Methods and Materials</strong>: SPECT images of non-uniform phantoms (4GBq 99mTc) along with MS (20MBq 99mTc) attached to each detector were acquired multiple times over 48 hours in photopeak and scatter energy window (EW) using Siemens-SymbiaS and GE-D670. Planar images of the MS alone were acquired. Photopeak counts for the MS ROIs were > 100kcts. Fractional DTloss uniformity across the FOV was evaluated by correlating count rates in different ROIs on projection images at different DTloss levels. The correction factor for each SPECT projection at every time point was calculated as the ratio of time-corrected MS count rates with & without the phantom.</p><p>The DTloss-corrected projections for each SPECT acquisition were decay corrected to one time point. The correction accuracy was assessed against DTloss estimated by paralyzable model. The accuracy of projection-based DTloss correction for SPECT was evaluated. A method to model projection DTloss based on a subset of measured projection DTloss was investigated. The relation of DTloss between photopeak and scatter EW was explored.</p><p><strong>Results: </strong>The fractional DTloss was uniform across the FOV (r > 0.99), validating condition 1. The MS method was accurate to > 99% for planar and SPECT. Measured DTloss from 3-to-5 projections/detector may be used to estimate DTloss with accuracy > 98% for all SPECT projections by modeling DTloss with measured projection rate. The correction factor in photopeak and scatter EW are equivalent with > 99% agreement.</p><p><strong>Conclusion</strong>: MS method can accurately correct planar and SPECT DTloss. Sparse sampling of the projection DTloss allows acquiring MS counts with high statistics with minimal additional study duration making it clinically practical.</p><p><strong>--------------------------------------</strong></p><p><strong>Cite this article as:</strong> Siman W, Kappadath SC. SPECT deadtime count loss correction using monitor source method. Int J Cancer Ther Oncol 2014; 2(2):020234. <strong>DOI: 10.14319/ijcto.0202.34</strong><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Siman
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/95
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
cam 3u
"140518 2014 eng "
dc
Geometrical determinations of IMRT photon pencil-beam path in radiotherapy wedges and limit divergence angle with the Anisotropic Analytic Algorithm (AAA)
Casesnoves, Francisco; Society for Industrial and Applied Mathematics (SIAM) (Individual Researcher), Denver, Colorado, USA.
Medical Physics
Radiotherapy; Intensity Modulated Radiation Therapy; Static Alloy Wedges; Analytic Geometry; Treatment Planning Optimization (TPO); Analytic Anisotropic Algorithm (AAA); Superposition-Convolution Models (SCM)
<p><strong>Purpose:</strong> Static wedge filters (WF) are commonly used in radiation therapy, forward and/or inverse planning. We calculated the exact 2D/3D geometrical pathway of the photon-beam through the usual alloy WF, in order to get a better dose related to the beam intensity attenuation factor(s), after the beam has passed through the WF. The objective was to provide general formulation into the Anisotropic Analytical Algorithm (AAA) model coordinates system (depending on collimator/wedge angles) that also can be applied to other models. Additionally, second purpose of this study was to develop integral formulation for 3D wedge exponential factor with statistical approximations, with introduction for the limit angle/conformal wedge.</p><p><strong>Methods</strong>: The radiotherapy model used to develop this mathematical task is the classical superposition-convolution algorithm, AAA (developed by Ulmer and Harder). We worked with optimal geometrical approximations to make the computational IMRT calculations quicker/reduce the planning-system time. Analytic geometry/computational-techniques to carry out simulations (for standard wedges) are detailed/developed sharply. Integral developments/integral-statistical approximations are explained. Beam-divergence limit Angle for optimal wedge filtration formulas is calculated/sketched, with geometrical approximations. Fundamental trigonometry is used for this purpose.</p><p><strong>Results: </strong>Extent simulation tables for WF of 15º, 30º, 45º, and 60º are shown with errors. As a result, it is possible to determine the best individual treatment dose distribution for each patient. We presented these basic simulations/numerical examples for standard manufacturing WF of straight sloping surface, to check the accuracy/errors of the calculations. Simulations results give low RMS/Relative Error values (formulated) for WF of 15º, 30º, 45º, and 60º.</p><p><strong>Conclusion</strong>: We obtained a series of formulas of analytic geometry for WF that can be applied for any particular dose delivery model. Simulations results gave acceptable trigonometrical approximations/data that can be used for LINAC applications/planning-system software. The integral formulas presented are practical for dose delivery calculations/3D-approximations when using WF/other similar types of beam modification devices. Limit angle formulation and conformal wedge concept was also presented.</p><p>..................................................</p><p><strong>Cite this article as:</strong> Casesnoves F. Geometrical determinations of IMRT photon pencil-beam path in radiotherapy wedges and limit divergence angle with the Anisotropic Analytic Algorithm (AAA). <em>Int J Cancer Ther Oncol </em>2014; <strong>2</strong>(3):02031. <strong>DOI:</strong><a href="http://dx.doi.org/10.14319/ijcto.0203.1" target="_blank"><strong>10.14319/ijcto.0203.1</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Casesnoves
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/132
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
cam 3u
"140823 2014 eng "
dc
Evaluation of the peripheral dose and the conformity index for three stereotactic radiotherapy techniques: Arcs, noncoplanar fixed fields and intensity modulation
Ammar, Hany; Department of Radiotherapy, Children's Cancer Hospital Egypt.
Eldebawy, Eman; Department of Radiotherapy, Children's Cancer Hospital Egypt.
Maarouf, Ehab; Department of Radiotherapy and Nuclear Medicine, National Cancer Institute, Cairo University.
Khalil, Wafaa; Department of Biophysics, Faculty of Science, Cairo University.
Zaghloul, MS; Department of Radiotherapy and Nuclear Medicine, National Cancer Institute, Cairo University.
Radiotherapy
Keywords: radiosurgery, conformity index,integral dose,peripheral dose
treatment planning in radiosurgery
<p><strong>Purpose: </strong>The main aim of this work is to compare the conformity index and the peripheral doses absorbed during stereotactic treatment of a brain lesion delivered using three stereotactic techniques; Arcs, noncoplanar fixed conformal fields (3DCRT) and intensity modulation (IMRT).<strong> </strong></p><p><strong>Methods</strong>: Ten patients with brain lesions who were previously treated with Stereotaxy radiosurgery (SRS) using the cones (Arcs technique), were re-planned both non-coplanar 3D Conformal fixed fields (3DCRT) and non-coplanar intensity modulated radiotherapy fixed fields (IMRT) with the same arrangement and orientation of the fields as the Arcs technique. To facilitate direct comparison between the competing techniques, the primary planning object was to cover 95% of the volume of PTV by 95% of the prescribed dose (1200 cGy). <strong></strong></p><p><strong>Results:</strong> The IMRT technique shows the highest dose conformity, Arcs technique is the next homogeneity followed by 3DCRT. The differences were statistically significant among the three different techniques (P < 0.01) for PITV (defined as the ratio of the prescription isodose volume (PI) and Target Volume (TV)) and Conformal Number (CN). The mean integral dose using the 3 different techniques for all studied patients were: 2.44 ± 0.36J, 2.31 ± 0.37J and 2.6 ± 0.37J in the Arcs, IMRT and 3DCRT techniques respectively, the differences were not statistically significant (p = 0.326). The results show that Arcs technique has the lowest volume of the body that received 2 Gy, IMRT is the next followed by 3DCRT and IMRT technique has the lowest volume of the body that received 5 Gy, Arcs technique is the next followed by 3DCRT. The differences were not statistically significant p = 0.126 for V2 and p = 0.118 for V5, but these differences might be clinically significant that need more clinical discussion and investigation. IMRT plan delivery time almost has two folded more than the two others techniques, and the arc the technique has the lowest estimated time compared to both IMRT and Conformal techniques. The differences were statistically significant (P < 0.01). <strong></strong></p><p><strong>Conclusion</strong>: The conformity index, dose homogeneity and the outfield dose are important aspects of plan quality, although they do not always receive clinically attention. Our results have been showed that the superiority of the IMRT in conformity, dose homogeneity and the lowest volume that received 5 Gy, Arcs technique has the superiority in lower treatment delivery time than IMRT and the lowest volume that received 2 Gy. The 3DCRT don't present a significant advantage among the competing techniques. Oncologist should be alert of the possibility of significantly increasing the secondary cancer risk particularly for pediatric patients, because children are more susceptible to the risk of second cancers.</p><p>---------------------------------------</p><p><strong>Cite this article as</strong>: Ammar H, Eldebawy E, Maarouf E, Khalil W, Zaghloul MS. Evaluation of the peripheral dose and the conformity index for three stereotactic radiotherapy techniques: Arcs, noncoplanar fixed fields and intensity modulation.<em> Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(4):02042. <strong>DOI</strong>:<a href="http://dx.doi.org/10.14319/ijcto.0204.2" target="_self"> <strong>10.14319/ijcto.0204.2</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0204.2
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/132/1616
http://www.ijcto.org/index.php/IJCTO/article/download/132/1617
http://www.ijcto.org/index.php/IJCTO/article/download/132/1618
http://www.ijcto.org/index.php/IJCTO/article/download/132/1619
http://www.ijcto.org/index.php/IJCTO/article/download/132/1620
http://www.ijcto.org/index.php/IJCTO/article/download/132/1621
http://www.ijcto.org/index.php/IJCTO/article/download/132/1622
http://www.ijcto.org/index.php/IJCTO/article/download/132/1623
http://www.ijcto.org/index.php/IJCTO/article/download/132/1624
http://www.ijcto.org/index.php/IJCTO/article/download/132/1625
http://www.ijcto.org/index.php/IJCTO/article/download/132/1626
http://www.ijcto.org/index.php/IJCTO/article/download/132/1627
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/231
2015-03-29T09:39:21Z
IJCTO:EDITORIAL
cam 3u
"141030 2014 eng "
dc
High Impact Papers from November – December, 2013
Office, Editorial
High impact papers from a particular <em>Issue</em> are selected based on the quality of the article and the number of citations. High impact papers are typically recognized once the <em>Issue </em>completes the publication time period of 12 months. View in <a href="/index.php/IJCTO/article/download/impact0102/ijcto.0102pdf" target="_blank"><strong>PDF</strong></a><br /><div><p>Following articles are recognized as High Impact Papers from <a href="/index.php/IJCTO/issue/view/9" target="_blank"><strong><span style="text-decoration: underline;">November-December, 2013</span></strong></a>.</p><p><strong>Lu L. Dose calculation algorithms in external beam photon radiation therapy. <em>Int J Cancer Ther Oncol</em> 2013; 1(2):01025.</strong><br /><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0102.5"><strong>10.14319/ijcto.0102.5</strong></a><strong></strong></p><p><a href="/index.php/IJCTO/article/view/Lu/ijcto.0102.5html" target="_blank"><strong>Read</strong></a> <strong><a href="/index.php/IJCTO/article/download/Lu/ijcto.0102.5pdf" target="_blank">Download</a> <a href="http://scholar.google.com/scholar?oi=bibs&hl=en&cites=69568978679751605&as_sdt=5" target="_blank">Citations<br /><br /></a></strong></p><p><strong>Khosa F, Khan A, Shuaib W, Clouse M, Budoff M, Blankstein R, Nasir K. Radiation exposure for coronary artery calcium score at prospective 320 row multi-detector computed tomography. <em>Int J Cancer Ther Oncol </em>2013; 1(2):01023.</strong><strong><br />DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0102.3"><strong>10.14319/ijcto.0102.3</strong></a></p><p><a href="/index.php/IJCTO/article/view/Khosa/ijcto.0102.3html" target="_blank"><strong>Read</strong> </a> <strong><a href="/index.php/IJCTO/article/download/Khosa/ijcto.0102.3pdf" target="_blank">Download </a> <a href="http://scholar.google.com/scholar?oi=bibs&hl=en&cites=3752779046215046769&as_sdt=5" target="_blank">Citations</a></strong></p><p>(High impact papers from <strong><span style="text-decoration: underline;">January-March, 2014</span></strong> will be recognized in the next <em>Issue</em> of the IJCTO)</p></div>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/impact0102
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/151
2015-03-29T11:59:32Z
IJCTO:ORIGINAL
cam 3u
"141223 2014 eng "
dc
Treatment of skin and subcutaneous cancer diseases by hyperthermic methods
Kovziridze, Zviad; Department of Chemical and Biological Technologies, Georgian Technical University, Tbilisi
Menteshashvili, Guram; Institute of Clinical Oncology, Tbilisi
Khorava, Paata; Institute of Clinical Oncology, Tbilisi
Bluashvili, Khatia; Department of Chemical and Biological Technologies, Georgian Technical University, Tbilisi
Controlled Local Hyperthermia; Necrosis; Ulceration; Metastasis
<p><strong>Purpose:</strong> The present work pursues perfection of highly efficient anticancer, principally new methodology and technology. It deals with the comparative study of anticancer activity of controlled local hyperthermia in animals and determination-de- velopment of optimal regimes and schemes. Furthermore, it also presents the work on new clinical device of high anticancer effect. <strong></strong></p><p><strong>Methods:</strong> Authors used controlled local hyperthermia for this study. In our experiments, we used 3 to 3.5 months-old non-pedigree (nonlinear) white mice (mass: 18-30 gram). After mice selection for the experiments, animals were placed in vivarium, in quarantine regime for 10 to 4 days. Individual protocols were drawn for each animal. Similar feeding and handling regimes were created for all animals. Transplantable malignant cancer strain, Erlich adenocarcinoma, was used. <strong></strong></p><p><strong>Results:</strong> Experiments on animals were successful. There are positive conclusions of pathological-anatomy laboratory “PathGeo”: Form # IV -200- 6A, for the examination # 3119-12 and # 15/02 and macro-morphological and micro-morphological description of the study # 15272-13. On the basis of the results of morphological study, it was proved that liver and lungs (the main target bodies) were intact, and secondary cancer injuries were not fixed. After three sessions of hyperthermia treatment, the decrease in sizes of cancer formations and necrosis of diseased sections were visualized, while massive necrosis was observed after seven sessions. In all cases, necrosis and ulceration of diseased places were observed, which refers to transition of cancer into phase of healing. After eight-ten sessions, necrosis of cancer and ulceration were observed, which refers to irreversibility of the process and efficiency of the applied method of hyperthermia. <strong></strong></p><p><strong>Conclusion:</strong> Anticancer effect of hyperthermia conditioned by temperature fields was proved, which was expressed in inhibition of cancer growth, resorption and increase of life length of experimental animals. The method of treatment was selected with maximum anticancer effect free of side effects and was offered as a new, perspective alternative or additional means for treatment of malignant cancers.</p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/0301.15
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/151/1860
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/258
2015-08-15T11:54:27Z
IJCTO:CASE
cam 3u
"150220 2015 eng "
dc
Volumetric modulated arc therapy for spine SBRT patients to reduce treatment time and intrafractional motion
Amoush, Ahmad; Department of Radiation Oncology, Georgia Regents University, Augusta, Georgia
Dalton, Allison; Department of Radiation Oncology, Georgia Regents University, Augusta, Georgia
Rabatic, Bryan; Department of Radiation Oncology, Georgia Regents University, Augusta, Georgia
Huang, Ke; Department of Radiation Oncology, Georgia Regents University, Augusta, Georgia
Al-Basheer, Ahmad; Department of Radiation Oncology, Georgia Regents University, Augusta, Georgia
Radiation Oncology: Medical physics
VMAT; SBRT; Spine
Case Study
Volumetric modulated arc therapy (VMAT) is an efficient technique to reduce the treatment time and intrafractional motion to treat spine patients presented with severe back pain. Five patients treated with spine stereotactic body radiation therapy (SBRT) using 9 beams intensity modulated radiation therapy (IMRT) were retrospectively selected for this study. The patients were replanned using two arcs VMAT technique. The average mean dose was 104% ± 1.2% and 104.1% ± 1.0% in IMRT and VMAT, respectively (p = 0.9). Accordingly, the average conformal index (CI) was 1.3 ± 0.1 and 1.5 ± 0.3, respectively (p = 0.5). The average dose gradient (DG) distance was 1.5 ± 0.1 cm and 1.4 ± 0.1 cm, respectively (p = 0.3). The average spinal cord maximum dose was 11.6 ± 1.0 Gy and 11.8 ± 1.1 Gy (p = 0.8) and V<sub>10Gy</sub> was 7.4 ± 1.4 cc and 8.6 ± 1.7 cc (p = 0.4) for IMRT and VMAT, respectively. Accordingly, the average number of monitor units (MUs) was 6771.7 ± 1323.3 MU and 3978 ± 576.7 MU respectively (p = 0.02). The use of VMAT for spine SBRT patients with severe back pain can reduce the treatment time and intrafractional motion.
International Journal of Cancer Therapy and Oncology
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.6
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/260
2015-08-15T11:54:27Z
IJCTO:ORIGINAL
cam 3u
"150404 2015 eng "
dc
A comparative study on patient specific absolute dosimetry using slab phantom, acrylic body phantom and goat head phantom
Gurjar, Om Prakash; Department of Physics, Mewar University, Chittorgarh
Mishra, Surendra Prasad; Department of Physics, Mewar University, Chittorgarh
Radiation Oncology; Medical Physics; Medical Dosimetry
Acrylic Body Phantom; Goat Head Phantom; Patient Specific Absolute Dosimetry
Medical Physics
<p><strong>Purpose: </strong>To compare the results of patient specific absolute dosimetry using slab phantom, acrylic body phantom and goat head phantom. <strong></strong></p><p><strong>Methods:</strong> Fifteen intensity modulated radiotherapy (IMRT) plans already planned on treatment planning system (TPS) for head-and-neck cancer patients were exported on all three kinds of phantoms viz. slab phantom, acrylic body phantom and goat head phantom, and dose was calculated using anisotropic analytic algorithm (AAA). All the gantry angles were set to zero in case of slab phantom while set to as it is in actual plan in case of other two phantoms. All the plans were delivered by linear accelerator (LA) and dose for each plan was measured by 0.13 cc ion chamber. The percentage (%) variations between planned and measured doses were calculated and analyzed. <strong></strong></p><p><strong>Results: </strong>The mean % variations between planned and measured doses of all IMRT quality assurance (QA) plans were as 0.65 (Standard deviation (SD): 0.38) with confidence limit (CL) 1.39, 1.16 (SD: 0.61) with CL 2.36 and 2.40 (SD: 0.86) with CL 4.09 for slab phantom, acrylic head phantom and goat head phantom respectively. <strong></strong></p><p><strong>Conclusion: </strong>Higher dose variations found in case of real tissue phantom compare to results in case of slab and acrylic body phantoms. The algorithm AAA does not calculate doses in heterogeneous medium as accurate as it calculates in homogeneous medium. Therefore the patient specific absolute dosimetry should be done using heterogeneous phantom mimicking density wise as well as design wise to the actual human body. </p>
International Journal of Cancer Therapy and Oncology
None
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.13
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/341
2016-01-03T12:17:49Z
IJCTO:CASE
cam 3u
"150610 2015 eng "
dc
Solitary pulmonary metastasis of pancreatic cancer presenting a thin-walled cavity
Matsuoka, Katsunari; Department of Thoracic Surgery, National Hospital Organization Himeji Medical Center, Himeji
Ueda, Mitsuhiro; Department of Thoracic Surgery, National Hospital Organization Himeji Medical Center, Himeji
Miyamoto, Yoshihiro; Department of Thoracic Surgery, National Hospital Organization Himeji Medical Center, Himeji
thoracic surgery, thoracic oncology
Pancreatic Cancer; Pulmonary; Metastasis; Cavity; Solitary
Because the prognosis of the patients with pancreatic cancer is very poor, there are few opportunities to perform surgery for pulmonary metastasis. Here we report the resection of a solitary pulmonary metastasis from pancreatic cancer, appearing as thin-walled cavity, which appeared 5 years after pancreaticoduodenectomy. Although the present patient underwent incomplete resection because of malignant pleural effusion and pleural dissemination, he is currently still alive without evident recurrence at 18 months after surgery.
International Journal of Cancer Therapy and Oncology
none
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.8
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/341/3265
http://www.ijcto.org/index.php/IJCTO/article/download/341/3266
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/359
2016-01-03T12:17:49Z
IJCTO:ORIGINAL
cam 3u
"150824 2015 eng "
dc
Correlation between gamma analysis for midline and lateralized tumors by using volumetric modulated arc therapy
Surendran Nair Ambika Devi, Syam; Department of Radiation Oncology, Division of Radiation Physics, Malabar Cancer Centre Thalassery, Kerala
Parakkat Thokkayil, Anjana; Department of Physics, University of Calicut, Kerala
Cheruparambil, Aswathi; Department of Physics, University of Calicut, Kerala
Gangadharan Padmini, Sitha; Department of Physics, University of Calicut, Kerala
Perumangat, Aparna; Department of Physics, University of Calicut, Kerala
Radiation Therapy; Medical Physics
Quality Assurance; VMAT; 2D Seven29 Array; Octavius; Gamma Analysis; Midline Tumor
<p><strong>Purpose: </strong>The aim of this study was to evaluate the fluence for midline and lateralized tumors for volumetric modulated arc therapy (VMAT) by using a two-dimensional array.</p><p><strong>Methods: </strong>For this study, we selected 60 patients who were undergoing VMAT. The octavius phantom was computed tomography (CT) scanned and imported to the planning system. Verification plans were created for each plan and exported. The measurements were performed using 2D seven29 ion chamber array. Fluence measurement values for all the delivered plans were analyzed using VeriSoft software. The TPS calculated values were then compared with the measured gamma values. <strong></strong></p><p><strong>Results: </strong>The gamma pass percentage for midline tumors was found to be higher than that for lateralized tumors. The standard deviations between the gamma values for midline and lateralized tumors were 1.96 and 2.86, respectively. Moreover, the standard deviations between the point doses for midline and lateralized tumors were 0.360 and 0.283, respectively. The mean gamma passing rate was 96.96% for midline tumors and 96.57% for lateralized tumors for 3%DD/3-mm criteria. There is no significance found in the gamma values for midline and lateralized tumors with <em>p</em>-value 0.08. <strong></strong></p><p><strong>Conclusion:</strong> No particular correlation was found between the gamma pass percentage for midline tumors and that for lateralized tumors. Only a marginal difference was found in the gamma pass percentage.</p>
International Journal of Cancer Therapy and Oncology
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.24
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/359/3360
http://www.ijcto.org/index.php/IJCTO/article/download/359/3505
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/428
2016-01-03T12:17:09Z
IJCTO:CONF
cam 3u
"151011 2015 eng "
dc
Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing
Song, ChunJiao; Shaoxing People’ s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000,
Zhejiang Province
Chen, Huan; Zhejiang Institute of Microbiology, Hangzhou, Zhejiang Province
Ru, GuoMei; Shaoxing People’ s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000,
Zhejiang Province
Ding, QianNan; Shaoxing People’ s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000,
Zhejiang Province
Yang, WanLei; Shaoxing People’ s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, 312000,
Zhejiang Province
<p align="left"><strong>Purpose: </strong>Prostate cancer (PCa) is the second leading cause of tumor mortality among males in western societies. In China, the diagnostic and fatality rate of PCa is increasing yearly. MicroRNAs (miRNAs) are small single stranded non-coding RNA molecules (~22 nucleotides) which impede protein production by directly interacting with 3’-untranslated regions of the target mRNAs. miRNAs are crucial regulators in malignant tumors. Recent profiling research suggests that miRNAs are aberrantly expressed in PCa, and these have been implicated in the regulation of apoptosis, cell cycle, epithelial to mesenchymal transition, PCa stem cells, and androgen receptor pathway.</p><p align="left"><strong>Methods: </strong>To find miRNAs differentially expressed in PCa and their relation to prognostic factors and therapeutic potentials, we studied 24 surgical specimens from men who underwent radical prostatectomy, through high-throughput Illumina sequencing and quantitative real-time PCR (qRT-PCR) methods. Moreover, a variety of biological information softwares and databases were applied to predict the target genes of miRNA, molecular functions, and signal pathways. We also discuss the functional significance of the differentially expressed miRNAs and the molecular pathways/targets regulated by these miRNAs.</p><p align="left"><strong>Results: </strong>Many miRNAs were differentially expressed (fold change 2, P<0.05) by sequencing. This was confirmed by qRT-PCR in more clinical tissue samples. In the tumors, miRNAs (miR-125b-5p, miR-126-5p, miR-141, miR-151a-5p, miR-221-3p and miR-222-3p) were significantly upregulated with downregulation of miR-486-5p and miR-488. In addition, 13 novel miRNAs were identified from three prostate tissue libraries, with 12 of them assayed in 21 human normal tissues by qRT-PCR. Multiple databases indicated target genes for these differentially expressed miRNAs. Function annotation of target genes indicated that most of them tend to target genes involved in signal transduction and cell communication, especially cancer-related PI3K-Akt and p53 signaling pathway. Moreover, miR-141 and miR-488 post-transcriptionally regulated androgen receptor (AR) expression, and inhibited the growth and metastasis of prostate gland epithelial cells.</p><p align="left"><strong>Conclusion: </strong>The small RNA transcriptomes obtained in this study uncovers the differentially expressed miRNAs, and provides a better understanding of the expression and function of miRNAs in the development of PCa and reveals several miRNAs in PCa that may have biomarker and therapeutic potentials.</p><p>-----------------------------------------</p><p><strong>Cite this article as: </strong>Song C, Chen H, Ru G, Ding Q, Yang W. Expression profile analysis of microRNAs in prostate cancer by next-generation sequencing. Int J Cancer Ther Oncol 2015; 3(4):3405.</p><p class="c-email">[This abstract was presented at the BIT’s 8<sup>th</sup> Annual World Cancer Congress, which was held from May 15-17, 2015 in Beijing, China.]</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.05
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/367
2016-07-16T06:27:47Z
IJCTO:ORIGINAL
cam 3u
"151220 2015 eng "
dc
Synergetic effect of green tea on polymer gel dosimeter and determination of optimal wavelength to choose light source for optical computed tomography
Raj, Sathiya; Division of Photonics, Nuclear and Medical Physics, School of Advanced Sciences, VIT University, Vellore
Jebaseelan Samuel, James; Division of Photonics, Nuclear and Medical Physics, School of Advanced Sciences, VIT University, Vellore
Kumar, Senthil; Department of Physics, School of Basic Sciences, Vel Tech University, Avadi, Chennai
Natanasabapathi, Gopishankar; Department of Neurosciences, Gamma Knife unit, All India Institute of Medical Sciences, New Delhi
Medical Physics
PAGAT, NIPAM, GTE, NIST XCOM, THPC, Polymer Gel Dosimeter
<p>Purpose: The ultimate aim of this study is to observe the effect of Green tea as a co-antioxidant in PAGAT gel dosimeter and evaluate the appropriate light source for scanning the PAGAT and NIPAM polymer gel.</p><p>Methods: Both PAGAT (Poly Acrylamide Gelatin Tetrakis hydroxyl phosphonium chloride) and NIPAM (N-Isopropyl acrylamide) gel were prepared in normoxic condition. The green tea extract (GTE) was prepared and tested only on PAGAT. Co-60 teletherapy machine has been used for irradiation purpose, and the gel samples were scanned using UV-Visible spectrophotometer. Water equivalency of the gel has been tested in terms of their electron density, effective atomic number and Ratio of oxygen and hydrogen (O/H). We have used NIST XCOM database to test the water equivalency.</p><p>Results: In this study we found that the GTE added to the gel do not respond to the given doses. By adding sugar we can enhance the sensitivity of the gel. Further investigations are required to use Green tea as a co antioxidant concentration of THPC (Tetrakis hydroxymethyl phosphonium chloride). The optimal wavelength with different region for scanning the PAGAT is 450 to 480 nm (Blue region), for NIPAM it is 540 nm and 570 nm (Green and yellow region). The PAGAT and NIPAM showed better sensitivity at 510 nm. Both gels have their effective atomic number closer to water (NIPAM-7.2, PAGAT-7.379).</p><p>Conclusion: As per our results, we concluded that GTE alone is not an effective co-antioxidant for polymer gels. When the GTE is combined with sugar and THPC, it protects the gel from pre-polymerization. This study strongly suggests that the blue light is an optimal source for scanning the PAGAT and green to yellow light for NIPAM gel. Though both gels were considered as water equivalent, the PAGAT is equivalent to water and the temporal stability of this gel is higher than NIPAM.</p>
International Journal of Cancer Therapy and Oncology
2016-03-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.2
International Journal of Cancer Therapy and Oncology; Vol 4, No 1 (2016): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/367/3419
http://www.ijcto.org/index.php/IJCTO/article/download/367/3661
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/454
2016-07-16T06:30:54Z
IJCTO:ORIGINAL
cam 3u
"160216 2016 eng "
dc
Preliminary experience of fractionated stereotactic radiosurgery with extend system of Gamma Knife
Bisht, Raj; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Kale, Shashank; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Nathanasabapathi, Gopishankar; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Kumar, Pratik; Department of Medical Physics (BRAIRCH), All India Institute of Medical Sciences, New Delhi
Singh, Manmohan; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Agarwal, Deepak; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Thulkar, Sanjay; Department of Radiodiagnosis (BRAIRCH), All India Institute of Medical Sciences, New Delhi
Garg, Ajay; Department of Neuroradiology, All India Institute of Medical Sciences, New Delhi
Julka, Pramod; Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi
Rath, Gaura; Department of Radiotherapy, All India Institute of Medical Sciences, New Delhi
Sharma, Bhawani; Department of Neurosurgery and Gamma Knife, All India Institute of Medical Sciences, New Delhi
Medical Physics
Gamma Knife, Stereotactic Radiosurgery, Positional Accuracy
Fractionated Radiosurgery
<p>Purpose: The purpose of this study is to present multisession stereotactic radiosurgery with initial experience using custom made extend system (ES) of Gamma Knife.</p><p>Methods: The ES is comprised of a carbon fiber frame also called extend frame, vacuum head rest cushion, patient surveillance unit and a configurable front piece with dental impression tray. The extend frame is a rigid connection between patient's head and patient positioning system (PPS) of Gamma Knife. A dental impression of patient was created and attached to the frontal piece of extend system. The treatment setup involves positioning the patient within the extend frame using patient specific headrest cushion and front piece. The reference patient’s head position was recorded through measurements of repositioning check tool (RCT) apertures using a high precision digital probe before computed tomography (CT) scan. The RCT measurements taken before treatment were compared with recorded reference position to ensure appropriate patient treatment position. Volumetric magnetic resonance (MR) scan was co-registered with stereotactic CT scan on Leksell Gamma plan. Fused MR to CT images on Gamma Plan was utilized to delineate regions of interest and prepare a precise treatment plan. The presented study includes positional reproducibility check and dosimetric evaluation of ten patients treated with ES.</p><p>Results: Forty-three fractions on ten patients with prescribed treatment format were delivered successfully. An average tumor volume of 11.26 cm<sup>3</sup> (range, 340 mm<sup>3</sup> to 59.12 cm<sup>3</sup>) was treated with ES. The mean tumor coverage of 91.91% (range, 90% to 95%) was able to achieve at 50% prescription isodose without compromising adjacent normal structure radiation dose tolerances. The mean inter-fraction positional variation of 0.69 mm influences an inherent strength of immobilization technique. Follow-up of seven patients at a median interval of 16 months (range, 9 months to 26 months) showed evidence of 100% radiographic control with improved clinical results.</p><p>Conclusion: Conjugative clinical outcome shows the efficacy of fractionation in various clinical indications.</p>
International Journal of Cancer Therapy and Oncology
Research section of "All India institute of Medical Sciences" New Delhi, India
2016-03-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.14
International Journal of Cancer Therapy and Oncology; Vol 4, No 1 (2016): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/488
2016-07-16T07:51:23Z
IJCTO:ORIGINAL
cam 3u
"160630 2016 eng "
dc
Statistical evaluation of dosimetric differences changes between the Modified Batho's density correction method and the Anisotropic Analytical Algorithm for clinical practice
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Balosso, Jacques; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Radiation Oncology; Medical Physics,
Heterogeneity correction, Modified Batho's density correction, AAA, Medical decision
Radiation Oncology; Medical Physics,
<p>Purpose: The aim of this work was to assess and to quantify, for clinical practice, the differences in computed doses using two types of dose calculation algorithm for the heterogeneity correction including target volumes and organs at risk (OARs).</p><p>Methods: 35 patients having lung, breast, spine, head & neck, brain and pelvic tumors, were studied. For each patient, 2 treatment plans were generated. In plan 1, the dose was calculated using the Modified Batho's (MB) density correction method integrated in the Pencil Beam Convolution algorithm. In plan 2, the dose was calculated using the Anisotropic Analytical Algorithm (AAA). To compare the two plans a dosimetric analysis was carried out including cumulative and differential dose volume histograms (DVH), coverage index, and conformity index. Wilcoxon signed rank and Spearman’s tests were used to calculate p-values and correlation coefficients (r), respectively. Bootstrap simulation with 1000 random samplings was used to calculate the 95% confidence interval (95% CI).</p><p>Results: The analysis of DVH showed that the AAA method calculated significantly higher doses for OARs for all cancer sites and lower doses for target volumes, especially for targets located in lung, with p < 0.05. The data demonstrated a strong correlation between MB and AAA for all cancer sites with r > 0.9.</p><p>Conclusion: This study confirms that using the AAA integrated into Eclipse<sup>®</sup> TPS, the calculated dose will be increased to OARs, and reduced to target volumes. Thus, when changing from the MB algorithm to AAA, attention should be paid to avoid any bias of over/under estimating the dose given by AAA and to hold discussions between physicists and oncologists regarding any necessary modification in the prescription method.</p>
International Journal of Cancer Therapy and Oncology
2016-06-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.17
International Journal of Cancer Therapy and Oncology; Vol 4, No 2 (2016): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/527
2016-09-18T08:59:14Z
IJCTO:CASE
cam 3u
"160918 2016 eng "
dc
Adenoid cystic carcinoma of lung: An oncologic rarity treated with definitive chemo-radiation
Purkayastha, Abhishek; Department of Radiation Oncology, Army Hospital Research & Referral, New Delhi
Sharma, Neelam; Department of Radiation Oncology, Army Hospital Research & Referral, New Delhi
Vishwanath, Sundaram; Department of Medical Oncology, Army Hospital Research & Referral, New Delhi
Sunita, B S; Department of Pathology and Molecular Sciences, Army Hospital Research & Referral, New Delhi
Radiation Oncology
Adenoid cystic carcinoma, Lung, Radiotherapy, Chemotherapy
Pulmonary System
<p>Adenoid Cystic Carcinoma is a rare variant of adenocarcinoma originating mainly from salivary glands of the head and neck region distributed throughout the upper aerodigestive tract with a propensity for perineural invasion. Primary adenoid cystic carcinoma of lungs is exceedingly rare accounting for a mere 0.04 to 0.2 percent of all pulmonary neoplasms. The existing scant case reports about this lung malignancy mostly describe small lung lesions managed with upfront surgery followed by adjuvant radiotherapy. We hereby present this case of primary lung parenchymal pathology where the disease was treated with definitive chemo-radiation and to the best of our knowledge; this case is one of the rarest and earliest reports of upfront chemo-radiation in an inoperable primary lung parenchymal ACC. A 43-year-old woman presented with complaints of cough, severe dyspnea, right sided chest pain associated with occasional hemoptysis. Radiographic imaging of thorax showed a large mass lesion with smooth margins measuring 10.2 × 7.3 × 6.8 cm right lower lobe with invasion of adjacent vital structures. Image guided biopsy and immunohistochemical analysis confirmed the diagnosis. She was eventually treated with definitive radiotherapy with concurrent chemotherapy as she was deemed inoperable. Post therapy evaluation by imaging showed a partial response to chemo-radiation, however there was significant symptomatic relief. In view of CD 117 positivity, she has started on oral imatinib mesylate. Presently she is on follow up with a <em>karnofsky performance status</em> of 90%. A thorough review of literature also reveals that our case may be the largest adenoid cystic primary parenchymal pulmonary pathology ever reported.<strong></strong></p>
International Journal of Cancer Therapy and Oncology
None
2016-07-13 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.15
International Journal of Cancer Therapy and Oncology; Vol 4, No 3 (2016): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/527/4319
http://www.ijcto.org/index.php/IJCTO/article/download/527/4646
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/588
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
cam 3u
"161228 2016 eng "
dc
Low-dose versus high-dose radioactive iodine ablation of differentiated thyroid carcinoma: a prospective randomized study
Ibrahim, Dina; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
Kelaney, Mohamed; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
Michael, Maha; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
El-Sayed, Zeinab; Clinical Oncology Department, Ain-Shams University, Cairo, Egypt
Differentiated thyroid carcinoma, Radioactive iodine remnant ablation, I-131 optimal dose, Randomized study.
<p>Purpose: Following total thyroidectomy of differentiated thyroid carcinoma (DTC), some patients are ablated with radioactive iodine I-131 (RAI). We compare the success of ablation with 30 millicurie (mCi) versus 80 mCi.</p><p>Methods: We randomized the patients to 30 mCi or 80 mCi RAI after surgery. T1-T3, N0-N1, M0 tumors were included (based on the AJCC 7th edition). Pre-ablation baseline serum thyroglobulin (sTg), and thyroglobulin antibody (Tg Ab) were performed. Six months post-ablation successful thyroid ablation was defined as a negative whole body scan (WBS) and undetectable sTg.</p><p>Results: Out of 50 patients with DTC, 45 patients fulfilled the eligibility criteria. Total thyroidectomy was performed in 27/ 45 (60%). 26/45 (57.8%) of patients received 30 mCi while 19/45 (42.2%) patients received 80 mCi. The median age was 37 and 36.5 years in the arms 80 and 30 mCi respectively. Papillary carcinoma predominated in 42/45 (93.3%) of patients. T2 tumors predominated in 10/19 (52.6%), and 15/26 (57.7%) of the 80 and 30 mCi arms respectively. According to the American Thyroid Association (ATA) risk classification, all of the patients had low risk disease. Success of ablation was achieved in 15/19 (78.9%), and in 15/26 (57. 7%) of the arms 80 and 30 mCi respectively. No patients developed distant metastases in both arms. The patients who received 80 mCi had longer hospital isolation than the 30 mCi arm (p 0.008). 6/26 (23.1%) patients in the 30 mCi arm were isolated for 2-4 days, whereas all the 80 mCi arm patients were isolated for 3-5 days.</p><p>Conclusion: Both 80 mCi and 30 mCi RAI have similar success rate in the ablation of thyroid remnant of low risk DTC patients. The low dose is associated with fewer side effects, shorter hospital admission duration, and is less expensive in low risk DTC patients. </p>
International Journal of Cancer Therapy and Oncology
2016-10-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.15
International Journal of Cancer Therapy and Oncology; Vol 4, No 4 (2016): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/750
2017-12-17T14:56:16Z
IJCTO:TECHNICAL
cam 3u
"171210 2017 eng "
dc
A preliminary investigation on long-term consistency of MPC as a quick daily QA application
Bhatt, CP; Batra Hospital and Medical Research Center, Delhi
Semwal, Manoj Kumar; Army Hospital (R&R), Delhi
Singh, Sukhvir; Army Hospital (R&R), Delhi
Chufal, Kundan Singh; Batra Hospital and Medical Research Center, Delhi
Sharma, Kiran; Graphic Era University, Dehradun, Uttrakhand
Medical Physics; Medical Dosimetry
Radiotherapy, Machine Performance Check (MPC), TrueBeam 2.0, Linac QA
Medical Physics
<p>Purpose: The purpose of this study was to establish Machine performance check (MPC) application as a comprehensive daily QA program in a clinical setting for a True Beam 2.0 system and investigate the first ten months (195 days) daily QA data generated by the MPC.</p><p>Methods: An automated daily quality assurance (QA) application named machine performance check (MPC) was recently launched by Varian Medical Systems with their TrueBeam 2.0 linear accelerator (linac) system. MPC performs all the essential machine tests such as Beam Constancy Check, and Geometry Check with the use of an IsoCal phantom. There is no systematic published study on long-term consistency and validation of MPC in a clinical set-up for its acceptance as an alternative QA application. In the present study, we collected data with the MPC for over ten months (195 days) on a TrueBeam 2.0 system. The data was analysed for reproducibility and also compared with the data collected with other statndard QA devices at the time of commissioning of the TrueBeam system for validation.</p><p>Results: The results showed that the reproducibility of MPC was at least an order of magnitude less than the tolerance values for the respective parameters and also the average measured values for all QA parameters studied. The MPC measured isocenter accuracy, and output values were close to the Winston-Lutz test (within 0.1 mm) and the ion-chamber measurements (within 0.1%), respectively.</p><p>Conclusion: With our long term result, it is evident that the MPC could be an alternative daily QA tool. A comprehensive and long-term validation of the MPC measured values with the other standard QA methods over the ten month period will be needed before accepting MPC as a reliable QA tool.</p>
International Journal of Cancer Therapy and Oncology
2017-02-12 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.17
International Journal of Cancer Therapy and Oncology; Vol 5, No 1 (2017): January - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/6
2014-05-31T18:23:38Z
IJCTO:ORIGINAL
cam 3u
"130831 2013 eng "
dc
Dosimetric impact of mixed-energy volumetric modulated arc therapy plans for high-risk prostate cancer
Pokharel, Shyam; Department of Medical Physics, Premier Oncology, Florida, USA.
Medical Physics; Radiation Oncology
Prostate Cancer, Mixed Energy Plan, VMAT, RapidArc
<p><strong>Purpose: </strong>This study investigated the dosimetric impact of mixing low and high energy treatment plans for prostate cancer treated with volumetric modulated arc therapy (VMAT) technique in the form of RapidArc.</p><p><strong>Methods: </strong>A cohort of 12 prostate cases involving proximal seminal vesicles and lymph nodes was selected for this retrospective study. For each prostate case, the single-energy plans (SEPs) and mixed-energy plans (MEPs) were generated. First, the SEPs were created using 6 mega-voltage (MV) energy for both the primary and boost plans. Second, the MEPs were created using 16 MV energy for the primary plan and 6 MV energy for the boost plan. The primary and boost MEPs used identical beam parameters and same dose optimization values as in the primary and boost SEPs for the corresponding case. The dosimetric parameters from the composite plans (SEPs and MEPs) were evaluated. <strong></strong></p><p><strong>Results: </strong>The dose to the target volume was slightly higher (on average <1%) in the SEPs than in the MEPs. The conformity index (CI) and homogeneity index (HI) values between the SEPs and MEPs were comparable. The dose to rectum and bladder was always higher in the SEPs (average difference up to 3.7% for the rectum and up to 8.4% for the bladder) than in the MEPs. The mean dose to femoral heads was higher by about 0.8% (on average) in the MEPs than in the SEPs. The number of monitor units and integral dose were higher in the SEPs compared to the MEPs by average differences of 9.1% and 5.5%, respectively.</p><p><strong>Conclusion: </strong>The preliminary results from this study suggest that use of mixed-energy VMAT plan for high-risk prostate cancer could potentially reduce the integral dose and minimize the dose to rectum and bladder, but for the higher femoral head dose.</p><p>-----------------------------------------------</p><p><strong>Cite this article as:</strong><br />Pokharel S. Dosimetric impact of mixed-energy volumetric modulated arc therapy plans for high-risk prostate cancer. <em>Int J Cancer Ther Oncol</em> 2013;<strong>1</strong>(1):01011.<br /><br /></p><p><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0101.1" target="_blank">http://dx.doi.org/10.14319/ijcto.0101.1</a></p><p> </p><div id="fb-root"> </div><script type="text/javascript">// <![CDATA[
(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); js.id = id;
js.src = "//connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.0";
fjs.parentNode.insertBefore(js, fjs);
}(document, 'script', 'facebook-jssdk'));
// ]]></script><div class="fb-like" data-href="http://ijcto.org/index.php/IJCTO/article/view/Pokharel" data-width="500" data-layout="standard" data-action="recommend" data-show-faces="false" data-share="true"> </div>
International Journal of Cancer Therapy and Oncology
2013-10-10 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Pokharel
International Journal of Cancer Therapy and Oncology; Vol 1, No 1 (2013): September - October
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/18
2014-03-18T19:11:12Z
IJCTO:TECHNICAL
cam 3u
"131122 2013 eng "
dc
Evaluation of planned dosimetry when beam energies are substituted for a fraction of the treatment course
Hawke, Samantha E; Genesiscare, Radiation Oncology Victoria, Murray Valley Private Hospital, Victoria
Torrance, Angela; Genesiscare, Radiation Oncology Victoria, Murray Valley Private Hospital, Victoria
Tremethick, Lindsay; Genesiscare, Radiation Oncology Victoria, Murray Valley Private Hospital, Victoria
Medical Physics
radiotherapy; fraction; treatment planning system; beam energy; substitution
Radiotherapy Treatment Planning
<p><strong>Purpose: </strong>The purpose of this technical study was to evaluate how the effect of changing beam energies for one to multiple fractions of a patient’s plan affected the overall dose delivered to the planning target volume (PTV) and surrounding organs at risk (OAR’s). <strong></strong></p><p><strong>Method:</strong> In this study, twenty-eight patient plans from treatment sites including the oesophagus, prostate, lung, spine, rectum, bladder, chest, scapula, and breast were evaluated in the Philips Pinnacle treatment planning system (TPS), of these 14 were originally planned with 15MV and 14 with 10MV. Each of these plans were substituted with a single to multiple fractions with 10MV and 15MV respectively while keeping the original monitor units the same.</p><p><strong>Results:</strong> It was determined that when the number of fractions of the substituted beam energy remained at one fifth or less of the overall fractions a change of dose of less than 2% to the PTV could be maintained. The OAR’s dose, when the plan had 20% of its fractions substituted with a different energy, were found to change by on average up to 3.5% and 2.3% for original plan energies of 15MV and 10MV respectively. The dose change calculated in the TPS was then verified using ion chamber measurements for bladder and oesophagus treatment plans. <strong></strong></p><p><strong>Conclusion:</strong> Results appear to indicate that the site of treatment was not an important factor when changing energy but the overall number of fractions versus the number of fractions substituted with an alternative energy was fundamental. These results may be clinically useful when a radiotherapy department have machines with different photon energies. In the event of a break down, when a patient needs to be urgently treated, it may be possible to treat them on another machine with a different energy, without an immediate recalculation in the TPS. This decision would depend upon the percentage of fractions of their overall treatment needing to be treated before the machine was repaired</p><p>-------------------------------</p><p><strong>Cite this article as:</strong><br />Hawke S, Torrance A, Tremethick L. Evaluation of planned dosimetry when beam energies are substituted for a fraction of the treatment course. <em>Int J Cancer Ther Oncol</em> 2013; <strong>1</strong>(2):01014.</p><p><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0102.4" target="_self">http://dx.doi.org/10.14319/ijcto.0102.4</a><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2013-12-04 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Hawke
International Journal of Cancer Therapy and Oncology; Vol 1, No 2 (2013): November - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/18/158
http://www.ijcto.org/index.php/IJCTO/article/download/18/159
http://www.ijcto.org/index.php/IJCTO/article/download/18/251
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/57
2014-04-12T11:23:47Z
IJCTO:EDU
cam 3u
"140211 2014 eng "
dc
The use of gold markers and electronic portal imaging for radiotherapy verification in prostate cancer patients: Sweden Ghana Medical Centre experience
Acquah, George Felix; Sweden Ghana Medical Centre
Medical physics; Health sciences, Applied physics.
Prostate Cancer; Gold Markers; Treatment Verification; EPID; DRRs
<p>The success of radiotherapy cancer treatment delivery depends on the accuracy of patient setup for each fraction. A significant problem arises from reproducing the same patient position and prostate location during treatment planning for every fraction of the treatment process. To analyze the daily movements of the prostate, gold markers are implanted in the prostate and portal images taken and manually matched with reference images to locate the prostate. Geometrical and fiducial markers are annotated onto a highly quality generated digitally reconstructed radiographs, that are compared with portal images acquired right before treatment dose delivery. A 0 and 270 degree treatment fields are used to calculate prostate shifts for all prostate cancer patients undergoing treatment at the Sweden Ghana Medical Centre, using an iViewGT portal imaging device. After aligning of the marker positions onto the reference images, the set-up deviations corrections are displayed and an on-line correction procedure applied. The measured migrations of the prostate markers are below the threshold of 3 mm for the main plans and 2 mm for the boost plans. With daily electronic portal imaging combined with gold markers, provides an objective method for verifying and correcting the position of the prostate immediately prior to radiation delivery.</p><p>--------------------------------------------</p><p><strong>Cite this article as:</strong> Acquah GF. The use of gold markers and electronic portal imaging for radiotherapy verification in prostate cancer patients: Sweden Ghana Medical Centre experience. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):020112.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.12" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.12</a></p>
International Journal of Cancer Therapy and Oncology
2014-02-23 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Acquah
International Journal of Cancer Therapy and Oncology; Vol 2, No 1 (2014): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/57/530
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/105
2014-05-14T17:01:16Z
IJCTO:CONF
cam 3u
"140408 2014 eng "
dc
Pretreatment CT texture features for prognostication in patient with Stage III Non-Small Cell Lung Cancer
Fried, David Vincent; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tucker, SL; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Zhou, S; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liao, ZX; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ibbott, Geoffrey; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Court, Laurence; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>To determine whether CT texture features can yield prognostic information in addition to conventional prognostic factors in stage III non-small cell lung cancer (NSCLC).</p><p><strong>Methods</strong>: We conducted a retrospective review of 91 patients with stage III NSCLC treated with definitive chemoradiation. All patients received a four-dimensional (4D) CT simulation, where we utilized the average image (average-CT) and an expiratory image (T50-CT), and a diagnostic contrast enhanced CT image (CE-CT). A penalized cox regression model was used for covariate selection and model development. Models incorporating texture features from the 3 image types and clinical factors were compared to models incorporating clinical factors alone for overall survival (OS), local-regional control (LRC), and freedom from distant metastases (FFDM). Predictive Kaplan-Meier curves were generated using leave-one-out cross-validation. Stratification into low-risk and high-risk groups was based on a patient’s predicted outcome being greater or less than the median. Reproducibility of texture features was evaluated using test-retest scans from independent patients. The concordance correlation coefficient (CCC) was used to assess texture feature reproducibility and classification accuracy was used to assess reproducibility of texture features within the context of our models. </p><p><strong>Results: </strong>Models incorporating both texture and clinical features demonstrated a significant improvement in stratification compared to models using clinical features alone in cross-validated Kaplan-Meier curves in terms of OS (p = 0.046), LRC (p = 0.01), and FFDM (p = 0.005). The average CCC was 0.89, 0.91, and 0.67 for texture features extracted from the average-CT, T50-CT, and CE-CT, respectively. Incorporating reproducibility uncertainties within our model yielded 80.4 (SD = 3.7), 78.3 (SD = 4.0), and 78.8 (SD = 3.9) percent classification accuracy for OS, LRC, and FFDM, respectively. </p><p><strong>Conclusion</strong>: Pretreatment<strong> </strong>tumor texture may provide prognostic information in additional to routinely obtained clinical features. Reproducibility of CE-CT appears inferior to average-CT and T50-CT; however model classification accuracy rates of ~80% were still achieved.</p><p>----------------------</p><p><strong>Cite this article as:</strong> Fried DV, Tucker SL, Zhou S, Liao ZX, Ibbott GS, Court LE. Pretreatment CT texture features for prognostication in patient with Stage III Non-Small Cell Lung Cancer. Int J Cancer Ther Oncol 2014; 2(2):020223. <strong>DOI: 10.14319/ijcto.0202.23</strong><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Fried
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/120
2014-05-14T17:01:18Z
IJCTO:CONF
cam 3u
"140409 2014 eng "
dc
2D vs 3D gamma analysis: Establishment of comparable clinical action limits
Pulliam, Kiley B; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
Huang, Jessie Y; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
Bosca, Ryan; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA.
Followill, David; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kry, Stephen F; Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>As clinics begin to use 3D metrics for intensity-modulated radiation therapy (IMRT) quality assurance; these metrics will often produce results different from those produced by their 2D counterparts. 3D and 2D gamma analyses would be expected to produce different values, because of the different search space available. We compared the results of 2D and 3D gamma analysis (where both datasets were generated the same way) for clinical treatment plans. </p><p><strong>Methods</strong>: 50 IMRT plans were selected from our database and recalculated using Monte Carlo. Treatment planning system-calculated (“evaluated”) and Monte Carlo-recalculated (“reference”) dose distributions were compared using 2D and 3D gamma analysis. This analysis was performed using a variety of dose-difference (5%, 3%, 2%, and 1%) and distance-to-agreement (5, 3, 2, and 1 mm) acceptance criteria, low-dose thresholds (5%, 10%, and 15% of the prescription dose), and data grid sizes (1.0, 1.5, and 3.0 mm). Each comparison was evaluated to determine the average 2D and 3D gamma and percentage of pixels passing gamma.</p><p><strong>Results: </strong>Average gamma and percentage of passing pixels for each acceptance criterion demonstrated better agreement for 3D than for 2D analysis for every plan comparison. Average difference in the percentage of passing pixels between the 2D and 3D analyses with no low-dose threshold ranged from 0.9% to 2.1%. Similarly, using a low-dose threshold resulted in a differences ranging from 0.8% to 1.5%. No appreciable differences in gamma with changes in the data density (constant difference: 0.8% for 2D vs. 3D) were observed.</p><p><strong>Conclusion</strong>: We found that 3D gamma analysis resulted in up to 2.9% more pixels passing than 2D analysis. Factors such as inherent dosimeter differences may be an important additional consideration to the extra dimension of available data that was evaluated in this study.</p><p><strong>------------------------------------</strong></p><p><strong>Cite this article as:</strong> Pulliam KB, Huang JY, Bosca R, Followill D, Kry SF. 2D vs. 3D gamma analysis: Establishment of comparable clinical action limits. Int J Cancer Ther Oncol 2014; 2(2):020231.<strong> DOI: 10.14319/ijcto.0202.31</strong><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Pulliam
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/94
2014-08-16T18:42:02Z
IJCTO:ORIGINAL
cam 3u
"140504 2014 eng "
dc
A 3D quantitative evaluation for assessing the changes of treatment planning system and irradiation techniques in radiotherapy
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical Physics,
Grenoble University Hospital
Giraud, Jean Yves; Department of Radiation Oncology and Medical Physics,
Grenoble University Hospital
Balosso, Jacques; Department of Radiation Oncology and Medical Physics,
Grenoble University Hospital
Irradiation therapy, Medical physics
Gamma Index; Dose Distributions; Gamma Voxels Histograms; Gamma Maps
Irradiation therapy
<p><strong>Purpose: </strong>This work proposes and compares two 3D global evaluation methods for assessing the alteration of calculated dose distributions when treatment planning system algorithms or irradiation techniques is modified in radiation therapy. <strong></strong></p><p><strong>Methods</strong>: The global analysis is based on gamma index (γ) proposed by Low <em>et al</em>.<sup>1</sup> and Chi (χ) index proposed by Bakai <em>et al</em>.<sup>2</sup>. The γ and χ values are signed in order to identify the over and under estimating dosage. The 3D maps, the cumulative Gamma Voxels Histograms (GVHs) and Chi Voxels Histograms (CVHs) were generated using two software. The γ and χ criteria were set to 3 mm for the distance to agreement and 3% for dose. Pearson's Chi-squared test was applied to assess the statistically significance between GVHs and CVHs. We illustrated this method for the change of dose calculation algorithms for lung cancer, and the change of irradiation techniques for breast cancer. For each patient, 2 treatment plans were generated. For the example of change of dose calculation algorithms, a plan 1 was calculated using Pencil Beam Convolution (PBC) algorithm and a plan 2 was calculated using Modified Batho method (PBC-MB). For the example of change of irradiation technique, a plan 1 was calculated using Source Skin Distance SSD technique and a plan 2 was calculated using a single isocenter technique. <strong></strong></p><p><strong>Results:</strong> The 3D analysis based on γ and χ indexes showed a significant effect on the dosimetric representation in the lung cancer when we change the PBC algorithm to PBC-MB method. The comparison between the two irradiation techniques showed that the single isocenter technique produces a better dose distribution for the treatment of breast cancer. Pearson's Chi-squared test showed that there was no statistically significance between GVHs and CVHs generated by γ and χ indexes, (<em>p </em>> 0.05). The global analysis using 3D for γ and χ indexes confirmed the results obtained from dosimetric analysis. <strong></strong></p><p><strong>Conclusion</strong>: The methods proposed in this study provide useful tools for radiotherapy to compare two dose distributions obtained using different algorithms or different irradiation techniques. The χ-index was (~190) times faster than γ-index. The χ-index is thus a valuable and more convenient method for 3D global analysis compared with γ-index.</p><p>------------------------</p><p><strong>Cite this article as:</strong> Chaikh A, Giraud JY, Balosso J. A 3D quantitative evaluation for assessing the changes of treatment planning system and irradiation techniques in radiotherapy. <em>Int J Cancer Ther Oncol </em>2014; <strong>2</strong>(3):02033. <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0203.3"><strong>10.14319/ijcto.0203.3</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0203.3
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/145
2014-08-16T18:42:02Z
IJCTO:ORIGINAL
cam 3u
"140801 2014 eng "
dc
A dosimetric analysis of the aeroformTM tissue expander in radiation therapy
Tran, Tai; Department of Physics, Radiation Oncology Victoria, Epping, Australia.
Ding, Wei; Department of Physics, Radiation Oncology Victoria, Epping, Australia.
Subramanian, Brindha; Department of Physics, Radiation Oncology Victoria, Epping, Australia.
Melven, Leon; Department of Radiation Therapy, Radiation Oncology Victoria, Epping, Australia.
Chao, Michael; Department of Oncology, Radiation Oncology Victoria, Ringwood, Australia.
Farrow, Hamish; Plastic and Reconstructive Surgery Unit, Austin Hospital, Heidelberg, Australia.
Baker, Caroline; Department of Surgery, Victorian Breast and Oncology Care, East Melbourne, Australia.
Radiation Oncology
Aeroform; Tissue Expander; Metal; Radiotherapy; Contour
Breast Expander
<p><strong>Purpose: </strong>The aim of this study is to evaluate the effects of the metallic reservoir and the use of gas within the Aeroform™ tissue expander with respect to the radiation dose distribution.</p><p><strong>Methods</strong>: Dosimetric effects of using a metallic reservoir within a breast tissue expander during external beam radiotherapy were investigated. To view the internal components of the reservoir, it was removed from the tissue expander and imaged on a Varian AS500 electronic portal imager. To calculate the relative density of each component within the reservoir, an ionization chamber within solid water was used to measure the dose and compared to a simulation within the Pinnacle treatment planning system (TPS). To examine the relative dose profile along the length of the reservoir, the reservoir was exposed on EBT3 film and analyzed using SNC Patient<sup>™</sup>. In-vivo Dosimetry was performed using a RANDO<sup>®</sup> Woman phantom. Thermo-luminescent dosimeters were placed within the wax bolus enveloping the tissue expander.</p><p><strong>Results: </strong>Imaging the reservoir on the electronic portal imager revealed it consists of 3 distinct components. The densities assigned in the TPS, which resulted in calculated doses which matched the measured doses were; Section 1 = 0 g/cm<sup>3</sup>, Section 2 = 2.8 g/cm<sup>3</sup> and Section 3 = 0.7 g/cm<sup>3</sup>. Relative dose reductions were observed due to the metallic case; Section 1 = 20%, Section 2 = 40% and Section 3 = 30%. Entrance doses ranged from 2.39 - 2.53 Gy for both the medial and lateral beams. Exit doses ranging from 1.10 - 1.71 Gy were observed in both beams. There was a significant difference in measured and calculated doses at exit locations in the beam.</p><p><strong>Conclusion</strong>: Dosimetric effects due to the metallic reservoir within the Aeroform breast tissue expander have been demonstrated and have been observed to be significant. To increase the dosimetric accuracy when contouring, individual components of the reservoir should be distinguished. Our in-vivo experiment showed that dose homogeneity was difficult due to the metallic reservoir and we recommend stringent patient dose monitoring when using this expander during radiotherapy.</p><p>-----------------------------</p><p><strong>Cite this article as</strong>: Tran T, Ding W, Subramanian B, Melven L, Chao M, Farrow H, Baker C. A dosimetric analysis of the aeroformTM tissue expander in radiation therapy. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(3):020316. <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0203.16" target="_blank"><strong>10.14319/ijcto.0203.16</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0203.16
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/170
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
cam 3u
"141012 2014 eng "
dc
A decision tool to adjust the prescribed dose after change in the dose calculation algorithm
Chaikh, Abdulhamid; Department of Radiation Oncology & Medical Physics, Grenoble University Hospital, Grenoble
Giraud, Jean-Yves; Department of Radiation Oncology & Medical Physics, Grenoble University Hospital, Grenoble
Marguet, Maud; Institute of Radiation Physics, CHUV Lausanne University Hospital, Vaud
Silva, David DA; University of California, Davis, California
Perrin, Emanuel; University Claude Bernard Lyon 1, Villeurbanne
Balosso, Jacques; Department of Radiation Oncology & Medical Physics, Grenoble University Hospital, Grenoble
Dose Calculation; Prescribed Dose; Gamma Index; Radiotherapy
<p><strong>Purpose:</strong> This work aims to introduce a method to quantify and assess the differences in monitor unites MUs when changing to new dose calculation software that uses a different algorithm, and to evaluate the need and extent of adjustment of the prescribed dose to maintain the same clinical results. <strong></strong></p><p><strong>Methods:</strong> Doses were calculated using two classical algorithms based on the Pencil Beam Convolution PBC model, using 6 patients presenting lung cancers. For each patient, 3 treatment plans were generated: Plan 1 was calculated using reference algorithm PBC without heterogeneity correction, Plan 2 was calculated using test algorithm with heterogeneity correction, and in plan 3 the dose was recalculated using test algorithm and monitor unites MUs obtained from plan 1 as input. To assess the differences in the calculated MUs, isocenter dose, and spatial dose distributions using a gamma index were compared. Statistical analysis was based on a Wilcoxon signed rank test. <strong></strong></p><p><strong>Results:</strong> The test algorithm in plan 2 calculated significantly less MUs than reference algorithm in plan 1 by on average 5%, (p < 0.001). We also found underestimating dose for target volumes using 3D gamma index analysis. In this example, in order to obtain the same clinical outcomes with the two algorithms the prescribed dose should be adjusted by 5%.</p><p><strong>Conclusion:</strong> This method provides a quantitative evaluation of the differences between two dose calculation algorithms and the consequences on the prescribed dose. It could be used to adjust the prescribed dose when changing calculation software to maintain the same clinical results as obtained with the former software. In particular, the gamma evaluation could be applied to any situation where changes in the dose calculation occur in radiotherapy.</p>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0204.14
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/170/2099
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/245
2014-12-13T14:36:25Z
IJCTO:ORIGINAL
cam 3u
"141213 2014 eng "
dc
Dose-to-medium vs. dose-to-water: Dosimetric evaluation of dose reporting modes in Acuros XB for prostate, lung and breast cancer
Rana, Suresh; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma, USA
Pokharel, Shyam; Department of Radiation Oncology, 21st Century Oncology, Naples, Florida, USA
Radiation Oncology; Medical Physics: Medical Dosimetry
Acuros XB; Dose-to-Medium; Dose-to-Water; Dose Calculation; Heterogeneity Correction
<p><strong>Purpose:</strong> Acuros XB (AXB) dose calculation algorithm is available for external beam photon dose calculations in Eclipse treatment planning system (TPS). The AXB can report the absorbed dose in two modes: dose-to-water (D<sub>w</sub>) and dose-to-medium (D<sub>m</sub>). The main purpose of this study was to compare the dosimetric results of the AXB_D<sub>m</sub> with that of AXB_D<sub>w</sub> on real patient treatment plans. <strong></strong></p><p><strong>Methods:</strong> Four groups of patients (prostate cancer, stereotactic body radiation therapy (SBRT) lung cancer, left breast cancer, and right breast cancer) were selected for this study, and each group consisted of 5 cases. The treatment plans of all cases were generated in the Eclipse TPS. For each case, treatment plans were computed using AXB_D<sub>w</sub> and AXB_D<sub>m</sub> for identical beam arrangements. Dosimetric evaluation was done by comparing various dosimetric parameters in the AXB_D<sub>w</sub> plans with that of AXB_D<sub>m</sub> plans for the corresponding patient case. <strong></strong></p><p><strong>Results:</strong> For the prostate cancer, the mean planning target volume (PTV) dose in the AXB_D<sub>w</sub> plans was higher by up to 1.0%, but the mean PTV dose was within ±0.3% for the SBRT lung cancer. The analysis of organs at risk (OAR) results in the prostate cancer showed that AXB_D<sub>w</sub> plans consistently produced higher values for the bladder and femoral heads but not for the rectum. In the case of SBRT lung cancer, a clear trend was seen for the heart mean dose and spinal cord maximum dose, with AXB_D<sub>w</sub> plans producing higher values than the AXB_D<sub>m</sub> plans. However, the difference in the lung doses between the AXB_D<sub>m</sub> and AXB_D<sub>w</sub> plans did not always produce a clear trend, with difference ranged from -1.4% to 2.9%. For both the left and right breast cancer, the AXB_D<sub>m </sub>plans produced higher maximum dose to the PTV for all cases. The evaluation of the maximum dose to the skin showed higher values in the AXB_D<sub>m</sub> plans for all 5 left breast cancer cases, whereas only 2 cases had higher maximum dose to the skin in the AXB_D<sub>m</sub> plans for the right breast cancer. <strong></strong></p><p><strong>Conclusion:</strong> The preliminary dosimetric results from our clinical study showed that the selection of either D<sub>m</sub> or D<sub>w</sub> in AXB is less likely to produce significant dosimetric differences in the clinical environment. However, the difference between the AXB_D<sub>m</sub> and AXB_D<sub>w</sub> calculations depends on the disease site, and even for the same type of disease (e.g., lung cancer), the results are patient specific.</p>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0204.21
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/243
2015-08-15T11:54:27Z
IJCTO:CASE
cam 3u
"150206 2015 eng "
dc
Radiotherapy for large cutaneous angiosarcoma of face with RapidArc (VMAT)
Ali, Mirza Athar; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Muntimadugu, Babaiah; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Nagaraju, Madhusudhan; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Vuba, Sujana; Department of Radiation Oncology, American Oncology Institute, Hyderabad
George, Geomcy; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Muralidhar, KR; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Rout, Birendra; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Mariappan, Prabhakar; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Radiation Oncology; Treatment planning; RapidArc (VMAT)
RapidArc; Cutaneous Angiosarcoma
RapidArc for superficial target.
<p>Angiosarcoma is a rare malignancy of vascular origin. It can affect any part of the body, head and neck region being probably the most common site of diagnosis. We present here a case of Angiosarcoma of face in a 67-year-old elderly gentleman who was treated with RapidArc – volumetric modulated arc therapy (VMAT) for recurrence after surgery, radiotherapy and chemotherapy. As an alternative to Electron Beam Therapy, RapidArc with skin bolus can be considered for large complex shaped targets with irregular surface and tissue inhomogeneity. RapidArc plan can achieve adequate target coverage with acceptable dose homogeneity and conformity.</p>
International Journal of Cancer Therapy and Oncology
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.3
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/281
2016-01-03T12:17:49Z
IJCTO:CONF
cam 3u
"150329 2015 eng "
dc
Volumic activities measurements and equivalent doses calculation of indoor 222Rn in Morocco
Choukri, Abdelmajid; Department of Physics, University of Ibn Tofail, Faculty of Sciences, Kenitra
Hakam, Oum Keltoum; Department of Physics, University of Ibn Tofail, Faculty of Sciences, Kenitra
Indoor Radon; Workplaces; Radioprotection; ionizing Radiations; Effective Dose; Natural Radioactivity
<p><strong>Purpose:</strong> As a way of prevention, we have measured the volumic activities of indoor <sup>222</sup>Rn and we have calculated the corresponding effective dose in some dwellings and enclosed areas in Morocco. Seasonal variation of Radon activities and Relationships between variation of these activities and some parameters such height, depth and type of construction were also established in this work.</p><p><strong>Methods</strong>: The passive time-integrated method of using a solid state nuclear track detector (LR-115 type II) was employed. These films, cut in pieces of 3.4 ´ 2.5 cm<sup>2</sup>, were placed in detector holders and enclosed in heat-scaled polyethylene bags.</p><p><strong>Results</strong>: The measured volumic activities of radon vary in houses, between 31 and 136 Bq/m<sup>3</sup> (0.55 and 2.39 mSv/year) with an average value of 80 Bq/m<sup>3</sup> (1.41 mSv/year). In enclosed work area, they vary between 60 Bq/m<sup>3</sup> (0.38 mSv/year) in an ordinary area to 1884 Bq/m<sup>3</sup> (11.9 mSv/year) at not airy underground level of 12 m. the relatively higher volumic activities of <sup>222</sup>Rn in houses were measured in Youssoufia and khouribga towns situated in regions rich in phosphate deposits. Measurements at the geophysical observatory of Berchid show that the volumic activity of radon increases with depth, this is most probably due to decreased ventilation. <strong></strong></p><p><strong>Conclusion</strong>: The obtained results show that the effective dose calculated for indoor dwellings are comparable to those obtained in other regions in the word. The risks related to the volumic activities of indoor radon could be avoided by simple precautions such the continuous ventilation. The reached high value of above 1884 Bq/m<sup>3</sup> don't present any risk for workers health in the geophysical observatory of Berchid because workers spend only a few minutes by day in the cellar to control and reregister data.</p>
International Journal of Cancer Therapy and Oncology
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.1
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/281/2942
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/316
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
cam 3u
"150602 2015 eng "
dc
Evaluation of a novel reference chamber “stealth chamber” through Monte Carlo simulations and experimental data
Vazquez Quino, Luis; Alyzen Medical Physics, Inc., 1801 S 54th Street, Paragould, Arkansas
Huerta Hernandez, Claudia; Alyzen Medical Physics, Inc., 1801 S 54th Street, Paragould, Arkansas
Calvo, Oscar; Alyzen Medical Physics, Inc., 1801 S 54th Street, Paragould, Arkansas
Deweese, Mark; Alyzen Medical Physics, Inc., 1801 S 54th Street, Paragould, Arkansas
Medical Physics
Reference Chamber; Monte Carlo Simulations; Linac Commissioning; Ion Chamber
<p><strong>Purpose:</strong> To evaluate a novel reference chamber (Stealth Chamber by IBA) through experimental data and Monte Carlo simulations for 6 and 15 MV photon energies. <strong></strong></p><p><strong>Methods:</strong> Monte Carlo simulations in a water phantom for field sizes ranging from 3×3 and 25×25 cm<sup>2</sup> were performed for both energies with and without the Monte Carlo model of the Stealth Chamber in the beam path, and compared to commissioning beam data. Percent depth doses (PDDs), profiles, and gamma analysis of the simulations were performed along with an energy spectrum analysis of the phase-space files generated during the simulation. Experimental data were acquired in water with IBA three-dimensional (3D) blue phantom in a set-up identical to the one used in the Monte Carlo simulations. PDD comparisons for fields ranging from 1×1 to 25×25 cm<sup>2</sup> were performed for photon energies. Profile comparison for fields ranging from 1×1 to 25×25 cm<sup>2</sup> were executed for the depths of dmax, 5, 10 and 20 cm. Criteria of 1%, 1 mm to compare PDDs and profiles were used. Transmission measurements with the Stealth Chamber and a Matrixx detector from IBA were investigated. Measurements for 6 and 15 MV with fields ranging from 3×3 to 25×25 cm<sup>2</sup> dimensions were acquired in an open field with and without the Stealth Chamber in the path of the beam. Profiles and gamma analysis with a 1%, 1 mm gamma analysis criterion were performed. <strong></strong></p><p><strong>Results:</strong> Monte Carlo simulations of the PDDs and profiles demonstrate the agreement between both simulations. Furthermore, the gamma analysis (1%, 1 mm) result of the comparison of both planes has 100% of the points passing the criteria. The spectral distribution analysis of the phase spaces for an open field with and without the chamber reveals the agreement between both simulations. Experimental measurements of PDDs and profiles have been conducted and reveal the comparability of relative dosimetric data acquired with the Stealth Chamber and our gold standard the CC13 chamber. Transmission data measured with an ion chamber array (Matrixx) showed the small attenuation caused by the use of the Stealth Chamber. <strong></strong></p><p><strong>Conclusion:</strong> Simulations and experimental results from this investigation indicate the benefits associated with chamber positioning and time expended during the acquisition of the relative measurements of PDDs and profiles for the beam commissioning of photon beams when the Stealth Chamber is used as a reference chamber to perform these tasks. The results demonstrate that relative profiles and PDDs scanned with the Stealth Chamber in place are consistent with those made using a CC13 chamber within a 1% and 1 mm criterion.</p>
International Journal of Cancer Therapy and Oncology
NA
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.22
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/316/3144
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/280
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
cam 3u
"150811 2015 eng "
dc
A quantitative method to implement and to assess the single isocenter technique for breast cancer radiation therapy
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Fayolle, Sara; UniversityJoseph Fourier, Grenoble
Gabelle-Flandin1, Isabelle; Department of Radiation Oncology and Medical physics, Grenoble University Hospital
Marguet, Maud; Institute of Radiation Physics, Lausanne University Hospital, Grand-Pré 1, Lausanne
Docquiere, Nicolas; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital
Giraud, Jean-Yves; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital
Balosso, Jacques; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital
Radiation Oncology; Medical Physics, Medical Oncology
Breast Cancer; Single Isocenter; Radiotherapy
Radiation oncology
<p><strong>Purpose:</strong> We propose a process of quality assurance to validate and implement the single isocenter technique for breast cancer radiotherapy. We evaluated the dosimetric and temporal gains using the single isocenter technique compared to classic source to skin distance (SSD) technique. <strong></strong></p><p><strong>Methods:</strong> 6 patients of breast cancer localization were studied. For each patient 2 treatment plans were generated. In plan 1 the dose was calculated using SSD technique. In plan 2 the dose was calculated using single isocenter technique. To implement the plan 2 a dosimetric analysis including monitor units (MU), isodose curves, cumulative and differential dose volume histograms cDVH, dDVH respectively, coverage index, conformity index for planning target volume were used. The measurements using a PMMA phantom consist of measuring point dose by an ionization chamber and 2D dose distributions using 2D diodes arrays. Wilcoxon signed rank and Spearman’s tests were used to calculate <em>p</em>-value and correlation coefficient, respectively.</p><p><strong>Results:</strong> The single isocenter technique reduced the MU by average on -30.1 ± 13.6%, (<em>p</em> = 0.03). We observed an improvement with statistical significance between the two techniques for the mean dose, minimum dose and volume receiving 95% of the prescribed dose without over-dosage. The analysis for dDVH showed that the dose distribution in the target volume calculated in the single isocenter technique is more homogeneous than the SSD technique. Wilcoxon test showed that the two treatment plans had the same quality (<em>p</em> > 0.05). The difference between calculated and measured dose was within 2.4 ± 3.3% for absolute point dose and the percentage of points passing gamma criteria was on average 99.8 ± 0.2%. <strong></strong></p><p><strong>Conclusion:</strong> This method provides a quantitative evaluation and comparison of the two irradiation techniques for breast cancer and the consequences of the technical change on dose calculation.</p>
International Journal of Cancer Therapy and Oncology
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.19
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/357
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
cam 3u
"151003 2015 eng "
dc
Clinically evaluating directional dependence of 2D seven29 ion-chamber array with different IMRT plans
Kumar, Syam; Department of Radiation Oncology, Division of Radiation Physics Malabar Cancer Centre Thalassery, Kerala
Cheruparambil, Aswathi; Department of Physics, University of Calicut, Thenhippalam, Kerala
Parakkat Thokkayil, Anjana; Department of Physics, University of Calicut, Thenhippalam, Kerala
Gangadharan Padmini, Sitha; Department of Physics, University of Calicut, Thenhippalam, Kerala
Perumangat, Aparna; Department of Physics, University of Calicut, Thenhippalam, Kerala
Radiation Therapy, Medical Physics
IMRT; 2D Array; Octavius Phantom; Gamma Analysis
<p><strong>Purpose:</strong> This study aims to clinically evaluate the directional dependence of a 2D seven29 ion-chamber array with different intensity-modulated radiotherapy (IMRT) plans. <strong></strong></p><p><strong>Methods:</strong> Twenty-five patients who had already been treated with IMRT plans were selected for the study. Verification plans were created in an Eclipse treatment planning system (TPS) for each treatment plan. The verification plans were executed twice for each patient. The first IMRT plan used a true gantry angle (plan-related approach), and the second plan used a 0° gantry angle (field-related approach). Measurements were performed using a Varian Clinac 2100 iX linear accelerator. The fluence was measured for all the delivered plans and analyzed using Verisoft software. A comparison of the fluence was performed between IMRT with a static gantry (0° gantry angle) and real gantry angles. <strong></strong></p><p><strong>Results:</strong> The results indicate that the Gamma average was 98.8 % for IMRT with a 0° gantry angle and 96.616% for IMRT with a true gantry angle. Average percent difference of normalized doses for IMRT delivered with zero degree gantry angle and IMRT with actual gantry angles is 0.15 and 0.88 respectively. <strong></strong></p><p><strong>Conclusion:</strong> The ion chamber of the 2D array used in IMRT verification has angular dependence, reducing the verification accuracy when the 2D array is used for measuring the actual beams of the treatment plan.</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.8
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/357/3502
http://www.ijcto.org/index.php/IJCTO/article/download/357/3582
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/394
2016-07-16T10:06:47Z
IJCTO:CONF
cam 3u
"150915 2015 eng "
dc
A survey of paediatric CT radiation doses in two selected hospitals in Kampala, Uganda: a radiation safety concern
Kisembo, Harriet
<p><strong>Purpose: </strong>We describe radiation doses imparted to paediatric patients during Computerised (CT) scan examinations by estimation Weighted CT dose index (CTDIw) and Dose Length Product (DLP) and compare these doses with the International dose reference values.</p><p><strong>Methods:</strong> Demographic data and acquisition parameters of 257paediatric CT scans done using Multi-Slice CT (MSCT) and Dual Slice CT (DSCT) were collected from request forms and CT scan consoles. The values of CTDIw, CTDIvol and DLP were calculated using ImPACT (Imaging Performance and Assessment of Computed Tomography) dosimetry software for Philips MX-1800 scanner and GE Hispeed Dual scanner. Data was analysed using mean, range, 3<sup>rd</sup> quartile, as well as chi square.</p><p><strong>Results: </strong>The commonest indication was head injury with the majority patient aged 0-4 years and 10-14 years for MSCT and DSCT, respectively. There were significantly higher doses imparted by MSCT compared to DSCT on both the head CTDIw (mGy) (40 vs 22, p = 0.000), CTDIvol (mGy) (60 vs 7, p = 0.000), DLPmGy.cm (1022 vs 114, p = 0.000) and body CTDIw (mGy) (41 vs 18, p =0.000), CTDIvol (mGy) (27 vs 6 p-value=0.000) and DLP (782 vs 73 p-value=0.001) respectively. Paediatric 3rd quartile values for CTDIvol (mGy) (57.7 vs 31) 0-1 year, (74.5 vs 47) 4-7 years and DLP mGy.cm (1068 vs 333) 0-1 year and (1168 vs 374) 4-6 years respectively for MSCT were higher than the recommended international values. The calculated CTDIvol for the head were significantly higher than the values displayed on the console (p-value=0.000, 95%CI) for MSCT.</p><p><strong>Conclusion: </strong>The radiation dose values for CTDIw, CTDIvol and DLP for MSCT were significantly higher than those for DSCT and other countries which raise a radiation safety concern. Studies to establish the factors responsible for these high doses are recommended.</p>
International Journal of Cancer Therapy and Oncology
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.27
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/459
2016-07-16T06:23:57Z
IJCTO:ORIGINAL
cam 3u
"160206 2016 eng "
dc
Quality assurance for dynamic tumor tracking using the Vero4DRT system
Miura, Hideharu; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima
Ozawa, Shuichi; Department of Radiation Oncology, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima
Tsuda, Shintaro; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima
Hayata, Masahiro; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima
Yamada, Kiyoshi; Hiroshima High-Precision Radiotherapy Cancer Center, Hiroshima
Nagata, Yasushi; Department of Radiation Oncology, Institute of Biomedical & Health Science, Hiroshima University, Hiroshima
Medical Physics; Medical Dosimetry
Vero4DRT, Dynamic Tumor Tracking, Quality Assurance, 4D modeling
<p>Purpose: We perform quality assurance (QA) for indirect dynamic tumor tracking (DTT) using four-dimensional radiation therapy (the Vero4DRT™ system).</p><p>Methods: A single photon beam was set with a 40 × 40 mm<sup>2</sup> field size at a gantry angle of zero degrees and a low monitor unit setting of 200. Doses were measured using a 0.016 cm<sup>3</sup> ionization chamber inserted in a phantom under stationary, DTT, and non-DTT conditions for sinusoidal (peak-to-peak) amplitude [<em>A</em>] and breathing period [<em>T</em>] (20 mm, 2 s; 20 mm, 4 s; and 40 mm, 4 s). The stationary condition was measured for comparison. Dose profiles were measured using Gafchromic EBT3 films in the phantom under the same conditions.</p><p>Results: For chamber measurement, the relative doses were as follows: 0.99 with non-DTT and 1.00 with DTT at <em>A</em> = 20 mm and <em>T</em> = 2 s; 0.99 with non-DTT and 1.00 with DTT at <em>A</em> = 20 mm and <em>T</em> = 4 s; and 0.84 with non-DTT and 1.00 with DTT at <em>A</em> = 40 mm and <em>T </em>= 4 s. For film measurement, the spatial distances between the 90% dose of the dose profiles were as follows: 6.53 mm for non-DTT and 0.40 mm for DTT at <em>A</em> = 20 mm and <em>T</em> = 2 s; 6.33 mm for non-DTT and 0.15 mm for DTT at <em>A</em> = 20 mm and <em>T</em> = 4 s; and 10.61 mm for non-DTT and 0.17 mm with DTT at <em>A</em> = 40 mm and <em>T</em> = 4 s.</p><p>Conclusion: Our results showed high dosimetric and geometric accuracy for DTT using four-dimensional modeling and marked reduction of the blurring effects on dose distribution. We recommend the use of a QA procedure for DTT performed using the Vero4DRT™ system.</p>
International Journal of Cancer Therapy and Oncology
2016-03-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.12
International Journal of Cancer Therapy and Oncology; Vol 4, No 1 (2016): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/459/3965
http://www.ijcto.org/index.php/IJCTO/article/download/459/3970
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/513
2016-07-13T06:51:30Z
IJCTO:CASE
cam 3u
"160619 2016 eng "
dc
A case report of long term bevacizumab treatment in multiresistant ovarian cancer
Kargo, Anette; Department of Oncology, Hospital Lillebaelt, Vejle
Adimi, Parvin; Department of Oncology, Hospital Lillebaelt, Vejle
Steffensen, Karina Dahl; Department of Oncology, Hospital Lillebaelt, Vejle
Medical Oncology
Ovarian cancer, Bevacizumab
<p>Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic treatment. Anti-angiogenic treatments have a less toxic profile, and bevacizumab has shown improvement of progression free survival (PFS) in front-line trials. Bevacizumab is generally introduced in combination with chemotherapy; however this case report will describe the use of single-agent bevacizumab for more than five years (102 cycles) in a patient with relapse of advanced ovarian cancer.<strong></strong></p>
International Journal of Cancer Therapy and Oncology
2016-06-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.14
International Journal of Cancer Therapy and Oncology; Vol 4, No 2 (2016): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/513/4242
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/517
2016-09-18T08:59:14Z
IJCTO:ORIGINAL
cam 3u
"160805 2016 eng "
dc
Quantitative expression of the eukaryotic translation initiation factor 4E (eIF4E) in egyptian acute leukemia patients and its clinical significance
Hammam, Amira Ahmed; Department of Clinical and Chemical Pathology, Faculty of Medicine, Beni-Suef University
EL-Wakil, Mohamed Aly; Department of Clinical Oncology, Faculty of Medicine, Beni-Suef University
Mahmoud, Sarah; Department of Clinical and Chemical Pathology, Faculty of Medicine, Beni-Suef University
Medical Oncology, Hematology; molecular biology
eIf4E, AML, ALL, RTQ-PCR.
<p>Purpose: The eukaryotic translation initiation factor eIF4E is part of the eIF4F protein complex, which includes, in addition to eIF4E, eIF4G (a scaffolding protein) and eIF4A (an ATP-dependent RNA helicase). The eukaryotic translation initiation factor eIF4E is a potent oncogene elevated in many cancers including leukemias.</p><p>Methods: In this study, the expression level of eIF4E gene was analyzed in 20 normal healthy controls and 64 patients with de novo acute leukemia (33 Acute myeloid leukemia (AML) and 31 Acute lymphoblastic leukemia (ALL)) using a real-time quantitative reverse-transcriptase polymerase chain reaction (RTQ-PCR) to investigate a possible relation, association or correlation with the clinical features at diagnosis, such as age, gender, lineage, hemoglobin (Hb), total leucocytic count (TLC), platelet count and bone marrow (BM) blast cell infiltration as well as its effect on patients̒ outcome.</p><p>Results: Comparing AML and ALL patients as regards their clinical and laboratory data showed no statistical significance for TLC and hemoglobin (<em>p</em>-0.838 and 0.920) respectively, but was of statistically significant difference for platelets (<em>p </em>= 0.022) and bone marrow blasts percentage (<em>p </em>= 0.007). Comparison between the 2 groups as regards eIF4E level was of no statistically significant difference, <em>p</em>-value being (<em>p </em>= 0.257) but there was statistically significant difference between eIF4E expression level in AML/Control (<em>p </em>= 0.002), ALL/Controls (<em>p </em>= 0.025). Also analysis of overall survival (OS) time and disease free survival (DFS) in each group and its relation to eIF4E gene showed no statistical significance (<em>p </em>= 0.843 and 0.310) respectively in AML group and (<em>p</em> = 0.971 and no <em>p</em>-value for DFS in ALL as all cases remained alive except for one case while 3 cases were relapsed) in ALL group. Correlation studies showed no significant correlation between AML group and eIF4E gene level as regards age, TLC, hemoglobin and platelets (r = -0.064, <em>p </em>= 0.722; r = 0.062, <em>p</em> = 0.732; r = 0.068, <em>p</em> = 0.712; and r = -0.318, <em>p </em>= 0.071) respectively, while there was significant positive moderate correlation on comparing bone marrow blast% and eIF4E gene level (r = 0.545 and <em>p = 0.001</em>). There was no significant correlation between ALL group and Eif4e gene level as regards age, TLC, hemoglobin, platelets and bone marrow blasts% (r = -0.214, <em>p</em> = 0.248; r = 0.175, <em>p</em> = 0.347; r = -0.056, <em>p</em> = 0.766; r = -0.072, <em>p</em> = 0.700; and r = -0.0004, <em>p</em> = 0.983) respectively.</p><p>Conclusion: eIF4E was found to be elevated in acute leukemia patients in relation to normal controls and its levels were more in myeloid than lymphoid leukemia and positively correlated with the blast percentage in AML thus its level may contribute to leukemogenesis. eIF4E levels and translation initiation may be an attractive target for anticancer therapeutics.</p>
International Journal of Cancer Therapy and Oncology
None
2016-07-13 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.12
International Journal of Cancer Therapy and Oncology; Vol 4, No 3 (2016): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/550
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
cam 3u
"161228 2016 eng "
dc
Guanylyl Cyclase C as a tumor marker for detection of circulating tumor cells in the peripheral blood of colorectal cancer patients
Moghbeli, Meysam; Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
Chavoshi, Somaye; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Tavallaie, Mahmud; Human Genetics Research Center, Baqiatallah University of Medical Sciences, Tehran, Iran
Dadkhah, Ezzat; School of Systems Biology, George Mason University, Manassass, VA, USA
Raeissosadati, Reza; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Farshchian, Moein; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran
Towliat Kashani, Mohsen; Department of Surgery, Baqiatallah University of Medical Sciences, Tehran, Iran
Ganji, Azita; Department of Internal Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Jangjoo, Ali; Department of Surgery, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Bromand Noughabi, Samaneh; Department of Pathology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
Abbaszadegan, Mohammad Reza; Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Guanylyl cyclase C, Colorectal cancer, Peripheral blood, Tumor marker, Circulating tumor cells
<p>Purpose: Guanylyl cyclase C (GCC) is one of the most frequent tumor markers to detect the circulating tumor cells (CTCs) in peripheral blood of colorectal cancer (CRC) patients. It has been proposed as a new marker for the molecular staging of CRC. The level of GCC mRNA expression in peripheral blood of CRC patients was evaluated to explore its probable correlations with the clinicopathological features.</p><p>Methods: Relative quantitative expression analysis of GCC mRNA was performed on 80 blood samples (40 patients and 40 normal) using the Real-time RT-PCR.</p><p>Results: GCC mRNA expression was detected in 70% of the CRC blood samples. The level of GCC mRNA expression in peripheral blood of patients was significantly higher than that in the normal cases (p = 0.031). Moreover, there was a significant correlation between the GCC copy number and advanced stages of tumor (p = 0.041). Furthermore, we have observed a significant correlation between tumor sizes and GCC copy numbers (p = 0.050).</p><p>Conclusion: GCC can be a useful marker not only for detection of CTCs in CRC blood samples, but also for the molecular staging of colorectal cancer. <strong></strong></p>
International Journal of Cancer Therapy and Oncology
2016-10-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.11
International Journal of Cancer Therapy and Oncology; Vol 4, No 4 (2016): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/550/4452
http://www.ijcto.org/index.php/IJCTO/article/download/550/4453
http://www.ijcto.org/index.php/IJCTO/article/download/550/4454
http://www.ijcto.org/index.php/IJCTO/article/download/550/4455
http://www.ijcto.org/index.php/IJCTO/article/download/550/4456
http://www.ijcto.org/index.php/IJCTO/article/download/550/4457
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/635
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
cam 3u
"170810 2017 eng "
dc
Preferred treatment position between supine and prone for pelvic radiation therapy; quantification of the intrafractional body motion component by 3D surface imaging system
Zhao, Hui; Department of Radiation Oncology, University of Utah, Salt Lake City
Sarkar, Vikren; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Huang, Long; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Wang, Brian; Department of Radiation Oncology, University of Louisville, Louisville, USA
Rassiah-Szegedi, Prema; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Huang, Y. Jessica; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Szegedi, Martin; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
Gonzalez, Victor; University of Arizona Cancer Center, Tucson, Arizona, USA
Salter, Bill; Department of Radiation Oncology, University of Utah, Salt Lake City, USA
AlignRT, Intrafractional motion, Supine, Prone
<p><strong>Purpose:</strong> We investigated the preferred treatment position between supine and prone during pelvic radiation treatment using real time tracking data from AlignRT. Our findings will provide valuable information regarding the role of intrafractional body motion in answering the question of prone versus supine position for pelvis radiation. <strong></strong></p><p><strong>Methods:</strong> Ten patients receiving pelvic radiation were enrolled in this study. For each patient, two simulation helical CT scans were performed, one in supine and one in prone position. Body surface contours were automatically generated and then exported to the AlignRT system as reference images. AlignRT continuous patient body motion tracking (1.5 to 2 minutes) was performed for both positions for each patient once per week for five weeks. The equivalent patient body motion along three principle directions was calculated from the six degree of freedom real time patient displacements data. The maximum and the standard deviation (STD) of equivalent patient body motion were calculated, so as the average of maximum and STD of equivalent patient motion over five fractions. These were then compared between supine and prone orientations. <strong></strong></p><p><strong>Results:</strong> A correlation was observed between the intrafractional body motion and large BMI. For overweight/obese patients, the intrafractional body motion was smaller for the supine position in both vertical and longitudinal directions. For normal range BMI patients, we observed no clear advantage for either supine or prone position in both vertical and longitudinal directions. In lateral direction, the intrafractional motion did not have statistically difference between two positions. <strong></strong></p><p><strong>Conclusion:</strong> Our study shows that the amount of intrafractional body motion between supine and prone orientation is correlated with patient BMI. Overweight/obese patients experienced significantly less overall body motion in supine orientation. The preferred treatment position for normal BMI patients was seen to be individually variable.</p>
International Journal of Cancer Therapy and Oncology
2017-02-12 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.8
International Journal of Cancer Therapy and Oncology; Vol 5, No 1 (2017): January - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/738
2018-06-24T14:49:11Z
IJCTO:CASE
cam 3u
"180624 2018 eng "
dc
Intraocular breast metastasis: a case report
Garcia, Stephen Joseph; University of the Philippines- Philippine General Hospital
Paraan, Ronald Gonin; University of the Philippines- Philippine General Hospital
Ngelangel, Corazon; University of the Philippines- Philippine General Hospital
Medical Oncology
Intraocular mass, Metastatic breast cancer, Breast cancer
metastatic breast cancer
Breast cancer accounts for approximately 16% of all newly diagnosed cancer cases in the Philippines. Among these, 5% are metastatic at presentation. The eye is an atypical location for metastatic spread from breast cancer. A 53-year-old Filipino female presented with a breast mass with concomitant blurring of vision. Further work-up showed invasive ductal carcinoma with bone metastasis. Ophthalmologic examination showed an intraocular mass with associated exudation and retinal detachment, which explained the blurring of vision. Chemotherapy for the breast cancer subsequently reduced tumor mass of both breast and eye, with progression of both after first line chemotherapy. Clinicians should be wary of patients presenting with a known primary mass lesion with associated ophthalmologic complaints. The possibility of metastatic disease in these patients should warrant ophthalmologic screening to possibly prevent the deterioration of the quality of life of these patients.
International Journal of Cancer Therapy and Oncology
2018-06-24 08:42:41
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.61.5
International Journal of Cancer Therapy and Oncology; Vol 6, No 1 (2018): January - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/26
2014-03-18T15:53:15Z
IJCTO:ORIGINAL
cam 3u
"131114 2013 eng "
dc
Radiation exposure for coronary artery calcium score at prospective 320 row multi-detector computed tomography
Khosa, Faisal; Emory University Hospital
Khan, Atif; Beth Israel Deaconess Medical Center, Harvard University
Shuaib, Waqas; Emory University Hospital
Clouse, Melvin; Beth Israel Deaconess Medical Center, Harvard University
Budoff, Matthew; Los Angeles Biomedical Research Institute
Blankstein, Ron; Brigham and Women's Hospital Harvard Medical School
Nasir, Khurram; Yale University School of Medicine
Cardiovascular Imaging
Calcium Score; Coronary Artery; MDCT; Radiation
Coronary Calcium Score
<p><strong>Purpose:</strong></p><p>To date there is extensive data on the radiation dose for assessing coronary artery calcium scores (CACS) with 4-64 row multidetector MDCT. However with the advent of 320 row MDCT, the entire heart can be imaged in one beat and thus potentially reduce the radiation dose. The aim of this study was to evaluate radiation dose for CACS on low-dose prospective EKG-triggered 320 row MDCT.</p><p><strong>Materials and Methods</strong>: Informed consent for this retrospective HIPAA-compliant study was waived and approved by our institution’s institutional review board IRB. One hundred and sixty eight consecutive patients (Male 133 (79%): female 35 (21%), mean body mass index BMI 29±5 and mean heart rate 58± bpm) underwent coronary calcium scoring with prospective gating. The scan parameters were 300 mA, 120 kVp, volume scan length (VSL) 160 mm, gantry rotation 0.350 msec and 320 x 0.5 mm detectors at 320 MDCT. Beta blockers were given to patients in a case heart rate HR > 65 bpm. The effective dose (ED) estimates were calculated for all patients from the dose length product and the conversion factor k (0.014 mSv/mGy/cm) as recommended by current guidelines.</p><p><strong>Results: </strong>The mean SD radiation was 1.89±0.79 mSv. Overall the range varied from 0.28-2.48 mSv. The radiation was significantly less in females as compared to males (2.02±0.73 vs. 1.41±0.87, p<0.0001). No differences were noted whether HR was <60 vs. >=60 bpm (1.87±0.79 vs. 1.77±0.84 mSv, p=0.45). On the other hand a higher radiation was noted among obese individuals as compared to those with BMI<30 (1.84±0.82 vs. 1.91±0.80 mSv, p=0.62).</p><p><strong>Conclusion</strong>: Radiation dose obtained from 320-MDCT is similar to those obtained with 4-64 row MDCT. Further studies are needed to assess the feasibility of further lowering the tube current and tube voltage.</p><p>------------------------------------------------</p><p><strong>Cite this article as:</strong><br />Khosa F, Khan A, Shuaib W, Clouse M, Budoff M, Blankstein R, Nasir K. Radiation exposure for coronary artery calcium score at prospective 320 row multi-detector computed tomography. <em>Int J Cancer Ther Oncol</em> 2013; <strong>1</strong>(2):01023.</p><p><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0102.3" target="_self">http://dx.doi.org/10.14319/ijcto.0102.3</a><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2013-12-04 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Khosa
International Journal of Cancer Therapy and Oncology; Vol 1, No 2 (2013): November - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/26/179
http://www.ijcto.org/index.php/IJCTO/article/download/26/180
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/35
2014-04-12T11:23:46Z
IJCTO:CASE
cam 3u
"140112 2014 eng "
dc
Atypical presentation of primary renal squamous cell cancer: a case report
Pahwa, Mrinal; Sir Ganga Ram Hospital, New Delhi
Pahwa, Archna Rautela; Lady Hardinge Medical college, New Delhi
Girotra, Mohit; University of Arkansas for Medical Sciences, Little Rock, Arkansas
Chawla, Arun; Southside Kidney Specialist, Richmond, Virginia
Squamous cell cancer; Urothelial malignancy; Phenacetin; Smoking; Squamous metaplasia
<p>Renal squamous cell cancer is one of the rare primary urothelial tumors with only a handful of cases reported in literature. Because of high grade, advanced and late presentation, they herald a grave prognosis. They are frequently associated with calculus disease, smoking, phenacetin consumption and foci of squamous metaplasia due to chronic irritation. Nephroureterectomy is the treatment of choice for such tumors. We hereby present a case of 59 year old female who presented with squamous cell cancer of renal pelvis. The case presented here is different from what has already been reported in literature, as the patient had no antecedent risk factors for renal squamous cell carcinoma.</p><p>-------------------------------------------------</p><p><strong>Cite this article as</strong>: Pahwa M, Pahwa AR, Girotra M, Chawla A. Atypical presentation of primary renal squamous cell cancer: a case report. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):02015.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.5" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.5</a></p>
International Journal of Cancer Therapy and Oncology
2014-02-23 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Pahwa
International Journal of Cancer Therapy and Oncology; Vol 2, No 1 (2014): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/35/337
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/100
2014-05-14T17:01:16Z
IJCTO:CONF
cam 3u
"140408 2014 eng "
dc
Effect of interfractional shoulder motion on low neck nodal targets for patients treated using volume modulated arc therapy (VMAT)
Casey, Kevin; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang, Pei-Fong; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tung, Samuel; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rosenthal, David; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Medical Physics
<p><strong>Purpose: </strong>To quantify the dosimetric impact of interfractional shoulder motion on targets in the low neck for head and neck patients treated with volume modulated arc therapy (VMAT).</p><p><strong>Methods</strong>: Three patients with head and neck cancer were selected. All three required treatment to nodal regions in the low neck in addition to the primary tumor site. The patients were immobilized during simulation and treatment with a custom thermoplastic mask covering the head and shoulders. One VMAT plan was created for each patient utilizing two full 360° arcs and a second plan was created consisting of two superior VMAT arcs matched to an inferior static AP supraclavicular field. A CT-on-rails alignment verification was performed weekly during each patient’s treatment course. The weekly CT images were registered to the simulation CT and the target contours were deformed and applied to the weekly CT. The two VMAT plans were copied to the weekly CT datasets and recalculated to obtain the dose to the deformed low neck contours.</p><p><strong>Results: </strong>The average observed shoulder position shift in any single dimension relative to simulation was 2.5 mm. The maximum shoulder shift observed in a single dimension was 25.7 mm. Low neck target mean doses, normalized to simulation and averaged across all weekly recalculations were 0.996, 0.991, and 1.033 (Full VMAT plan) and 0.986, 0.995, and 0.990 (Half-Beam VMAT plan) for the three patients, respectively. The maximum observed deviation in target mean dose for any individual weekly recalculation was 6.5%, occurring with the Full VMAT plan for Patient 3.</p><p><strong>Conclusion</strong>: Interfractional variation in dose to low neck nodal regions was quantified for three head and neck patients treated with VMAT. Mean dose was 3.3% higher than planned for one patient using a Full VMAT plan. A Half-Beam technique is likely a safer choice when treating the supraclavicular region with VMAT.</p><p>-------------------------------------------</p><p><strong>Cite this article as:</strong> Casey K, Wang P, Tung S, Rosenthal D. Effect of interfractional shoulder motion on low neck nodal targets for patients treated using volume modulated arc therapy (VMAT). Int J Cancer Ther Oncol 2014; <strong>2</strong>(2):020218. <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0202.18"><strong>10.14319/ijcto.0202.18</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Casey
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/115
2014-05-14T17:01:17Z
IJCTO:CONF
cam 3u
"140409 2014 eng "
dc
A plan quality classifier derived with overlap-wall-histogram of hollow organs for automatic IMRT plan quality control of prostate cancer cases
Song, Ting; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Tian, Zhen; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Jia, Xun; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Zhou, Linghong; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Jiang, Steve; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Gu, Xuejun; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>We developed a plan quality classification model to assess IMRT plan quality of prostate cancer patients for automatic plan quality control. </p><p><strong>Methods</strong>: For hollow organs such as rectum and bladder, dose-wall-histogram (DWH) was used to evaluate OAR dose sparing in our institution. Correspondingly, we proposed a new descriptor called overlap-wall-histogram (OWH) to describe the complex spatial relationship between PTV and a hollow organ. Two metrics calculated from the OWH and DWH are introduced to quantitatively evaluate the difficulty of patient geometry for planning and plan quality in terms of OAR sparing, respectively. A linear correlation between these two metrics was observed after plotting plan quality metric as a function of geometry difficulty metric studied from a database of prostate cases treated in our institution with acceptable plan quality. Thus, a fitting line was built acting as the boundary of high quality and poor quality plans. A query plan falling above the boundary is assessed as high quality, vice versa poor quality. </p><p><strong>Results: </strong>15 prostate IMRT plans were used to test our model. One was identified as poor quality and the others were common-level. After re-planning all plans, the dose constraints for bladder wall W75 (percentage of wall receiving more than 75Gy), W<sub>70</sub>, W<sub>65</sub> and W<sub>60</sub> can be reduced by 3.34%, 3%, 6.99%, 6.54% for that poor quality plan and 1.11%, 0.95%, 1.45% and 1.81% averagely for the common-level quality group, without sacrificing PTV coverage and rectum dose sparing. </p><p><strong>Conclusion</strong>: An effective model was built to provide automatic IMRT plan quality control by evaluating hollow OAR dose sparing for prostate cancer patients. Furthermore, for the query plan with poor quality, potential improvement of plan quality can be estimated and a good reference plan with similar or harder geometry can be automatically chosen from our database to help guide the re-planning if necessary.</p><p>---------------------------</p><p><strong>Cite this article as</strong>: Song T, Tian Z, Jia X, Zhou L, Jiang SB, Gu X. A plan quality classifier derived with overlap-wall-histogram of hollow organs for automatic IMRT plan quality control of prostate cancer cases. Int J Cancer Ther Oncol 2014; 2(2):020241. <strong>DOI: 10.14319/ijcto.0202.41</strong><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Song
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/81
2014-05-14T17:01:18Z
IJCTO:TECHNICAL
cam 3u
"140411 2014 eng "
dc
Public exposure from I-131 hospitalized isolated patients in NIMRA Jamshoro Pakistan
Memon, Sajjad Ahmed; Nuclear Institute of Medicine And Radiotherapy (NIMRA), Jamshoro Pakistan.
Laghari, Naeem Ahmed; Nuclear Institute of Medicine and Radiotherapy (NIMRA), Jamshoro Pakistan.
Qureshi, Sadaf Tabasum; Institute of Plant Sciences, University of Sindh, Jamshoro Pakistan.
Ahmad, Asrar; Nuclear Institute of Medicine and Radiotherapy (NIMRA), Jamshoro Pakistan.
Khan, Amin Ali; Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar Pakistan.
Hussain, Muhammad Mubashar; Nuclear Institute of Medicine and Radiotherapy (NIMRA), Jamshoro Pakistan.
Unsealed Source; Isolation Room; ALARA; Radioiodine; Exposure Rate
<p><strong>Purpose/</strong> <strong>Background: </strong>To treat the cancerous tissues the unsealed radioisotopes are being in clinical practice since 7 decades. From these unsealed sources, I-131 is the choice of treatment for the treating thyroid cancers. Orally administered I-131 patients are to be kept isolated in hospital for some period until captured activity in the body reaches to national and international limits for the avoidance of unacceptably high radiation exposures to patients' family members and the general public to keep ALARA (as low as reasonably achievable) principal in mind. The main rationale of this study was to calculate the exposure/dose of the general public. <strong></strong></p><p><strong>Material and</strong> <strong>Methods</strong>: This work presents the exposure rate and dose to the general public in the corridor and the non-radioactive patients admitted in adjacent room from I-131 administered isolated patients treated at NIMRA (Nuclear Institute of Medicine and Radiotherapy) Jamshoro Pakistan. In this study exposure from 23 thyroid cancer patients treated with different activities of I-131 (50 to 200 mCi) from January 2011 to December 2012 were included. <strong></strong></p><p><strong>Results: </strong>The average exposure rate in the corridor was about 5.17 µSv/hr (2.14 µSv/hr to 8.15 µSv/hr) and the cumulative dose to nonradioactive patients residing in an adjacent room was 0.647 mSv (0.192 mSv to 1.664 mSv). <strong></strong></p><p><strong>Conclusion</strong>: This study concludes that the exposure rate to the general public especially the admitted non-radioactive patient in the adjacent room is almost within the limits of 1 mSv as specified in national and international standards.</p><p>-----------------------------------------</p><p><strong>Cite this article as</strong>: Memon SA, Laghari NA, Qureshi ST, Ahmad A, Khan AA, Hussain MM. Public exposure from I-131 hospitalized isolated patients in NIMRA Jamshoro Pakistan. Int J Cancer Ther Oncol 2014; 2(2):020214. <strong>DOI: </strong><a href="http://dx.doi.org/10.14319/ijcto.0202.14" target="_blank"><strong>10.14319/ijcto.0202.14</strong></a></p>
International Journal of Cancer Therapy and Oncology
NIL
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Memon
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/55
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
cam 3u
"140615 2014 eng "
dc
Presentation and outcome of twenty patients with synchronous stage IV rectal carcinoma
Aboziada, Mohamed A; Department of Radiation Oncology, South Egypt Cancer Institute, University of Assiut, Egypt.
Attia, Alia M; Department of Radiation Oncology, South Egypt Cancer Institute, University of Assiut, Egypt.
Alhamad, Abelaziz A; Department of Oncology, Prince Sultan Military Medical City, Riyadh Saudi Arabia.
Rectum; Chemo-radiation; Metastases
<p><strong>Purpose: </strong>Palliative treatment techniques for advanced stage rectal cancer should be designed according to the patients’ major symptoms. Combined chemo-radiation therapy is effective choice for symptomatic patients with good performance status. In this study, we reviewed our patients' stage IV rectal carcinoma in regard to most common presentation, outcome and possible prognostic features.</p><p><strong>Methods</strong> Medical chart of twenty patients who were diagnosed with stage IV rectal carcinoma, were reviewed based on the hospital database information, which included images, radiotherapy charts, and their follow up notes. <strong></strong></p><p><strong>Results: </strong>All patients were young with age less than 40 years. Bleeding per rectum, pain, and symptoms of obstruction were the most common presentation. Seven patients had solitary lesion and 13 patients had multiple lesions. Eleven patients with multiple metastases were treated with palliative chemotherapy and radiotherapy. Patients who had solitary metastases to liver had a median survival time of 49 months versus 13.5 months for other patients (p = 0.001). <strong></strong></p><p><strong>Conclusion</strong>: Patients who presented with solitary liver metastases could be treated with a course of neoadjuvant chemo-radiotherapy similar to the curative one.</p><p>-----------------------------------</p><p align="left"><strong>Cite this article as:</strong> Aboziada MA, Attia AM, Alhamad AA. Presentation and outcome of twenty patients with synchronous stage IV rectal carcinoma. <em>Int J Cancer Ther Oncol </em>2014; <strong>2</strong>(3):020313. <strong>DOI</strong>:<a href="http://dx.doi.org/10.14319/ijcto.0203.13" target="_blank"><strong>10.14319/ijcto.0203.13</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Aboziada
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/55/484
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/157
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
cam 3u
"140929 2014 eng "
dc
Quality control test for electronic portal imaging device using QC-3 phantom with PIPSpro
Rout, Birendra Kumar; Department of Radiation Physics, Aditya Birla Memorial Hospital, Pune, India
Department of Physics, Jawaharlal Nehru Technological University, Hyderabad, India
Shekar, Mukka Chandra; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad, India
Kumar, Alok; Department of Radiation Physics, Mahavir Cancer Sansthan, Patna, India
Ramesh, Kondapalli Kesava Durga; Department of Radiation Oncology, Navodaya Cancer Institute & Research Center, Bhopal, India
Medical Physics
EPID; QC-3 Phantom; PIPSpro; Spatial Resolution; CNR; Noise
Radiation Physics
<p><strong>Purpose</strong>:A Quality control (QC) test suitable for routinely daily use has been established for electronic portal imaging device (EPID) using PIPSpro software version 4.4 (Standard Imaging, Middleton, WI). It provides an objective and quantitative test for tolerable image quality on the basis of the high contrast spatial resolution, the contrast-to-noise ratio (CNR) and noise.</p><p><strong>Methods:</strong> The test uses a QC-3 phantom consisting of five sets of high contrast rectangular bar patterns with spatial frequeinces of 0.10, 0.20, 0.25, 0.43 and 0.75 lp/mm using 6MV and 15MV photon energy for accquiring high quality images. A “base line” value for the relative square wave modulation transfer function (RMTF), CNR and Noise data was obtained during a one week calibration period and one month test period.</p><p><strong>Results</strong>: Subsequent measurements shows significant deviations from baseline values, resulting in warning messages “potential problems in system performance”. The QC test uses high contrast spatial resolution and CNR for the system with acceptable performance.<strong> </strong></p><p><strong>Conclusion:</strong> The method provides an automatic, objective, and sensitive measure of the system's imaging performance. This is a useful implementation during acceptance testing, commissioning, and routine quality control.</p>
International Journal of Cancer Therapy and Oncology
NIL
2014-12-22 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0204.9
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/182
2015-03-29T11:59:33Z
IJCTO:REVIEW
cam 3u
"141129 2014 eng "
dc
Monitoring methods for skin dose in interventional radiology
Chaikh, Abdulhamid; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital, France
Gaudu, Arnaud; Department of Radioprotection, Grenoble University Hospital, France
Balosso, Jacques; Department of Radiation Oncology and Medical Physics, Grenoble University Hospital, France
Department of Radiation Oncology and Medical Physics, University Joseph Fourier, Grenoble, France
Radiology; Medical Physics
Skin Dose; Interventional Radiology; Dosimeters; Fluoroscopy; Radiography
<p>Interventional radiology makes an increasing use of X-ray for diagnostic and therapeutic procedures. The dose received by the patient sometime exceeds the threshold value of deterministic effects, and this requires monitoring of the dose delivered to the patients. Delivered dose could be assessed through either direct or indirect methods. The direct methods use dosimeters that are placed on the skin during the procedure, whereas, the indirect methods are based on measured quantities derived from the equipment itself. Each method has its own limitations; however, the main concern is the ability to measure the dose more accurately due to complexity of the anatomical structures of the patient and the variable course of each procedure. This review article summarizes the principle and main advantages and disadvantages of each method. A comparison of the performances of each method for interventional fluoroscopy and radiography in its ability to monitor the patient’s skin dose is provided. </p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/0301.1
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/205
2015-03-29T11:59:33Z
IJCTO:TECHNICAL
cam 3u
"150117 2015 eng "
dc
Impact of head immobilization position on dose distribution in patients of brainstem glioma
Sharma, Seema; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Chaudhari, Pritee; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Biswas, Ahitagni; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Manigandan, Durai; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Shukla, Peeyush; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Subramani, Vellaiyan; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Chander, Subhash; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Julka, Pramod; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Rath, Goura; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Brainstem Glioma; Immobilization Position; Dose distribution; Calculation Algorithm
<p><strong>Purpose:</strong> The purpose of this study is to investigate the impact of patient position (supine and prone) on conventional bilateral field, three dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) treatment plans in patients of brainstem glioma with a view to exploring the possibility of avoiding beam entry through immobilization accessories. <strong></strong></p><p><strong>Methods:</strong> Five patients of brainstem glioma were immobilized and scanned in supine and prone positions with a combination of head rest and thermoplastic cast. Each patient was planned with three techniques: (i) 2-fields bilateral (ii) 3-fields 3DCRT, and (iii) 5-fields IMRT. Plan quality was analyzed in terms of planning target volume (PTV) coverage and dose to various critical organs at risk (OAR) for both the supine and prone treatment positions. <strong></strong></p><p><strong>Results:</strong> In case of bilateral fields (parallel opposed) planning, the PTV coverage and dose to the OAR were almost similar for both the supine and prone positions. In 3DCRT plan, although the PTV coverage and dose to critical structures were comparable for both the supine and prone position, dose to cochlea was lower for the prone position plan. A modest decrease in maximum dose to optic nerves and mean dose to temporal lobes were also observed for the prone position plan. In IMRT plans, the PTV coverage and homogeneity were comparable in both the supine and prone positions. Reduction in average maximum and mean doses to all OARs with functional subunit (FSU) in series and parallel respectively was observed in the IMRT plan for prone position when compared to the supine position.</p><p><strong>Conclusion:</strong> Supine and prone positions resulted in almost similar dose distribution in all the three techniques applied. At some instances, the prone position showed better normal tissues sparing when compared to supine. Moreover, prone position is more likely to avoid attenuation due to immobilization devices and uncertainty in dose calculation under large inhomogeneities.</p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/0301.16
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/328
2015-03-29T11:59:31Z
IJCTO:NEWS
cam 3u
"150329 2015 eng "
dc
Novel Approaches to the Treatment of Cancer in London UK
Black, Judith
<p><strong>An intensive and in-depth two-day conference providing an advanced level update</strong><br /><br />KEY TOPICS TO BE COVERED:</p><ul><li>New paradigms for targeted therapies</li><li>New anti-cancer agents ~ industry viewpoint</li><li>Novel approaches to the treatment of breast cancer, melanoma and pancreatic cancer</li><li>Drug development and precision radiotherapy</li><li>European drug development initiatives</li><li>Market access to novel cancer drugs</li><li>Regulatory issues in marketing authorisation of anti-cancer products</li><li>Gene and cell therapies and trial endpoints</li><li>Developing cancer vaccines</li></ul><p><strong style="color: #333333; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 11.1999998092651px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff;"><span style="color: #0000ff;"><span style="color: #000000;"><span style="color: #ff0000;"><a style="text-decoration: underline; color: #006699;" href="http://www.ijcto.org/index.php/IJCTO/pages/view/novelapproach" target="_blank"><span style="color: #ff0000;">CLICK HERE</span></a></span><span class="Apple-converted-space"> </span>for more information</span></span></strong></p><p> </p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
http://www.ijcto.org/index.php/IJCTO/article/view/manageforum2015
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/313
2015-08-15T11:54:26Z
IJCTO:ORIGINAL
cam 3u
"150507 2015 eng "
dc
CBCT-based dosimetric verification and alternate planning techniques to reduce the normal tissue dose in SBRT of lung patients
Narayanasamy, Ganesh; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Feddock, Jonathan; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Gleason, John; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
McGarry, Ronald; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Molloy, Janelle; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
Medical Physics
SBRT; Dose Verification; Dose Optimization; Margin Reduction; Prescription Isodose
Dosimetric Verification
<p><strong>Purpose:</strong> Confirmation of treatment delivery accuracy in stereotactic body radiotherapy (SBRT) of lung tumors suggests the possibility of treatment margin, or aperture reduction. In this investigation, the dose delivery to lung tumors using SBRT techniques was verified, and the feasibility of normal tissue sparing via aperture reduction or altered prescription isodose line was assessed. <strong></strong></p><p><strong>Methods:</strong> Planned and delivered doses to the gross tumor volume (GTV) and planning target volume (PTV) were compared for 10 patients using planning CT and conebeam CT image. Potential for reduction in normal tissue dose were assessed using 2 alternate treatment plans – reduced PTVs and alternate prescription techniques. Plans were assessed using conformity index, homogeneity index and the ratio of 50% / 100% isodose volumes (R<sub>50%</sub>). <strong></strong></p><p><strong>Results:</strong> The planned and delivered mean doses were consistent to within 4%. However, the mean dose delivered to the GTV exceeded the prescription dose (Rx) by 19% and is consistent with our planning technique of prescribing to the 80% isodose line. When reducing treatment margins and retaining a constant dose-volume constraint, block margins had to be increased which produced a constant effective field aperture outside of the GTV. Prescription to a lower isodose line using stereotactic-like planning techniques yielded the only method by which the volume of the prescription isodose could be affected, although this yielded increases in normal tissue dose due to the increased monitor units required. Conversely, conventional prescription techniques using wider field apertures were effective in reducing absolute values of normal tissue dose. Although dose conformity was similar across different prescription isodose lines, homogeneity index and R<sub>50%</sub> values were significantly different in the 60%-70% prescription isodose line plans than the 80%, 90% prescription plans.</p><p><strong>Conclusion:</strong> Traditional margin reduction techniques did not affect a reduction in the volume of normal tissue irradiated to the prescribed dose. Prescribing to low isodose lines yields reduced volumes of the prescribed dose, but at the expense of normal tissue dose. </p>
International Journal of Cancer Therapy and Oncology
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.18
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/349
2016-01-03T12:17:49Z
IJCTO:TECHNICAL
cam 3u
"150717 2015 eng "
dc
Quality assurance of simultaneous treatment of two targets in pelvic region planned with single isocenter using three dimensional conformal radiotherapy (3DCRT) technique
Putha, Suman Kumar; Department of Radiotherapy & Oncology, Kasturba Medical College Hospital, Mangalore
Srinivas, Challapalli; Department of Radiotherapy & Oncology, Kasturba Medical College Hospital, Mangalore
Bejadi Manjunath, Vadhiraja; Department Radiation Oncology, Manipal Hospital, Bangalore
Elavunkal Sukumaran, Arun Kumar; Department of Radiotherapy & Oncology, Kasturba Medical College Hospital, Mangalore
Chinthamani, Sridhar; Department of Radiation Oncology, Father Muller Oncology Center, Mangalore
Saxena, Prakash; Department of Radiotherapy & Oncology, Kasturba Medical College Hospital, Mangalore
Banerjee, Sourjya; Department of Radiotherapy & Oncology, Kasturba Medical College Hospital, Mangalore
Pai Kasturi, Dinesh; Department of Radiotherapy & Oncology, Kasturba Medical College Hospital, Mangalore
Medical Physics
Quality Assurance; Two Targets; Single Isocenter; Conformal Radiotherapy
Quality Assurance
<p><strong>Purpose</strong>: The purpose of this study was to conduct quality assurance of a three dimensional conformal radiotherapy (3DCRT) of two targets in pelvis region planned with single isocenter technique. <strong></strong></p><p><strong>Methods:</strong> A treatment plan was generated with two identical water phantoms with ionization chamber (IC) sleeves (IC-1 & IC-2), simulated as if targets are in pelvis region, simultaneously irradiated with single isocenter technique with a dose prescription of 300 cGy for point dose verification. A two dimensional ion chamber array detector was used for fluence verification.</p><p><strong>Results:</strong> Calculated minimum, mean and maximum dose (in cGy) for IC-1 & IC-2 were 295, 303 and 307 as per dose volume histogram. The global dose maximum was found to be 307.4 cGy. Measured point doses to both lesions were within ±2.5% of the computed dose. A pass percentage of 97% was obtained with the set of criteria 3 mm distance to agreement and 3% dose difference for fluence verification.</p><p><strong>Conclusion:</strong> Treatment execution of two targets simultaneously with single isocenter can reduce positional errors and delivery time.</p>
International Journal of Cancer Therapy and Oncology
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.15
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/349/3580
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/346
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
cam 3u
"150920 2015 eng "
dc
Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy
Kim, Hyun-Jun; Department of Obstetrics and Gynecology, Konkuk University College of Medicine, Chungju
Kim, Kyoung Ha; Department of Internal Medicine, Soonchunghyang University College of Medicine, Seoul
Kim, Seung Tae; Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul
Park, Se Hoon; Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul
Medical Oncology, Gastroenterology
Gastric Cancer; Chemotherapy; Young Age
<p><strong>Purpose:</strong> Despite conflicting data regarding survival after curative surgery, little is known about the prognosis of metastatic gastric cancer (MGC) in young adults. The current study was performed to determine whether younger age is an independent prognostic factor among MGC patients receiving first-line chemotherapy and to evaluate how age relates to other known prognostic parameters. <strong></strong></p><p><strong>Methods:</strong> The records of 1843 MGC patients who were consecutively treated with first-line combination chemotherapy at Samsung Medical Center (Seoul, Korea) between 2000 and 2007, including 570 patients aged 45 years or younger, were retrieved from a prospective cancer chemotherapy database.</p><p><strong>Results:</strong> In the younger group, there were significantly more bone metastases, ascites, poor performance status, low albumin, elevated alkaline phosphatase, and resections that were non-curative than in the older patients. Progression-free survival (PFS) and overall survival (OS) was shorter in younger patients (PFS, 4.2 months; OS, 7.1 months) than in older ones (PFS, 5.1 months; OS, 8.4 months). Nonetheless, younger age did not show an independent association with PFS or OS. Stratified analyses showed that younger age was related with poor outcome in the subgroups of good performance status and no bone metastasis. <strong></strong></p><p><strong>Conclusion:</strong> When matched for other prognostic factors, the prognosis of younger MGC patients receiving first-line combination chemotherapy does not differ from that of older patients. The poor survival of younger patients may be attributed to the association with other adverse prognostic factors.</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.4
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/346/3286
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/435
2016-01-03T12:17:09Z
IJCTO:CONF
cam 3u
"151011 2015 eng "
dc
Transition from Hospital to Community Care: The Experience of Cancer Patients
Admi, Hanna; Oncology Division, Rambam Health Care Campus, Haifa, Israel, Haifa 31096
Muller, Ella; Oncology Division, Rambam Health Care Campus, Haifa, Israel, Haifa 31096
Shadmi, Efrat; Department of Nursing and Faculty of Social Welfare and Health Sciences,
University of Haifa, Mount Carmel
<p><strong>Purpose:</strong> This study examines care transition experiences of cancer patients and assesses barriers to effective transitions.</p><p><strong>Methods:</strong> Participants were adult Hebrew, Arabic, or Russian speaking oncology patients and health care providers from hospital and community settings. Qualitative (n=77) and quantitative (n=422) methods such as focus groups, interviews and self-administered questionnaires were used. Qualitative analysis showed that patients faced difficulties navigating a complex and fragmented healthcare system.</p><p><strong>Results:</strong> Mechanisms to overcome barriers included informal routes such as personal relationships, coordinating roles by nurse coordinators and the patients' general practitioners (GPs). The most significant variable was GPs involvement, which affected transition process quality as rated on the CTM (p<0.001). Our findings point to the important interpersonal role of oncology nurses to coordinate and facilitate the care transition process.</p><p><strong>Conclusion:</strong> Interventions targeted towards supporting the care transition process should emphasize ongoing counseling throughout a patient’s care, during and after hospitalization.</p><p>-----------------------------------------</p><p><strong>Cite this article as: </strong>Admi H, Muller E, Shadmi E. Transition from Hospital to Community Care: The Experience of Cancer Patients. Int J Cancer Ther Oncol 2015; 3(4):34011.</p><p class="c-email">[This abstract was presented at the BIT’s 8<sup>th</sup> Annual World Cancer Congress, which was held from May 15-17, 2015 in Beijing, China.]</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.011
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/373
2016-07-16T06:33:59Z
IJCTO:TECHNICAL
cam 3u
"160109 2016 eng "
dc
A study of X-ray volume imaging system in image guided radiotherapy with variable gantry rotations
Sresty, NVN Madhusudhana; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Alluri, Krishnam Raju; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Thogata, Ramanjappa; Department of Physics, Sri Krishnadevaraya University, Anantapur, Andhra Pradesh
Ahmed, Shabbir; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Venkataramana Puriparthi, Lakshmi; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Ketham, Ramakrishna; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
Mogulagani, Vijay Kumar; Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad
IGRT, Partial Rotation, XVI
<p>Purpose: The main purpose of this work is to investigate the optimal usage of X-ray volume imaging (XVI) system in image-guided radiotherapy with different gantry rotations in order to reduce scanning volume.</p><p>Methods: A total of 60 scans of 16 individual patients with breast and head and neck cancer were used in this study. Full and partial gantry rotations were performed at the same time with same setup on the couch using XVI system by changing the preset information. The reference and localization images were matched with this system. The set up errors were evaluated with XVI software.</p><p>Results: Variation in translational errors with full and half gantry rotations in breast cases were <2 mm in 86.6% of measurements. Similarly, variations between full and partial gantry rotations in head and neck cases were <1 mm in 95.5% of measurements. Results showed almost similar translational and rotational shifts in both full and partial gantry rotations in the majority of the cases.</p><p>Conclusion: Based on selected cases in this study, partial rotation of the gantry for acquiring 3D cone beam computerized tomography (CBCT) is very useful option in reducing scanning volume and total treatment time in IGRT. However, the use of partial rotation of the gantry depends on patient thickness and area to be reconstructed to track anatomical changes near to the target.</p>
International Journal of Cancer Therapy and Oncology
2016-03-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.1
International Journal of Cancer Therapy and Oncology; Vol 4, No 1 (2016): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/373/3446
http://www.ijcto.org/index.php/IJCTO/article/download/373/3447
http://www.ijcto.org/index.php/IJCTO/article/download/373/3448
http://www.ijcto.org/index.php/IJCTO/article/download/373/3449
http://www.ijcto.org/index.php/IJCTO/article/download/373/3450
http://www.ijcto.org/index.php/IJCTO/article/download/373/3451
http://www.ijcto.org/index.php/IJCTO/article/download/373/3452
http://www.ijcto.org/index.php/IJCTO/article/download/373/3453
http://www.ijcto.org/index.php/IJCTO/article/download/373/3454
http://www.ijcto.org/index.php/IJCTO/article/download/373/3455
http://www.ijcto.org/index.php/IJCTO/article/download/373/3456
http://www.ijcto.org/index.php/IJCTO/article/download/373/3457
http://www.ijcto.org/index.php/IJCTO/article/download/373/3458
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/514
2016-07-16T06:10:15Z
IJCTO:ORIGINAL
cam 3u
"160523 2016 eng "
dc
Serum vascular cell adhesion molecule-1 (VCAM1) level is elevated in colorectal cancer regardless of the tumor stage
Ciftci, Rumeysa; Bakirkoy Dr Sadi Konuk Education and Research Hospital, Medical Oncology Department, Istanbul,
Tambas, Makbule; Istanbul University, Institute of Oncology, Radiation Oncology Department,
Istanbul
Kilic, Leyla; Istanbul University, Institute of Oncology, Medical Oncology Department,
Istanbul
Tilgen Yasasever, Ceren; Istanbul University, Institute of Oncology, Basic Oncology Department,
Istanbul
Gurdal, Necla; Istanbul University, Institute of Oncology, Radiation Oncology Department,
Istanbul
Serilmez, Murat; Istanbul University, Institute of Oncology, Basic Oncology Department ,
Istanbul
Celebi, Koray; Istanbul University, Institute of Oncology, Medical Oncology Department,
Istanbul
Pilanci, Kezban Nur; Haseki Education and Research Hospital, Medical Oncology Department,
Istanbul
Duranyildiz, Derya; Istanbul University, Institute of Oncology, Basic Oncology Department ,
Istanbul
Yasasever, Vildan; Istanbul University, Institute of Oncology, Basic Oncology Department ,
Istanbul
Vatansever, Sezai; Istanbul University, Institute of Oncology, Medical Oncology Department ,
Istanbul
Aykan, Nuri Faruk; Istanbul University, Institute of Oncology, Medical Oncology Department ,
Istanbul
Medical Oncology
Colorectal Cancer, Serum VCAM1, Survival
<p>Purpose: Vascular cell adhesion molecule-1 (VCAM1) is a transmembrane glycoprotein, which is expressed on endothelium and plays role in inflammation. It is over-expressed on colorectal cancer (CRC) cells and plays role in metastasis development and angiogenesis. We aimed to compare serum VCAM1 levels of CRC patients with heathy controls and evaluate its relationship with clinicopathological parameters, treatment response and overall survival (OS).</p><p>Methods: The study enrolled 111 patients with histopathologically confirmed CRC followed-up in our clinic and 30 sex- and age-matched healthy controls. Pre-treatment serum VCAM1 levels were determined by the solid-phase sandwich ELISA method.</p><p>Results: Metastatic disease was present in 57 patients. Forty percent of 40 metastatic patients receiving systemic therapy had partial or complete response. The median serum VCAM1 level was significantly higher in CRC patients than controls (<em>p</em><0.001). In addition, serum VCAM1 level was significantly higher in diabetic CRC patients than those without diabetes (<em>p </em>= 0.03). There was no significant relationship between VCAM1 and other clinicopathological parameters including stage and response to systemic therapy. The median follow-up period was 12 (±8.2) months. Twenty patients were dead at the time of analysis. The presence of metastasis (<em>p </em>< 0.001) and elevated CEA level (<em>p </em>< 0.001) were factors affecting OS significantly. However, serum VCAM1 did not have a significant impact on OS (<em>p</em> = 0.55).</p><p>Conclusion: Serum VCAM1 level is significantly elevated in CRC patients regardless of the tumor stage. However, it has no prognostic or predictive role for response to systemic therapy.</p>
International Journal of Cancer Therapy and Oncology
None
2016-06-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.5
International Journal of Cancer Therapy and Oncology; Vol 4, No 2 (2016): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/507
2016-09-18T08:59:14Z
IJCTO:CASE
cam 3u
"160716 2016 eng "
dc
Extra-abdominal desmoid tumor: A case report
Kopric, Dijana; Department of Medical Oncology, University Clinical Center Tuzla, Tuzla
Alidzanovic Nurkanovic, Lejla; Department of Medical Oncology, University Clinical Center Tuzla, Tuzla
Alidzanovic, Jasmina; Department of Medical Oncology, University Clinical Center Tuzla, Tuzla
Altumbabic, Amela; Department of Medical Oncology, University Clinical Center Tuzla, Tuzla
Arnautalic, Lejla; Department of Radiology, University Clinical Center Tuzla, Tuzla
Iljazovic, Ermina; Department of Pathology, University Clinical Center Tuzla, Tuzla
Medical Oncology; Radiation Oncology
Aggressive fibromatosis, Extra-abdominal, Desmoid tumor, Irradiation, Imatinib
<p>Desmoid tumor represents a rare monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Although histologically benign, desmoids are locally invasive and associated with a high local recurrence rate, but lack of metastatic potential. Many issues regarding the optimal treatment of patients with desmoids remain controversial. Surgical resection and radiotherapy are standard treatment options for these patients. Due to heterogeneity of the biological behavior of desmoids, including long periods of stable disease or even spontaneous regression, treatment needs to be individualized to optimize local tumor control and preserve patient's quality of life. Therapeutic approaches to the treatment of recurrent or unresectable desmoid tumors comprise anti-hormonal therapy, non-steroidal anti-inflammatory drugs, classic chemotherapy regimens and tyrosine kinase inhibitor, with highly variable results. It has not yet been possible to establish an optimal therapy protocol for this disease. In this case report we present our experience with the treatment of recurrent extra-abdominal desmoid tumor. </p>
International Journal of Cancer Therapy and Oncology
2016-07-13 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.3
International Journal of Cancer Therapy and Oncology; Vol 4, No 3 (2016): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/507/4196
http://www.ijcto.org/index.php/IJCTO/article/download/507/4197
http://www.ijcto.org/index.php/IJCTO/article/download/507/4198
http://www.ijcto.org/index.php/IJCTO/article/download/507/4199
http://www.ijcto.org/index.php/IJCTO/article/download/507/4347
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/546
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
cam 3u
"161226 2016 eng "
dc
Dosimetric analysis of 3D-conformal radiotherapy and intensity modulated radiotherapy for treatment of advanced stage cervical cancer: A comparative study
Sri Krishna, Gangarapu; 1Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad -500004, Telangana
Venkata Ramireddy, Marella; 1Department of Radiotherapy, MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad -500004, Telangana
Ayyangar, Komanduri; Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska
Yadagiri Reddy, Palreddy; Department of Physics, University College of Science, Osmania University, Hyderabad, Telangana-500007
Medical Physics
Three dimensional conformal radiotherapy, Intensity modulated radiotherapy, Organs at risk, Uniformity index, Conformity index, Homogeneity index, Dose spillage index.
Medical Physics
<p>Purpose: The purpose of this study is to analyze the dosimetric parameters of three dimensional conformal radiotherapy (3DCRT), intensity modulated radiotherapy (IMRT) with seven and nine fields (7F-IMRT, 9F-IMRT) in selected advanced stage cervical cancer cases.</p><p>Methods: Fifteen cases of cervical cancer (IIB to IIIB) were selected for retrospective analysis. All the cases were previously treated with 3DCRT technique with prescribed dose of 50 Gy in 25 fractions. For this study, plans with seven fields IMRT and nine fields IMRT were generated for all patients following Radiation Therapy Oncology Group (RTOG) guidelines. The plans were compared on the basis of planning target volume (PTV) coverage (dose to 1%, 5%, 95% and 99% of target), maximum dose and mean dose to organs at risk (OARs) and also doses at different volumes of OARs. Apart from this, uniformity index (UI), homogeneity index (HI), conformity index (CI) and dose spillage index (R50%) were also calculated with respect to PTV coverage.</p><p>Results: The average dose value of PTV coverage for all three techniques were comparable and all the DVH indices for 7field IMRT (UI (1.04±0.01), HI (0.07 ±0.02), CI (0.75±0.03) and R50% (4.47±0.36)) were better than 3DCRT and 9F-IMRT techniques. All OAR doses were significantly reduced in 7F- IMRT compared to 3DCRT and 9F- IMRT. The target volumes ranged from 769.2 ml to 1375.6 ml with average target volume of 1071.9 ml (SD: 205.38 ml).</p><p>Conclusion: This study showed that significant dose reduction to OARs could be achieved with seven field IMRT plans by maintaining the PTV coverage compared to 3DCRT or 9F- IMRT for treating cervical cancer in advanced stages particularly from IIB to IIIB.</p>
International Journal of Cancer Therapy and Oncology
2016-10-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.5
International Journal of Cancer Therapy and Oncology; Vol 4, No 4 (2016): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/546/4437
http://www.ijcto.org/index.php/IJCTO/article/download/546/4823
http://www.ijcto.org/index.php/IJCTO/article/download/546/4825
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/598
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
cam 3u
"170625 2017 eng "
dc
Gamma Putty shielding effect in megavoltage photon beam
Gloi, Aime M; HSHS St vincent Hospital
Radiation Oncology
Gamma Putty, Tray factor, Linear attenuation, Surface dose
Medical Physics
<p><strong>Purpose:</strong> Traditionally, lead and Cerrobend have been employed for field shaping in radiation therapy. Lately, another shielding material called Gamma Putty has emerged. The objective of this report is to examine its dosimetric and shielding characteristics in megavoltage photon beam.</p><p><strong>Methods:</strong> All measurements were carried out in a dual energy linac. Data were collected using a calibrated ionization chamber. Percent transmission, linear attenuation, and field size dependence were evaluated for open square fields (4 × 4 cm<sup>2</sup> to 10 × 10 cm<sup>2</sup>) defined by collimator jaws and for different Gamma Putty thicknesses (t = 0, 0.3, 0.5, 1.0, 1.5, 2.0, and 2.5 cm) at 6 and 18 MV photon beams. The measurements were performed both in air using appropriate acrylic buildup cap and in solid water.</p><p><strong>Results:</strong> The Gamma Putty tray factor (GPTF) increased steadily with field size for both 6 and 18 MV. It was characterized by a half value thickness (HVT) of 2.513 ± 0.101 and 2.855 ± 0.024 cm for 6 and 18 MV, respectively. The reduction in surface dose was about 6%, 14.5%, 22%, 36.37%, and 54% for 6 MV and 2.75 %, 9.36 %, 16.25 %, 28.95 %, and 44.47 % for 18 MV for Gamma Putty thicknesses of 0.3, 0.5, 1.0, 1.5, 2.0, and 2.5 cm.</p><p><strong>Conclusion:</strong> The result of Gamma Putty shielding on the photon beam output increases with thickness, beam energy, and field size. Therefore, clinical use of Gamma Putty tray factors should be tailored for all thicknesses, beam energies, and field sizes. </p>
International Journal of Cancer Therapy and Oncology
none
2017-02-12 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.5
International Journal of Cancer Therapy and Oncology; Vol 5, No 1 (2017): January - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/756
2017-12-17T14:56:16Z
IJCTO:ORIGINAL
cam 3u
"171224 2017 eng "
dc
Investigation the impact of maximum control point on dose calculation in Eclipse treatment planning system for lung SBRT
Kingkaew, Sakda; The School of Medical Physics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok
Asavaphatiboon, Sawwanee; Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok
Apipunyasopon, Lukkana; Department of Radiological Technology and Medical Physics, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok, Thailand
Control point, Stereotactic body radiation therapy, Dynamic multileaf collimator, Intensity modulated radiation therapy.
<p>Purpose: Choosing an appropriate parameter on the computerized treatment planning systems (TPSs) influences on the accuracy of dose calculation. Several dosimetric parameters have been studied to achieve a more accurate dose and qualitative plan. The purpose of this study was to determine the impact of maximum control point on the dose calculation on Eclipse TPSs for lung Stereotactic Body Radiation Therapy (SBRT) considering the plan quality, the computation time and the treatment file size.</p><p>Methods: Dose distributions for the 8 lung SBRT plans with varying maximum control point of 64, 166, and 320 were calculated by Eclipse TPSs with flattening filter free (FFF) beam. The treatment dose was prescribed at 85% isodose level of 54 Gy to the planning target volume (PTV). The dosimetric impact can be evaluated from target coverage, conformity index (CI), homogeneity index (HI), and organ at risk (OAR) doses, while the computation time and the file storage space were compared with the recommended number of control point.</p><p>Results: The use of 64 control points per subfields tended to increase the dose at PTV and OARs comparing with the 166 and 320 control point plans, while the HI and CI values were similar. The average increases of OARs doses including the spinal cord, heart, esophagus and total lung depended on the photon beam energy. The higher average control point (AVG) number leaded to increase the computation time and the file size for both 6X-FFF and 10X-FFF photon beams. The correlations between AVG and plan storaage space were observed in the same ratio as the computation time.</p><p>Conclusion: Using the minimal number of control point, the quantitative analysis in the PTV and OARs showed no clinically significant variation in dose, therefore choosing an optimal number of fixed control points leaded to balance the plan quality, the computation time and the file size.</p>
International Journal of Cancer Therapy and Oncology
2017-02-12 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.20
International Journal of Cancer Therapy and Oncology; Vol 5, No 1 (2017): January - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/9
2014-03-16T15:38:27Z
IJCTO:SCIENTIFIC
cam 3u
"130920 2013 eng "
dc
Robotic Cystectomy - Important considerations before commencing the procedure independently
Vasdev, Nikhil; Hertfordshire and South Bedfordshire Urological Robotic Cancer Centre, Lister Hospital, UK.
Lamb, Ben
Lane, Tim
Boustead, Gregory
Adshead, James M
<div><p>This article does not include an abstract. Full text of this article is available in <a href="/index.php/IJCTO/article/view/Vasdev2/ijcto.0101.7html" target="_blank">HTML</a> and <a href="http://www.ijcto.org/index.php/IJCTO/article/view/Vasdev2/ijcto.0101.7pdf" target="_blank">PDF</a>.</p><p><strong>Cite this article as</strong>:<br />Vasdev N, Lamb B, Lane T, Boustead G, Adshead J. Robotic Cystectomy : Important considerations before commencing the procedure independently. <em>Int J Cancer Ther Oncol</em> 2013;<strong>1</strong>(1):01017.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0101.7" target="_self">http://dx.doi.org/10.14319/ijcto.0101.7</a></p></div>
International Journal of Cancer Therapy and Oncology
2013-10-10 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Vasdev2
International Journal of Cancer Therapy and Oncology; Vol 1, No 1 (2013): September - October
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/20
2014-04-12T11:23:47Z
IJCTO:EDU
cam 3u
"131229 2013 eng "
dc
Current status of robotic training in the UK – a trainees perspective
Chan, Kaite E; Department of urology Royal Devon and Exeter Hospital, UK
Vasdev, Nikhil; Hertfordshire and South Bedfordshire Urological Robotic Cancer Centre, Lister Hospital, UK.
Robotic Surgery
Training; Robotic; Simulation; Programme; Fellowship; Validation
<p>The validation of robotic surgery in a growing number of operative procedures has increased its acceptance nationwide and its usage is becoming widespread. Training needs to reflect this fast paced environment to ensure that surgeons continue to progress competently and safely. Current surgical training in the UK is validated through the Intercollegiate Surgical Curriculum Programme (ISCP) with progression assessed through an Annual Review of Curriculum Progress (ARCP). There has been some resistance to this since its introduction and many trainees remain dissatisfied with this programme. Training in robotic surgery is currently focused through fellowships with little regular exposure to urology trainees at more junior levels. Robotic simulation provides a useful adjunct to training for both technical and non-technical skills. Its usage is particularly valuable to more inexperienced trainees but may be of limited benefit in those with more advanced skills. Training programmes such as the fundamental skills in robotic surgery (FSRS) have been created to facilitate robotic training and it is likely that the future of robotic surgery training will include a combination of theoretical learning, training programmes and fellowship training.</p><p>-------------------------------------------------------</p><p><strong>Cite this article as</strong>: Chan KE, Vasdev N. Current status of robotic training in the UK – a trainees perspective. Int J Cancer Ther Oncol 2014; 2(1):02013.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.3">http://dx.doi.org/10.14319/ijcto.0201.3</a><br /><br /><br /></p>
International Journal of Cancer Therapy and Oncology
Nil
2014-02-23 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Chan
International Journal of Cancer Therapy and Oncology; Vol 2, No 1 (2014): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/71
2014-05-14T17:01:15Z
IJCTO:ORIGINAL
cam 3u
"140325 2014 eng "
dc
Computational system to create an entry file for replicating I-125 seeds simulating brachytherapy case studies using the MCNPX code
Boia, Leonardo da Silva; Universidade Federal do Rio de Janeiro (UFRJ)
Junior, Juraci P. R.; Universidade Federal do Rio de Janeiro (UFRJ)
Menezes, Artur F.; Universidade Federal do Rio de Janeiro (UFRJ)
Silva, Ademir X.; Universidade Federal do Rio de Janeiro (UFRJ)
Nuclear Physics; Radiation therapy; Computer Simulation
C++ programming language; Brachytherapy; phantom MAX06; Voxel; MCNPX.
<p><strong>Purpose:</strong> A computational system was developed for this paper in the C++ programming language, to create a <sup>125</sup>I radioactive seed entry file, based on the positioning of a virtual grid (template) in voxel geometries, with the purpose of performing prostate cancer treatment simulations using the MCNPX code.</p><p><strong>Methods:</strong> The system is fed with information from the planning system with regard to each seed’s location and its depth, and an entry file is automatically created with all the cards (instructions) for each seed regarding their cell blocks and surfaces spread out spatially in the 3D environment. The system provides with precision a reproduction of the clinical scenario for the MCNPX code’s simulation environment, thereby allowing the technique’s in-depth study.</p><p><strong>Results and Conclusion:</strong> The preliminary results from this study showed that the lateral penumbra of uniform scanning proton beams was less sensitive In order to validate the computational system, an entry file was created with 88 <sup>125</sup>I seeds that were inserted in the phantom’s MAX06 prostate region with initial activity determined for the seeds at the 0.27 mCi value. Isodose curves were obtained in all the prostate slices in 5 mm steps in the 7 to 10 cm interval, totaling 7 slices. Variance reduction techniques were applied in order to optimize computational time and the reduction of uncertainties such as photon and electron energy interruptions in 4 keV and forced collisions regarding cells of interest. Through the acquisition of isodose curves, the results obtained show that hot spots have values above 300 Gy, as anticipated in literature, stressing the importance of the sources’ correct positioning, in which the computational system developed provides, in order not to release excessive doses in adjacent risk organs. The 144 Gy prescription curve showed in the validation process that it covers perfectly a large percentage of the volume, at the same time that it demonstrates a large decline for short distances.</p><p>------------------------------</p><p><strong>Cite this article as</strong>: Boia LS, Junior J, Menezes AF, Silva AX. Computational system to create an entry file for replicating I-125 seeds simulating brachytherapy case studies using the MCNPX code. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(2):02023.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0202.3" target="_blank">http://dx.doi.org/10.14319/ijcto.0202.3</a></p>
International Journal of Cancer Therapy and Oncology
CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior); CNPQ (Conselho Nacional de Desenvolvimento Científico e Tecnológico); FAPERJ (Fundação Nacional de Amparo à Pesquisa do Estado do Rio de Janeiro).
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Boia
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/71/557
http://www.ijcto.org/index.php/IJCTO/article/download/71/558
http://www.ijcto.org/index.php/IJCTO/article/download/71/559
http://www.ijcto.org/index.php/IJCTO/article/download/71/560
http://www.ijcto.org/index.php/IJCTO/article/download/71/561
http://www.ijcto.org/index.php/IJCTO/article/download/71/562
http://www.ijcto.org/index.php/IJCTO/article/download/71/563
http://www.ijcto.org/index.php/IJCTO/article/download/71/564
http://www.ijcto.org/index.php/IJCTO/article/download/71/565
http://www.ijcto.org/index.php/IJCTO/article/download/71/568
http://www.ijcto.org/index.php/IJCTO/article/download/71/791
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/110
2014-05-14T17:01:17Z
IJCTO:CONF
cam 3u
"140409 2014 eng "
dc
Ultrafast cone-beam CT scatter correction with GPU-based Monte Carlo simulation
Xu, Yuan; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Bai, Ti; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Yan, Hao; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Ouyang, Luo; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Wang, Jing; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Pompos, Arnold; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Zhou, Linghong; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Jiang, Steve; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Jia, Xun; Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>Scatter artifacts severely degrade image quality of cone-beam CT (CBCT). We present an ultrafast scatter correction framework by using GPU-based Monte Carlo (MC) simulation and prior patient CT image, aiming at automatically finish the whole process including both scatter correction and reconstruction within 30 seconds.</p><p><strong>Methods</strong>: The method consists of six steps: 1) FDK reconstruction using raw projection data; 2) Rigid Registration of planning CT to the FDK results; 3) MC scatter calculation at sparse view angles using the planning CT; 4) Interpolation of the calculated scatter signals to other angles; 5) Removal of scatter from the raw projections; 6) FDK reconstruction using the scatter-corrected projections. In addition to using GPU to accelerate MC photon simulations, we also use a small number of photons and a down-sampled CT image in simulation to further reduce computation time. A novel denoising algorithm is used to eliminate MC noise from the simulated scatter images caused by low photon numbers. The method is validated on one simulated head-and-neck case with 364 projection angles.</p><p><strong>Results: </strong>We have examined variation of the scatter signal among projection angles using Fourier analysis. It is found that scatter images at 31 angles are sufficient to restore those at all angles with < 0.1% error. For the simulated patient case with a resolution of 512 × 512 × 100, we simulated 5 × 10<sup>6</sup> photons per angle. The total computation time is 20.52 seconds on a Nvidia GTX Titan GPU, and the time at each step is 2.53, 0.64, 14.78, 0.13, 0.19, and 2.25 seconds, respectively. The scatter-induced shading/cupping artifacts are substantially reduced, and the average HU error of a region-of-interest is reduced from 75.9 to 19.0 HU.</p><div><p><strong>Conclusion</strong>: A practical ultrafast MC-based CBCT scatter correction scheme is developed. It accomplished the whole procedure of scatter correction and reconstruction within 30 seconds.</p></div><p>----------------------------</p><p><strong>Cite this article as</strong>: Xu Y, Bai T, Yan H, Ouyang L, Wang J, Pompos A, Zhou L, Jiang SB, Jia X. Ultrafast cone-beam CT scatter correction with GPU-based Monte Carlo simulation. Int J Cancer Ther Oncol 2014; 2(2):020245. <strong>DOI: 10.14319/ijcto.0202.45</strong></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Xu
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/127
2014-05-14T17:01:18Z
IJCTO:CONF
cam 3u
"140408 2014 eng "
dc
90Y PET/CT quantitative accuracy and image quality
Siman, Wendy; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Mawlawi, Osama R; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Kappadath, Cheenu S; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>To optimize 90Y-PET/CT image reconstruction for quantitative accuracy and optimal image quality.</p><p><strong>Methods</strong>: PET/CT scans of a NEMA IEC phantom (3GBq 90YCl2, sphere uptake ratio of ~7) were acquired on 4 GE (BGO:DSTE, DST & LYSO:DRX, D690) and 1 Siemens (LSO:mCT) scanners in 3D list mode with 30 min/bed; replayed to 20, 15, 10 min/bed. Iterative reconstruction parameters explored were SUB × IT (3 – 80) and post-reconstruction filters: transaxial: 5 – 25 mm cutoff & z-axis (GE only): std vs. heavy. The effects of PSF modeling and TOF correction were evaluated for D690 and mCT. VOIs were drawn inside spheres and in adjacent background regions. The accuracy of sphere activity concentration (AC in kBq/mL) and contrast to noise ratio (CNR) was calculated as function of SUB × IT. Reconstructed PET images were also evaluated qualitatively for sphere detectability and artifacts.</p><p><strong>Results: </strong>AC converged to 70 – 90% accuracy for 37 mm sphere and further degraded for smaller spheres. Spheres at max CNR might not reach AC convergence yet. Smaller spheres have slower convergence but reach CNR max together with other spheres. Scan duration did not strongly affect sphere convergence but shorter scans increased noise and reduced detectability; 13 mm spheres were not visible going from 30 to 15 min/bed. Heavy z-axis (GE) and transaxial filter with 10 – 15 mm cutoff helped suppress noise and increase sphere detectability at the expense of accuracy. Images with PSF+TOF corrections had higher sphere detectability and converged faster. Hot cluster artifacts 5 – 7 times the background were seen in some cases with SUB × IT near convergence and lower filtration.</p><p><strong>Conclusion</strong>: Accurate 90Y AC was not achieved even at convergence and noise is a major concern. 90YPET/CT reconstruction parameters are different than those for 18F and benefit substantially from PSF+TOF corrections. Optimum image quality and accurate AC may not be simultaneously achievable.</p><p><strong>----------------------------------------</strong></p><p><strong>Cite this article as:</strong> Siman W, Mawlawi O, Kappadath SC. 90Y PET/CT quantitative accuracy and image quality. Int J Cancer Ther Oncol 2014; 2(2):020235. <strong>DOI: 10.14319/ijcto.0202.35</strong><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Siman1
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/96
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
cam 3u
"140522 2014 eng "
dc
Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code
Barbosa, Nilseia Aparecida; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
da Rosa, Luiz Antonio Ribeiro; Instituto de Radioproteção e Dosimetria
de Menezes, Artur Ferreira; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
Reis, Juraci; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
Facure, Alessandro; Comissão Nacional de Energia Nuclear
Braz, Delson; Universidade Federal do Rio de Janeiro
COPPE/UFRJ
Medical Physics; Brachytherapy; Monte Carlo
Eye Brachytherapy; Monte Carlo; Dose Distribution; Ruthenium-106
<p><strong>Purpose: </strong>Melanoma at the choroid region is the most common primary cancer that affects the eye in adult patients. Concave ophthalmic applicators with <sup>106</sup>Ru/<sup>106</sup>Rh beta sources are the more used for treatment of these eye lesions, mainly lesions with small and medium dimensions. The available treatment planning system for <sup>106</sup>Ru applicators is based on dose distributions on a homogeneous water sphere eye model, resulting in a lack of data in the literature of dose distributions in the eye radiosensitive structures, information that may be crucial to improve the treatment planning process, aiming the maintenance of visual acuity. <strong></strong></p><p><strong>Methods</strong>: The Monte Carlo code MCNPX was used to calculate the dose distribution in a complete mathematical model of the human eye containing a choroid melanoma; considering the eye actual dimensions and its various component structures, due to an ophthalmic brachytherapy treatment, using <sup>106</sup>Ru/<sup>106</sup>Rh beta-ray sources. Two possibilities were analyzed; a simple water eye and a heterogeneous eye considering all its structures. Two concave applicators, CCA and CCB manufactured by BEBIG and a complete mathematical model of the human eye were modeled using the MCNPX code. <strong></strong></p><p><strong>Results </strong><strong>and Conclusion</strong><strong>: </strong>For both eye models, namely water model and heterogeneous model, mean dose values simulated for the same eye regions are, in general, very similar, excepting for regions very distant from the applicator, where mean dose values are very low, uncertainties are higher and relative differences may reach 20.4%. For the tumor base and the eye structures closest to the applicator, such as sclera, choroid and retina, the maximum difference observed was 4%, presenting the heterogeneous model higher mean dose values. For the other eye regions, the higher doses were obtained when the homogeneous water eye model is taken into consideration. Mean dose distributions determined for the homogeneous water eye model are similar to those obtained for the heterogeneous eye model, indicating that the homogeneous water eye model is a reasonable one. The determined isodose curves give a good visualization of dose distributions inside the eye structures, pointing out their most exposed volume.</p><p>...................................................</p><p><strong>Cite this article as:</strong><br />Barbosa NA, da Rosa LAR, de Menezes AF, Reis JP, Facure A, Braz D. Assessment of ocular beta radiation dose distribution due to 106Ru/106Rh brachytherapy applicators using MCNPX Monte Carlo code. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(3):02038. <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0203.8" target="_blank"><strong>10.14319/ijcto.0203.8</strong></a><br /><br /></p>
International Journal of Cancer Therapy and Oncology
Nilséia Aparecida Barbosa would like to acknowledge the Brazilian Conselho Nacional de Pesquisas, CNPq, for her financial support. This research work was supported by CNPq project INCT em Metrologia das Radiações em Medicina.
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Barbosa
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/154
2014-12-13T14:36:24Z
IJCTO:ORIGINAL
cam 3u
"140826 2014 eng "
dc
Utility of CT angiography in cervical spine trauma: analysis of radiation and cost
Shuaib, Waqas; Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta, GA.
Ali Khan, Aizaaz; Department of Emergency Medicine, Grady Memorial Hospital, Atlanta, GA.
Singh Mehta, Ajeet; Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta, GA.
Vijayasarathi, Arvind; Department of Radiology and Imaging Sciences, Emory University Hospital, Atlanta, GA.
Hidalgo, Joseph; Department of Surgery, Plaza de la salud, Santo Domingo, DR.
CTA; Cerebrovascular Injury; Cervical Trauma
<p><strong>Purpose:</strong> Vertebral artery injuries (VAIs) can be seen in cervical injuries. This investigation was conducted to assess the impact of head and neck computed tomography (CT) angiography (CTA) on planning treatment of vertebral artery injuries, if these tests were ordered appropriately, and to estimate cost and associated exposure to radiation and contrast material. <strong></strong></p><p><strong>Methods</strong>: This retrospective review included all patients who underwent CT of the cervical spine and CTA of the head and neck from March 2011 to October 2012 at a single institution. Patients were divided into two groups, those with and those without cervical spine fracture appreciated on CT of the cervical spine. The frequency of vascular injury on CTA in those with a cervical fracture was assessed. The frequency of vascular injury treatment and modifications owed to a positive CTA of head and neck were also assessed. A study was considered appropriate if it was ordered in accordance with the modified Denver Screening criteria. Effective radiation dose (mSv) was calculated by multiplying dose length product (DLP) from the scanner with the standard conversion coefficient (k) (k = 0.0021 mSv/mGy x cm).</p><p><strong>Results: </strong>In the 387 CTAs of head and neck, a cervical injury was recorded in 128 patients. Twenty CTA scans were correctly ordered for non-spinal indications, and 19 were ordered off protocol. CTA was found positive in 1 patient for whom the imaging was off protocol and 1 for whom the clinical indication was non-cervical. There were 19 positive CTA cases of head and neck, none of which underwent surgical intervention. CTA was positive in 13 of 48 patients who had suffered a C2 fracture; this accounted for 13 of the 19 positive CTA studies (p < 0.01). Estimated fee for CTA was $3783, and radiation exposure was 4 mSv with a standard deviation (±1.3). <strong></strong></p><p><strong>Conclusion</strong>: CTA of head and neck ordered off an institutional imaging protocol has a low probability of being positive. Adherence to protocols for CTA of head and neck can reduce costs and decrease unnecessary exposure to radiation and contrast medium.</p><p>---------------------------------------</p><p><strong>Cite this article as:</strong><br />Shuaib W, Khan AA, Mehta AS, Vijayasarathi A, Hidalgo J. Utility of CT angiography in cervical spine trauma: analysis of radiation and cost. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(4):02043. <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0204.3" target="_blank">10.14319/ijcto.0204.3</a><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0204.3
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/154/1884
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/232
2014-12-13T14:36:24Z
IJCTO:EDITORIAL
cam 3u
"141031 2014 eng "
dc
Acknowledgement to Reviewers
Office, Editorial
<p align="center"><strong><span style="font-size: medium;">Acknowledgement to Reviewers</span></strong></p><p><span style="font-size: medium;"><strong>The editorial board of International Journal of Cancer Therapy and Oncology (IJCTO) wishes to acknowledge the help of reviewers who have generously contributed their valuable time and efforts during the period September 2013–October 2014 in the appraisal of manuscripts submitted to the IJCTO</strong>. </span></p><p><span style="font-size: medium;">Abdulhamid Chaikh (France)</span></p><p><span style="font-size: medium;">Alok Singh (USA)</span></p><p><span style="font-size: medium;">Anamika Basu (USA)</span></p><p><span style="font-size: medium;">Anish Banerjee (India)</span></p><p><span style="font-size: medium;">Antonella Fogliata (Switzerland)</span></p><p><span style="font-size: medium;">Arun Oinam (India)</span></p><p><span style="font-size: medium;">Birendra Kumar Rout (India)</span></p><p><span style="font-size: medium;">Brindha Subramanian (Australia)</span></p><p><span style="font-size: medium;">Charles Bloch (USA)</span></p><p><span style="font-size: medium;">Charles Shang (USA)</span></p><p><span style="font-size: medium;">Chee-Wai Cheng (USA)</span></p><p><span style="font-size: medium;">Chih-Yao Cheng (USA)</span></p><p><span style="font-size: medium;">Daniel Bailey (USA)</span></p><p><span style="font-size: medium;">Danijela Scepanovic (Slovakia)</span></p><p><span style="font-size: medium;">Ersalan Hernandez (USA)</span></p><p><span style="font-size: medium;">Esmaeel Ghasroddashti (Canada)</span></p><p><span style="font-size: medium;">H Sudahar (India)</span></p><p><span style="font-size: medium;">He Wang (USA)</span></p><p><span style="font-size: medium;">Kanan Jassal (India)</span></p><p><span style="font-size: medium;">Lanchun Lu (USA)</span></p><p><span style="font-size: medium;">Lei Guo (USA)</span></p><p><span style="font-size: medium;">Leonardo da Silva Boia (USA)</span></p><p><span style="font-size: medium;">Luiz Antonio Ribeiro da Rosa (Brasil)</span></p><p><span style="font-size: medium;">Maria Chan (USA)</span></p><p><span style="font-size: medium;">Ming Yan (USA)</span></p><p><span style="font-size: medium;">Mohamed Fawzy (Egypt)</span></p><p><span style="font-size: medium;">Mohammad Rafiqul Islam (USA)</span></p><p><span style="font-size: medium;">Nilseia Aparecida Barbosa (Brasil)</span></p><p><span style="font-size: medium;">Nita Nair (India)</span></p><p><span style="font-size: medium;">Panayiotis Mavroidis (USA)</span></p><p><span style="font-size: medium;">Paul Sijens (Netherlands)</span></p><p><span style="font-size: medium;">Paulo Roberto Fonseca (Brasil)</span></p><p><span style="font-size: medium;">Pei-Hsin Cheng (USA)</span></p><p><span style="font-size: medium;">Prabhakar Ramachandran (Australia)</span></p><p><span style="font-size: medium;">Pradip Maiti (India)</span></p><p><span style="font-size: medium;">Pratik Kumar (India)</span></p><p><span style="font-size: medium;">Qinghui Zhang (USA)</span></p><p><span style="font-size: medium;">Qiyong Fan (USA)</span></p><p><span style="font-size: medium;">Radu Alin Vasilache (Romania)</span></p><p><span style="font-size: medium;">Rajesh Thiyagarajan (India)</span></p><p><span style="font-size: medium;">Ranjita Shegokar (Germany)</span></p><p><span style="font-size: medium;">Rick Sims (New Zeland)</span></p><p><span style="font-size: medium;">Sara Bresciani (Italy)</span></p><p><span style="font-size: medium;">Saurabh Varshney (India)</span></p><p><span style="font-size: medium;">Shyam Pokhrel (USA)</span></p><p><span style="font-size: medium;">Sunder Goyal (India)</span></p><p><span style="font-size: medium;">Supriya Chopra (India)</span></p><p><span style="font-size: medium;">Suresh Rana (USA)</span></p><p><span style="font-size: medium;">Toks Yerokun (USA)</span></p><p><span style="font-size: medium;">Tulika Seth (USA)</span></p><p><span style="font-size: medium;">V. Kannan (India)</span></p><p><span style="font-size: medium;">Waldemar Ulmer (Germany)</span></p><p><span style="font-size: medium;">Waqas Shuaib (USA)</span></p><p><span style="font-size: medium;">Xiang-Ming Ding (USA)</span></p><p><span style="font-size: medium;">Yida Hu (USA)</span></p><p><span style="font-size: medium;">Yong Chen (USA)</span></p><p><span style="font-size: medium;">Yu Wang (USA)</span></p><p><span style="font-size: medium;">Yuanming Feng (USA)</span></p><p><span style="font-size: medium;">Yulin Song (USA)</span></p>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
http://www.ijcto.org/index.php/IJCTO/article/view/Acknowledgment2014
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/204
2015-03-29T11:59:32Z
IJCTO:ORIGINAL
cam 3u
"141223 2014 eng "
dc
Comparative dosimetric analysis of IMRT and VMAT (RapidArc) in brain, head and neck, breast and prostate malignancies
Ali, Mirza Athar; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Babaiah, Muntimadugu; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Madhusudhan, Nagaraju; Department of Radiation Oncology, American Oncology Institute, Hyderabad
George, Geomcy; Department of Radiation Oncology, Advanced Cancer Diagnostic Treatment and Research Centre (ACDTRC), Bathinda
Jain, Shanu; Department of Radiation Oncology, SGPGI, Lucknow
Ramalingam, Kuppuswami; Department of Radiation Oncology, Yashoda Cancer Institute, Hyderabad
Kumar, Sangaiah Ashok; Department of Radiation Oncology, Yashoda Cancer Institute, Hyderabad
Karthikeyan, Kalyanasundaram; Department of Radiation Oncology, Yashoda Cancer Institute, Hyderabad
Anantharaman, Ayyalusamy; Department of Radiation Oncology, Yashoda Cancer Institute, Hyderabad
Radiation Oncology; Treatment planning; IMRT; VMAT
VMAT; RapidArc; IMRT; Plan Comparison
Dosimetric plan comparison: IMRT vs VMAT
<p><strong>Purpose:</strong> Intensity modulated radiotherapy (IMRT) in the recent past has established itself as a gold standard for organs at risk (OAR) sparing, target coverage and dose conformity. With the advent of a rotational treatment technology such as volumetric modulated arc therapy (VMAT), an inter-comparison is warranted to address the advantages and disadvantages of each technique. <strong></strong></p><p><strong>Methods:</strong> Twenty patients were selected retrospectively from our patient database. Sites included were brain, head and neck, chest wall, and prostate, with five patients for each site. For all the selected patients, both the IMRT and VMAT treatment plans were generated. Plan comparison was done in terms of OAR dose, dose homogeneity index (HI), dose conformity index (CI), target coverage, low isodose volumes, monitor units (MUs), and treatment time.</p><p><strong>Results:</strong> The VMAT showed better sparing of “parotids minus planning target volume (PTV)”, spinal cord and head of femur as compared to the IMRT. The lung V<sub>40</sub> for VMAT was lower, whereas the lung V<sub>10</sub>, contralateral lung mean dose, contralateral breast mean dose and mean body dose were lower with IMRT for chest wall cases. Both the VMAT and IMRT achieved comparable HI except for the brain site, where IMRT scored over VMAT. The CI achieved by the IMRT and VMAT were similar except for chest wall cases, whereas the VMAT achieved better dose conformity. The target coverage was comparable with both the plans. The VMAT clearly scored over IMRT in terms of average MUs (486 versus 812 respectively) and average treatment time (2.54 minutes versus 5.54 minutes) per treatment session. <strong></strong></p><p><strong>Conclusion:</strong> The VMAT (RapidArc) has a potential to generate treatment plans for various anatomical sites which are comparable with the corresponding IMRT plans in terms of OAR sparing and plan quality parameters. The VMAT significantly reduces treatment time as compared to the IMRT, thus VMAT can increase the throughput of a busy radiotherapy department.</p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/0301.9
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/291
2015-08-15T11:54:27Z
IJCTO:CASE
cam 3u
"150220 2015 eng "
dc
Xanthogranulomatous Colitis masquerading as carcinoma of colon
Kapoor, Akhil; Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, Rajasthan
Soni, Dharam Pal; Department of Pathology, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, Rajasthan
Paramanandhan, Murali; Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, Rajasthan
Kini, Lata; Department of Pathology, Core Diagnostics Pvt. Limited, New Delhi
Beniwal, Surender; Department of Medical Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, Rajasthan
Kumar, Harvindra; Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment & Research Institute, Sardar Patel Medical College and Associated Group of Hospitals, Bikaner, Rajasthan
Oncology; Oncopathology; Surical Oncology
Xanthogranulomatous Inflammation; Colitis; Immunohistochemistry; Colon Cancer
Xanthogranulomatous inflammation (XGI) is an uncommon pathological diagnosis involving various organ systems, the most common being the gall bladder and kidney. It can masquerade as a malignant mass thus, requiring a clinical suspicion for accurate and timely diagnosis. A 65-year-old woman presented with acute onset of obstipation and vomiting suggesting acute obstruction. Contrast enhanced computed tomography of abdomen revealed a solid irregular mass in the ascending colon with large necrotic areas and surrounding enlarged nodes suggestive of malignancy arising from right colon. Right hemi-colectomy was performed. Histopathology of the surgical specimen showed florid inflammatory infiltrate with collection of histiocytes, lymphocytes and polymorphs. Further immunohistochemistry was conducted, and CD68 and CD45 were found to be positive and pan-cytokeratin was negative. A clinico-pathological diagnosis was thus established to be xanthogranulomatous colitis.
International Journal of Cancer Therapy and Oncology
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.0302.5
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/223
2015-08-15T11:54:27Z
IJCTO:TECHNICAL
cam 3u
"150405 2015 eng "
dc
Evaluation of collapsed cone convolution superposition (CCCS) algorithms in prowess treatment planning system for calculating symmetric and asymmetric field size
Dawod, Tamer; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura
Medical physics
Symmetric and Asymmetric Fields; Dose Calculation; Treatment Planning System
<p><strong>Purpose:</strong> This work investigated the accuracy of prowess treatment planning system (TPS) in dose calculation in a homogenous phantom for symmetric and asymmetric field sizes using collapse cone convolution / superposition algorithm (CCCS). <strong></strong></p><p><strong>Methods:</strong> The measurements were carried out at source-to-surface distance (SSD) set to 100 cm for 6 and 10 MV photon beams. Data for a full set of measurements for symmetric fields and asymmetric fields, including inplane and crossplane profiles at various depths and percentage depth doses (PDDs) were obtained during measurements on the linear accelerator.</p><p><strong>Results:</strong> The results showed that the asymmetric collimation dose lead to significant errors (up to approximately 7%) in dose calculations if changes in primary beam intensity and beam quality. It is obvious that the most difference in the isodose curves was found in buildup and the penumbra regions. <strong></strong></p><p><strong>Conclusion:</strong> The results showed that the dose calculation using Prowess TPS based on CCCS algorithm is generally in excellent agreement with measurements.</p>
International Journal of Cancer Therapy and Oncology
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.11
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/223/2413
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/320
2015-08-15T11:54:27Z
IJCTO:ORIGINAL
cam 3u
"150619 2015 eng "
dc
Co-expression of CXCR4 and CD133 in gastric neoplastic tissue and their correlation with clinicopathological factors and prognosis in gastric cancer
Poddar, Snigdha; Department of Zoology, Unit of Biochemistry, School of Life Science, University of Madras,
Maraimalai Campus, Guindy, Chennai, Tamil Nadu
D’Cruze, Lawrence; Department of Pathology, Sri Ramachandra Medical College, Porur, Chennai, Tamil Nadu
Halagowder, Devaraj; Department of Zoology, Unit of Biochemistry, School of Life Science, University of Madras,
Maraimalai Campus, Guindy, Chennai, Tamil Nadu
Clinical Oncology
Cancer Stem Cell; Gastric Cancer; CXCR4; CD133; Immunohistochemical Study; Co-immunolocalisation; RT-PCR
<p><strong>Purpose:</strong> Worldwide Gastric carcinoma considered as the second most common cause of cancer related death. Cancer stem cell plays significant role in prognosis and invasion of gastric cancer. CXCR4 is a chemokine receptor and plays an important role in self renewal, differentiation potential, and cell adhesion of cancer stem cell (CSC). On the other hand CD133 is a cell surface glycoprotein and could serve as a prognostic indicator for tumor re-growth, malignant progression, and patient survival. The aim of this study was to establish the expression pattern of CXCR4 and CD133 in gastric cancer tissues; and their correlation with clinicopathological factors like age and gender of patients, position, size and depth of tumor, lymphatic invasion and node metastasis.</p><p><strong>Methods:</strong> Expression of CXCR4 and CD133 proteins were assessed by immunohistochemical and immunofluorescence staining of paraffin–embedded tissues, and followed by RT-PCR in 90 tumors (observed group) and 30 normal gastric samples. The clinical pathological data was statistically analyzed by chi-square methods. <strong></strong></p><p><strong>Results:</strong> The positive rate of CXCR4 and CD133 expression in the observed group was 94.44 (85/90) and 95.55 (86/90) respectively. The expression of CXCR4 and CD133 were correlated with age and gender of patients, and position, size, & depth of the tumor, lymphatic invasion and node metastasis (<em>p </em>< 0.05). While CXCR4 was positive, CD133 had a positive rate of 92.22% but the positive rate was 2.22% when CXCR4 expression was negative (χ<sup>2</sup> = 58.657; <em>p</em> < 0.001). <strong></strong></p><p><strong>Conclusion:</strong> Overall this data suggests that increased expression of CXCR4 and CD133 might be attributed with disease progression and malignant transformation of gastric epithelium cells. A significant correlation was found in between CXCR4 and CD133 expression and their co-expression may play significant role in invasiveness of gastric cancer.</p>
International Journal of Cancer Therapy and Oncology
2015-01-22 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.32.21
International Journal of Cancer Therapy and Oncology; Vol 3, No 2 (2015): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/320/3170
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/371
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
cam 3u
"150825 2015 eng "
dc
Study of inter-fraction movements of tongue during radiation therapy in cases of tongue malignancy using volumetric cone beam computed tomography (CBCT) imaging
Ali, Mirza Athar; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Babaiah, Muntimadugu; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Raut, Birendra Kumar; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Madhusudhan, Nagaraju; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Muralidhar, KR; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Vuba, Sujana Priya; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Mariappan, Prabhakar; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Pangam, Suresh; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Ponaganti, Srinivas; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Kolla, Jayaramakrishna; Department of Radiation Oncology, American Oncology Institute, Hyderabad
Radiation Oncology
Inter-Fraction Movements; Tongue; CBCT; PTV Margins
Organ Motion Study
<p><strong>Purpose:</strong> Tongue is a mobile organ in head and neck region predisposing it for geographic miss during the course of fractionated radiotherapy for tongue malignancy. This study analyses movement of tongue during the course of radiotherapy using volumetric KV-cone beam computed tomography (KV-CBCT) imaging for patients of tongue malignancy treated without using tongue bite. <strong></strong></p><p><strong>Methods: </strong>We analysed 100 KV-cone beam CTs performed on 10 patients with carcinoma of tongue undergoing fractionated radiotherapy. All the patients underwent thermoplastic mask immobilisation and CT simulation. During the course of radiotherapy, all patients underwent volumetric KV-CBCT imaging to assess the movements of tongue. Five arbitrary reference points were used to analyse the movements of tongue in 3-dimensions: 1) Point A: Tip of tongue; 2) Point B: Point over right lateral border, 4 cm posterior to the tip of tongue; 3) Point C: Point over left lateral border, 4 cm posterior to the tip of tongue; 4) Point D: Point over superior most part (dorsum) of tongue, 4 cm posterior to the tip of tongue; 5) Point E: Point over the surface of base of tongue at the level of tip of epiglottis. <strong></strong></p><p><strong>Results: </strong>Mean movements of point A: +0.21 cm (SD: 0.12) and -0.23 cm (SD: 0.14), point B: +0.14 cm (SD: 0.04) and -0.19 cm (SD: 0.1), point C: +0.12 cm (SD: 0.05) and -0.14 cm (SD: 0.06), point D: +0.15 cm (SD: 0.07) and -0.29 cm (SD: 0.22) and point E: +0.23 cm (SD: 0.15) and -0.23 cm (SD: 0.14). <strong></strong></p><p><strong>Conclusion: </strong>Organ movement is one of the great challenges encountered during radiotherapy. Tongue is one such organ in head and neck region. Concept of internal target volume (ITV) margin which takes into account the internal organ movements should be considered for tongue malignancies. ITV to PTV margin will depend on the setup accuracy, immobilization device and imaging modality utilised for setup verification. In an IGRT (Image Guided Radio Therapy) setup, a PTV margin of 0.3 to 0.5 cm from ITV would be safe.</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.1
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/429
2016-01-03T12:17:09Z
IJCTO:CONF
cam 3u
"151011 2015 eng "
dc
The AMPK-related Kinase HUNK: Potential Target for HER2-positive Breast Cancer
Yeh, Elizabeth S; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina
Hill, Elizabeth G; Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina
<p><strong>Purpose: </strong>Approximately 25% of breast cancer patients are diagnosed with HER2-positive breast cancers.<strong> </strong>Although several targeted inhibitors to HER2 are approved for use in breast cancer, many patients either fail therapy or eventually become resistant to HER2 inhibitors. Therefore, understanding the molecular mechanisms that allow breast cancer cells to overcome treatment and become resistance is of critical importance.</p><p><strong>Methods: </strong>We have characterized an AMPK-related protein kinase called Hormonally Upregulated Neu-associated Kinase (HUNK) as a potential target for primary HER2-positive breast cancer using breast cancer cell and HER2/neu-induced mouse mammary tumor models. We have also investigated whether inhibiting HUNK impairs in vivo tumor growth that is initiated by primary (HER2 inhibitor sensitive) and HER2 inhibitor resistant breast cancer cells.</p><p><strong>Results:</strong> We found that HUNK supports the survival of primary HER2/neu-positive breast and mammary tumor cells as well as that of HER2 inhibitor resistant breast cancer cells. Therefore, targeting HUNK in primary HER2-positive breast cancers as well as those that are resistant to the HER2 inhibitor trastuzumab, inhibits tumorigenesis.</p><p><strong>Conclusions: </strong>We conclude from our findings that targeting HUNK is a potential therapeutic strategy for primary and resistant HER2-positive breast cancers.</p><p>-----------------------------------------</p><p><strong>Cite this article as: </strong>Yeh ES, Hill EG. The AMPK-related Kinase HUNK: Potential Target for HER2-positive Breast Cancer. Int J Cancer Ther Oncol 2015; 3(4):3406.</p><p class="c-email">[This abstract was presented at the BIT’s 8<sup>th</sup> Annual World Cancer Congress, which was held from May 15-17, 2015 in Beijing, China.]</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.06
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/409
2016-07-16T06:32:50Z
IJCTO:TECHNICAL
cam 3u
"151220 2015 eng "
dc
Impact of patient positioning on radiotherapy dose distribution: An assessment in parotid tumor
Sharma, Seema; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Goyal, Shikha; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Muzumdar, Sandeep; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Manigandan, Durai; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Sahai, Puja; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Biswas, Ahitagni; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Subramani, Velliyan; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Chander, Subhash; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi
Medical Dosimetry
Conformal Radiotherapy, Dose Distribution, Head Position, Intensity-Modulated Radiotherapy, Parotid Neoplasm
<p>Purpose: We intended to study the impact of patient positioning on the dose distribution within target volume and organs at risk in patients with parotid malignancies treated with 3D conformal radiotherapy (3D-CRT) with photon wedge pair (WP) or intensity modulated radiotherapy (IMRT).</p><p>Methods: Three patients with a non-Hodgkin’s lymphoma of the right parotid gland were consecutively immobilized using thermoplastic cast in 2 positions: supine with head in neutral position (HN) and with head turned 90° to the left side (HT). Images for treatment planning purpose were acquired in both positions. For both positions, photon WP plans and 5 field IMRT plans were generated, after contouring clinical target volume (CTV), planning target volume (PTV= CTV + 5 mm margin) and organs at risk (OAR). All plans were evaluated for target coverage and dose to OARs.</p><p>Results: Both CTV and PTV were apparently larger in HN compared with HT (31.76±8.89 cc, 30.31±7.83 cc and 62.49±19.01 cc, 58.89±15.33 cc) respectively. The CI value for PTV was slightly better for HT compared to HN position in both the WP and IMRT plans. The homogeneity was comparable in both the head positions in case of WP plan. The mean HI of PTV was increased in case of IMRT plan at HT versus HN position (1.108 vs. 1.097). A change in head position from HN to HT with wedge pair plan resulted in a reduction of brainstem D<sub>max</sub> and D<sub>mean</sub>. Lesser dose was observed in HN position for contralateral parotid. A difference of 0.9 Gy in the average D<sub>max</sub> to spinal cord was seen. The values of D<sub>mean</sub> to mandible, oral cavity, ipsilateral and contralateral cochlea were higher in the HT position. A change in head position from HN to HT with IMRT plan resulted in a dose reduction in average D<sub>max</sub> to brainstem. The spinal cord D<sub>max</sub> increased at the HT position by 1.2 Gy. The dose to contralateral parotid and cochlea was comparable in both the positions. However, the D<sub>mean</sub> to oral cavity was reduced at HT position. Whereas for IMRT versus wedge pair plan at head neutral position average D<sub>mean</sub> to the contralateral parotid was reduced with the IMRT plan. A considerable reduction in D<sub>max</sub> to spinal cord and D<sub>mean</sub> to ipsilateral cochlea was observed. A slight increase in average D<sub>max</sub> to brainstem and was observed with the IMRT plan. The doses to the remaining OARs were lesser in case of IMRT plan. For IMRT versus wedge pair plan at head tilt position slight increase in average D<sub>max</sub> to brainstem was observed in case of IMRT plan. A considerable reduction in D<sub>max</sub> to spinal cord and D<sub>mean</sub> to ipsilateral cochlea was observed. The doses to the remaining OARs were reduced with IMRT plan.</p><p>Conclusion: Change in head position from neutral to 90° contralateral tilt for wedge pair plan in parotid tumor may considerably reduce dose to the brainstem and spinal cord with a modest increase in dose to mandible, oral cavity, contralateral parotid, and bilateral cochlea. The alteration in head position has minimal impact on IMRT planning.</p>
International Journal of Cancer Therapy and Oncology
2016-03-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.6
International Journal of Cancer Therapy and Oncology; Vol 4, No 1 (2016): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/446
2016-07-16T06:07:27Z
IJCTO:ORIGINAL
cam 3u
"160303 2016 eng "
dc
Commissioning and quality control of a dedicated wide bore 3T MRI simulator for radiotherapy planning
Xing, Aitang; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Holloway, Lois; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Arumugam, Sankar; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Walker, Amy; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Rai, Robba; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Juresic, Ewa; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Cassapi, Lynette; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Goozee, Gary; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Liney, Gary; Liverpool and Macarthur Cancer Therapy Centres & Ingham Institute, Liverpool Hospital, Sydney
Medical Physics; Radiation Oncology
MRI in Radiotherapy, Wide-Bore 3T MRI Scanner, Radiotherapy Planning, Quality Control
<p>Purpose: The purpose of this paper is to describe a practical approach to commissioning and quality assurance (QA) of a dedicated wide-bore 3 Tesla (3T) magnetic resonance imaging (MRI) scanner for radiotherapy planning.</p><p>Methods: A comprehensive commissioning protocol focusing on radiotherapy (RT) specific requirements was developed and performed. RT specific tests included: uniformity characteristics of radio-frequency (RF) coil, couch top attenuation, geometric distortion, laser and couch movement and an end-to-end radiotherapy treatment planning test. General tests for overall system performance and safety measurements were also performed.</p><p>Results: The use of pre-scan based intensity correction increased the uniformity from 61.7% to 97% (body flexible coil), from 50% to 90% (large flexible coil) and from 51% to 98% (small flexible coil). RT flat top couch decreased signal-to-noise ratio (SNR) by an average of 42%. The mean and maximum geometric distortion was found to be 1.25 mm and 4.08 mm for three dimensional (3D) corrected image acquisition, 2.07 mm and 7.88 mm for two dimensional (2D) corrected image acquisition over 500 mm × 375 mm × 252 mm field of view (FOV). The accuracy of the laser and couch movement was less than ±1 mm. The standard deviation of registration parameters for the end-to-end test was less than 0.41 mm. An on-going QA program was developed to monitor the system’s performance.</p><p>Conclusion: A number of RT specific tests have been described for commissioning and subsequent performance monitoring of a dedicated MRI simulator (MRI-Sim). These tests have been important in establishing and maintaining its operation for RT planning.</p>
International Journal of Cancer Therapy and Oncology
2016-06-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.1
International Journal of Cancer Therapy and Oncology; Vol 4, No 2 (2016): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/480
2016-07-16T06:12:02Z
IJCTO:ORIGINAL
cam 3u
"160630 2016 eng "
dc
Comprehensive assessment of xerostomia in patients receiving radiation for head and neck cancer
Yadaraju, Vijaya Aditya; Department of Radiation Oncology, Health Care Global, Vishakapatanam
Manur Gururajachar, Janaki; Department of Radiation Oncology, M. S. Ramaiah Medical College, Bangalore
Elagandula, Jyosthna; Department of Radiation Oncology, M. S. Ramaiah Medical College, Bangalore
Agrahara Sreenivasa, Kirthi Koushik; Department of Radiation Oncology, M. S. Ramaiah Medical College, Bangalore
Radiation Oncology
Scintigraphy, Xerostomia, Quality of Life, Head and Neck Cancer, Radiotherapy
Head and Neck Cancer
<p>Purpose: Xerostomia is a well known complication of radiation for head and neck cancer. It causes significant impairment of Quality Of Life (QOL).Comprehensive assessment is possible with the help of scintigraphy, Dose-volume histogram (DVH) parameters as well as QOL questionnaire.</p><p>Methods: Thirty patients of head and neck cancer undergoing radiation were assessed for xerostomia. Scintigraphic assessment of parotid gland function was done before and at six weeks after radiation. QOL questionnaire was administered before, during, and at six weeks after radiation as well as at two years of follow up. Dose received by parotids were correlated with scintigraphic and QOL outcomes.</p><p>Results: Mean parotid gland volume and dose received were 24.9 cc and 45.3 Gy respectively. Mean Salivary Excretion Factor (SEF) decreased from 54.1 to 12 at six weeks after radiation. QOL scores worsened from first week (mean value: 2.37) of radiotherapy (RT) to fourth week (mean value: 15.50, p < 0.0000) , remained same till completion of RT (mean value: 17.57, p = 0.1063) and at six weeks after radiation (mean value:16.10, p = 0.2519 ). There was a significant decrease in QOL scores between post RT six weeks versus two years follow up (p < 0.0000). Mean parotid dose and QOL scores correlated at six weeks (p < 0.0000), whereas no correlation was found between SEF and QOL.</p><p>Conclusion: Comprehensive assessment of parotid gland function with Scintigraphy, QOL questionnaire and its correlation with dose volume parameters is helpful in quantifying xerostomia. Even though radiation induced xerostomia persisted for a long time after radiation, it did not translate to decreased QOL.</p>
International Journal of Cancer Therapy and Oncology
Nil
2016-06-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.16
International Journal of Cancer Therapy and Oncology; Vol 4, No 2 (2016): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/533
2016-09-18T09:01:49Z
IJCTO:TECHNICAL
cam 3u
"160918 2016 eng "
dc
Autologous fat transfer as prostate-rectal spacer: Technique description and early results
Borghi, Marcelo; Department of Urology, Centro de Urología – CDU, Buenos Aires
Montes de Oca, Luis; Department of Urology, Centro de Urología – CDU, Buenos Aires
Becher, Edgardo; Department of Urology, Centro de Urología – CDU, Buenos Aires
Bou, Marcelo; Department of Urology, Centro de Urología – CDU, Buenos Aires
Aviles, Lijia Elizabeth; Department of Radiation Oncology, Vidt Centro Médico-21st Century Oncology, Buenos Aires
Filomia, Maria Luisa; Department of Radiation Oncology, Vidt Centro Médico-21st Century Oncology, Buenos Aires
Chiozza, Jorge; Department of Radiation Oncology, Vidt Centro Médico-21st Century Oncology, Buenos Aires
Radiation Oncology, Prostate Brachytherapy
Autologous fat transfer, Brachytherapy, Recto-prostatic pacer
Prostate Brachytherapy
<p>Purpose: Several attempts have been made to increase the distance between the prostate and the rectum through injection of different synthetic compounds, generating space between organs. To report an original technique to increase the distance between the rectum and the prostate, by autologous fat implantation into the rectoprostatic space, with the aim of providing physical dosimetry protection and rectal dose sparing.</p><p>Methods: We prospectively evaluated twelve patients subjected to autologous fat implantation as recto-prostatic spacer subsequently receiving prostate either radical (n = 6), or salvage brachytherapy for local recurrence after external beam radiation therapy (EBRT) (n = 6). Standard permanent prostate brachytherapy seed implantation was performed through transperineal approach and under transrectal ultrasonography (TRUS) and template guidance. Prescribed D90 dose for Iodine - 125 monotherapy was 140 - 160 Gy, reduced by 30% for rescue cases to obtain a Rectum V100 under 1 cc.</p><p>Results: Lipo-transfer was completed in all 12 patients. Control CT scan at 1 month showed average distances of: 10.7 mm (range) (2.8 - 15.9 mm), 7.6 (1.8 - 11.6 mm) and 6.8 (4.2 - 8.3) mm at prostate base, middle and apex, respectively. Shortest separation distance observed was at apex and midline, while largest was observed the sides and at seminal vesicles level. Control CT at 3 months showed average distances of 9.6 mm (1.9 - 14.6 mm), 6.3 mm (1.8 - 10.2 mm) and 5.4 mm (3.8 - 7.2 mm) at prostate base, middle and apex, respectively. Most complications were minor.</p><p>Conclusion: Autologous fat transfer is a feasible and simple procedure for experienced practitioners with low complication rates, which allows dose escalation to the prostate. </p>
International Journal of Cancer Therapy and Oncology
2016-07-13 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.16
International Journal of Cancer Therapy and Oncology; Vol 4, No 3 (2016): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/533/0
http://www.ijcto.org/index.php/IJCTO/article/download/533/0
http://www.ijcto.org/index.php/IJCTO/article/download/533/4674
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/595
2017-02-12T15:24:28Z
IJCTO:ORIGINAL
cam 3u
"161228 2016 eng "
dc
Anti-tumor effects of interferon-beta cell therapy in murine model of melanoma
Nakamura, Masaki; Department of Microbiology, Kitasato University School of Allied Health Sciences
Kagawa, Lisa; Department of Microbiology, Kitasato University School of Allied Health Sciences
Nakada, Norihiro; Department of Pathology, Kitasato University School of Medicine
Satoh, Masashi; Department of Immunology, Kitasato University School of Medicine
Maehana, Shotaro; Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences
Kojima, Fumiaki; Department of Pharmacology, Kitasato University School of Allied Health Sciences
Amano, Hideki; Department of Pharmacology, Kitasato University School of Medicine
Murakumo, Yoshiki; Department of Pathology, Kitasato University School of Medicine
Iwabuchi, Kazuya; Department of Immunology, Kitasato University School of Medicine
Majima, Masataka; Department of Pharmacology, Kitasato University School of Medicine
Kitasato, Hidero; Department of Microbiology, Kitasato University School of Allied Health Sciences
Cancer Biology; Gene Therapy; Cell Therapy
Cell therapy, Interferon-beta, Melanoma
<p>Purpose: Recombinant interferon beta (IFN-β) has been used for a treatment of cancers. However, the efficacy of recombinant IFN-β is limited because of its short half-life and side effects. To overcome these problems, we focused on the efficacy of cell-based therapy (cell therapy) using IFN-β-producing cells in the treatment of melanoma.</p><p>Methods: IFN-β-producing therapeutic cells were constructed by gene transduction using retrovirus vector. Anti-tumor effects of the cell therapy were investigated by a murine melanoma model.</p><p>Results: IFN-β cell therapy significantly suppressed the proliferation of B16 melanoma <em>in vitro</em> and the growth of B16-derived tumor <em>in vivo</em>, accompanied with the activation of natural killer (NK) cells. IFN-β cell therapy did not show any systemic side-effects concerning hepatic dysfunction and bone marrow suppression.</p><p>Conclusion: IFN-β cell therapy could be a candidate as a novel cancer treatment. </p>
International Journal of Cancer Therapy and Oncology
2016-10-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.12
International Journal of Cancer Therapy and Oncology; Vol 4, No 4 (2016): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/595/4726
http://www.ijcto.org/index.php/IJCTO/article/download/595/4727
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/603
2017-12-17T14:56:15Z
IJCTO:ORIGINAL
cam 3u
"171210 2017 eng "
dc
Evaluation of Eclipse 3D plans using an independent treatment planning system
Ayyalasomayajula, Anil kumar; Department of Nuclear Physics, Swami Jnanananda Laboratories for Nuclear Research, Andhra University
Ayyangar, Komanduri; Department of Medical physics, University of Nebraska Medical Center, Omaha, NE
Vuppu, Srinivas; Medical Physics, MNJ Institute of Oncology and Regional Cancer Center, Hyderabad,
Roopa Rani, Akula; Medical Physics, MNJ Institute of Oncology and Regional Cancer Center, Hyderabad,
Lakshmi Narayana, Paladugu venkata; Department of Nuclear Physics, Swami Jnanananda Laboratories for Nuclear Research, Andhra University
Rao, Angalakuduru Durga Prasada; Department of Nuclear Physics, Swami Jnanananda Laboratories for Nuclear Research, Andhra University
Radiation Oncology
Quality Assurance, 3D Treatment Planning, DVH analysis, Eclipse TPS, ROPS TPS
<p>Purpose: The goal of the current investigation was to compare complex 3D conformal plans generated on Eclipse™ treatment planning system (TPS) with independent dose calculations from radiation oncology planning system (ROPS™) TPS used as a secondary quality assurance check.</p><p>Methods: Fifteen cancer patients that were treated with complex conformal treatment plans with cobalt and linac beams, using Eclipse TPS, were selected for this study. The structure sets, treatment beam data and prescription information were exported from the Eclipse TPS using DICOM-RT export. Using custom software, these data were imported into ROPS TPS. Independent dose calculation on the ROPS planning system using Clarkson summation algorithm was done. The dose volume histograms (DVH) from both planning systems were extracted and analyzed using custom software. Dose assessment was accomplished by defining criteria based on gross tumor volume (GTV) dose coverage, dose homogeneity and mean dose. For organs at risk (OAR) other than GTV, the main dose parameters were, mean dose and percentage of volume receiving 95% of prescription dose.</p><p>Results: For the GTV, all 15 cases met the criteria set for the mean dose and dose homogeneity index. However, breast cases were found to have deviation in the percentage volume receiving the 95% of prescription dose.</p><p>Conclusion: Using the criteria set for plan acceptance, all the 15 clinical cases were evaluated. Except for breast tangent plans, all plans passed all the criteria set. The large deviation for breast tangent plans was attributed to differences in dose calculation algorithms.</p>
International Journal of Cancer Therapy and Oncology
This work was sponsored by a grant from the Atomic Energy Regulatory Board, Mumbai, India.
2017-02-12 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto51.25
International Journal of Cancer Therapy and Oncology; Vol 5, No 1 (2017): January - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/603/4770
http://www.ijcto.org/index.php/IJCTO/article/download/603/4771
http://www.ijcto.org/index.php/IJCTO/article/download/603/4773
http://www.ijcto.org/index.php/IJCTO/article/download/603/4774
http://www.ijcto.org/index.php/IJCTO/article/download/603/4775
http://www.ijcto.org/index.php/IJCTO/article/download/603/4776
http://www.ijcto.org/index.php/IJCTO/article/download/603/4777
http://www.ijcto.org/index.php/IJCTO/article/download/603/4778
http://www.ijcto.org/index.php/IJCTO/article/download/603/4779
http://www.ijcto.org/index.php/IJCTO/article/download/603/4780
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/8
2014-03-16T15:04:27Z
IJCTO:SCIENTIFIC
cam 3u
"130904 2013 eng "
dc
Laser photobiomodulation: A new promising player for the multi-hallmark treatment of advanced cancer
Santana-Blank, Luis; Fundalas’ Cancer, Immunology and Neuroscience Programs, Venezuela.
Rodríguez–Santana, Elizabeth; Fundalas, Foundation for Interdisciplinary Research and Development
Reyes, Heberto; Fundalas, Foundation for Interdisciplinary Research and Development, Caracas-Venezuela
Hospital José María Vargas, Radiology Department, Caracas-Venezuela
Clínica Ávila, Radiology Department, Caracas-Venezuela
Santana-Rodríguez, Jesús Alberto; Fundalas, Foundation for Interdisciplinary Research and Development
Santana-Rodríguez, Karin Elizabeth; Fundalas, Foundation for Interdisciplinary Research and Development
Oncology; Photomedicine
Photobiomodulation, cancer, water dynamics
Treatment
<p>This article does not include an abstract. Full text of this article is available in <a href="http://www.ijcto.org/index.php/IJCTO/article/view/Santana-Blank/ijcto.0101.2pdf" target="_blank">PDF</a>.</p><p><strong>Cite this article as</strong>:<br />Santana-Blank L, Rodríguez-Santana E, Reyes H, Santana-Rodríguez J, Santana-Rodríguez K. Laser photobiomodulation: A new promising player for the multi-hallmark treatment of advanced cancer. <em>Int J Cancer Ther Oncol</em> 2013;<strong>1</strong>(1):01012.<br /> <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0101.2" target="_self">10.14319/ijcto.0101.2</a><br /><br />--------------------------------------<br /><!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>X-NONE</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:DontVertAlignCellWithSp/>
<w:DontBreakConstrainedForcedTables/>
<w:DontVertAlignInTxbx/>
<w:Word11KerningPairs/>
<w:CachedColBalance/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--></p><p><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="267">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]--><!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:"Times New Roman","serif";}
</style>
<![endif]--></p>
International Journal of Cancer Therapy and Oncology
2013-10-10 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Santana-Blank
International Journal of Cancer Therapy and Oncology; Vol 1, No 1 (2013): September - October
en
http://www.ijcto.org/index.php/IJCTO/article/download/8/28
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/42
2014-03-16T22:40:11Z
IJCTO:EDITORIAL
cam 3u
"131202 2013 eng "
dc
Recent advances in treatment of childhood cancer : role of targeted therapy
Al-Tonbary, Youssef; Department of Pediatric Oncology, Mansoura University, Daqahlia
<p>This article is an editorial, and it doesn't include an abstract. Full text of this article is also available in <a href="/index.php/IJCTO/article/view/Al-Tonbary/ijcto.0102.8html" target="_blank">HTML</a> and <a href="/index.php/IJCTO/article/view/Al-Tonbary/ijcto.0102.8pdf" target="_blank">PDF</a>.</p><p><strong>Cite this article as</strong>: <br />Al-Tonbary Y. Recent advances in treatment of childhood cancer: role of targeted therapy. Int J Cancer Ther Oncol 2013; <strong>1</strong>(2):01028.</p><p><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0102.8" target="_blank">http://dx.doi.org/10.14319/ijcto.0102.8</a></p>
International Journal of Cancer Therapy and Oncology
2013-12-04 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Al-Tonbary
International Journal of Cancer Therapy and Oncology; Vol 1, No 2 (2013): November - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/78
2014-04-12T11:23:44Z
IJCTO:EDITORIAL
cam 3u
"140215 2014 eng "
dc
The openness of pluripotent epigenome - Defining the genomic integrity of stemness for regenerative medicine
Parsons, Xuejun H; San Diego Regenerative Medicine Institute;
California Consortium for Regenerative Medicine Startup;
Xcelthera
Stem Cell
<p>This article is an editorial, and it doesn't include an abstract. Full text of this article is available in <a href="/index.php/IJCTO/article/view/Parsons/ijcto.0201.14html" target="_blank"><strong>HTML</strong></a> and <a href="/index.php/IJCTO/article/view/Parsons/ijcto.0201.14pdf" target="_blank"><strong>PDF</strong></a>.</p><p align="left"><strong>Cite this article as:</strong> Parsons XH. The openness of pluripotent epigenome - Defining the genomic Integrity of stemness for regenerative medicine. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):020114.</p><p><strong>DOI:</strong> <a href="http://dx.doi.org/10.14319/ijcto.0201.14" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.14</a></p>
International Journal of Cancer Therapy and Oncology
2014-02-23 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Parsons
International Journal of Cancer Therapy and Oncology; Vol 2, No 1 (2014): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/66
2014-05-14T17:01:18Z
IJCTO:SCIENTIFIC
cam 3u
"140409 2014 eng "
dc
The MIQE Revolution: implementation of standards for the reporting of quantitative PCR studies
Ayers, Duncan; Department of Pathology, Faculty of Medicine & Surgery, University of Malta, Msida, Malta.
Faculty of Medical & Human Sciences, The University of Manchester, Manchester, UK.
qPCR; MIQE; Guidelines; Standardisation
<p>The discovery of the polymerase chain reaction (PCR) a few decades ago initiated a global impact on the entirety of the medical and life sciences research spheres. Nowadays, essentially all laboratories focusing on such vital research employ in-house PCR techniques on a near-daily basis, due to the wide spectrum of applications which PCR technology can adopt itself to. Unfortunately, ubiquitously available and affordable technologies, such as RT-qPCR, do have a major passive drawback: inter-laboratory reproducibility. Variations in the routine methodologies implemented by individual laboratories can inevitably lead to severe lapse of data robustness and reliability for publication in peer-reviewed journals. In order to address this pressing issue, a consortium of eminent research group leaders in the field of RT-qPCR technology decided to propose a distinct set of standardized guidelines for the reporting of RT-qPCR study results, known as the Minimum Information for Publication of Quantitative Real Time PCR Experiments (MIQE), which were published in early 2009.<sup>2</sup> This concept is very much similar to the one leading to the development of the Minimum Information for Microarray Experimets (MIAME) guidelines for reporting of microarray-based studies. In order to address this pressing issue, a consortium of eminent research group leaders in the field of RT-qPCR technology decided to propose a distinct set of standardized guidelines for the reporting of RT-qPCR study results, known as the Minimum Information for Publication of Quantitative Real Time PCR Experiments (MIQE), which were published in early 2009. This concept is very much similar to the one leading to the development of the Minimum Information for Microarray Experimets (MIAME) guidelines for reporting of microarray-based studies.</p><p>-------------------</p><p><strong>Cite this article as:</strong> Ayers D. The MIQE Revolution: Implementation of standards for the reporting of quantitative PCR studies. Int J Cancer Ther Oncol 2014; 2(2):02026. <strong>DOI: 10.14319/ijcto.0202.6</strong></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Ayers
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/121
2014-05-14T17:01:18Z
IJCTO:CONF
cam 3u
"140409 2014 eng "
dc
Are output measurements always necessary after CT tube replacement?
Stauduhar, Paul J; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Jones, Aaron Kyle; The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Medical Physics
<p><strong>Purpose: </strong>TX regulations and the ACR require that CT radiation output be measured within 30 days of major service. The most common major service is tube replacement. We hypothesized that historical QC data could be used instead to determine if output measurements are necessary, reducing the need for costly output measurements.</p><p><strong>Methods</strong>: We reviewed 66 records of tube replacements to determine with what frequency output falls outside specifications. We also conducted an experiment to verify that clinically significant output changes could be identified by comparing image noise in historical QC data with the same data after tube replacement. We used 30 days of historical QC data to establish a baseline noise level and 95% confidence interval (CI) for individual noise measurements. To simulate output changes, we acquired phantom images with our QC protocol while manually changing output (mA). We acquired 10 images using the baseline output and 10 images at each different “output”. We evaluated individual images and subsets of images at each “output” to determine if the system was within the manufacturer’s specifications.</p><p><strong>Results: </strong>None of the 66 tube replacements resulted in an output change that exceeded specifications. Analysis of 30 days of historic QC data for our experimental system indicated a mean noise of 5.4 HU with 95% CI of 5.1 ‒ 5.7 HU. When using the mean noise of 10 images acquired at each of the varying outputs, we were able to identify, with 100% accuracy, images acquired at outputs outside manufacturer’s specifications.</p><p><strong>Conclusion</strong>: The results of our review of historical tube replacement data indicated the likelihood of output falling outside manufacturer’s specifications is low. Considering this, it is likely that by using QC data from programs required by regulation and the ACR physicists can reliably verify radiation output stability remotely instead of making physical measurements.</p><p>--------------------</p><p><strong>Cite this article as:</strong> P Stauduhar, A Jones. Are output measurements always necessary after CT tube replacement? Int J Cancer Ther Oncol 2014; 2(2):020238. <strong>DOI: 10.14319/ijcto.0202.38</strong><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-03-25 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Stauduhar
International Journal of Cancer Therapy and Oncology; Vol 2, No 2 (2014): April - June
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/86
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
cam 3u
"140504 2014 eng "
dc
Clinical trends and outcomes of male breast cancer: Experience of a tertiary oncology centre in India
Mukherjee, Anindya; Department of Radiation Oncology, Medical College, Kolkata
Saha, Aramita; Department of Medical Oncology, Apollo Gleneagles Cancer Hospital
Chattopadhyay, Subrata; Department of Radiation Oncology, Medical College, Kolkata
Sur, Prabir Kumar; Department of Radiotherapy, Hemalata Cancer Institute, Bhubaneswar,
Oncology
Male Breast Cancer; Rare; Advanced Stage; Poor Outcome
Breast Cancer
<p><strong>Purpose: </strong>Because of its rarity in any oncology centre, the clinical trends of male breast cancer specific to its geographical distribution have remained relatively unexplored. This study was done to analyze the clinico-pathological data, treatment given and survival patterns of male breast cancer patients visiting our tertiary medical centre and compare our results with available literature. <strong></strong></p><p><strong>Methods</strong>: All male breast cancer patients registered at our clinic from 2003 to 2009 were included.<strong> </strong>Frequency distribution analysis of the demographic and clinico-pathological data and treatment variables was done. Treatment outcome was examined from Kaplan-Meir survival estimates. <strong></strong></p><p><strong>Results:</strong> Thirty-three male breast cancer patients were encountered. The median age of presentation was sixty years. Mostly (87.9%) they presented with lump in breast or axilla and were clinically staged to be ‘3’ (57.6%).Obesity and alcohol were the commonest risk factors identified. Modified radical mastectomy was the commonest (69.6%) definitive therapy rendered with (only for clinically staged 3 patients) or without neo-adjuvant chemotherapy. Infiltrating ductal carcinoma was identified in most cases. Twenty-two patients received adjuvant chemotherapy and twenty-four received adjuvant radiotherapy. Eighteen (54.5%) patients were hormone-receptor positive and received tamoxifen. The median Overall survival (OS) and Progression-free survival (PFS) came out to be 14.3 months (standard error, SE of 1.185; 95% confidence interval, CI 12-16.6) and 15.7 (SE 5.35, 95% CI 5.2-26.19) months respectively.</p><p><strong>Conclusion</strong>: Male breast cancers usually carry a poor prognosis due to presentation at later stages. Most of our results correlate with previous literature. Multi-centric prospective studies are required to validate the etiological factors and prognostic determinants of survival.</p><p>-----------------------------</p><p><strong>Cite this article as:</strong> Mukherjee A, Saha A, Chattopadhyay S, Sur P. Clinical trends and outcomes of Male Breast Cancer: experience of a tertiary oncology centre in India. Int J Cancer Ther Oncol 2014;<strong> 2</strong>(3):02035. <strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0203.5" target="_blank"><strong>10.14319/ijcto.0203.5</strong></a><br /><br /><br /></p>
International Journal of Cancer Therapy and Oncology
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/Mukherjee
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/147
2014-08-16T18:42:03Z
IJCTO:ORIGINAL
cam 3u
"140806 2014 eng "
dc
Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery?
Shang, Charles; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Kasper, Michael E; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Kathriarachchi, Vindu; Department of Physics, Florida Atlantic University, Boca Raton, FL, USA.
Benda, Rashmi K; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Kleinman, Joseph H; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Cole, Jeremy; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Williams, Timothy R; Department of Radiation Oncology, Lynn Cancer Institute, Boca Raton Regional Hospital, Boca Raton, FL, USA.
Radiation Oncology; Clinic
Lung SBRT, FDG-PET, Local Control
Lung Cancer
<p><strong>Purpose: </strong>Although [<sup>18</sup>F] FDG-positron emission tomography (PET) provides vital information in diagnosing lung malignancies, the inherent uncertainties of standard uptake value (SUV) compromises its confidence. People have attempted to reduce this uncertainty by comparing the normal tissues, such as liver and spleen. However, those common reference structures may be inappropriate in some cases when pathological conditions exist. Hence, using alternative reference structures becomes valuable in such practice. The purpose of this study is to explore an alternative reference-correction method to reduce the inherent variation of SUV in the tumor or irradiated region. <strong></strong></p><p><strong>Methods</strong>: 106 analyzable FDG-PET scans from 49 cases who received lung SBRT for non-small cell lung cancer were retrospectively analyzed. The follow-up time ranges from 14.5 weeks to 113.2 weeks. The maximal SUV (SUVmax) was measured within the lung lesion or its corresponding region in post-SBRT. SUVmax was then corrected (or divided) by a reference SUV, or the mean SUV of the adjacent aorta, and results in the new SUVcmax. <strong>Results: </strong>SUVcmax of the positive group are significant higher than that of locally controlled cases (5.82 ± 3.10 vs. 1.45 ± 0.55, p = 0.026), while inconsequential differences were identified between the groups (p = 0.086). Respectively 85.2% and 96.3% of locally controlled cases post SBRT showed decreased values in the latter PET using SUVmax and SUVcmax. PET taken 24 weeks or sooner post-SBRT yielded higher uncertainties.</p><p><strong>Conclusion</strong>: Comparing with the conventional SUVmax, the alternative regional background-corrected SUV indicator, SUVcmax of PTV suggests a stronger correlation between low (<2.5 - 3.0) values and the local tumor control post lung SBRT for NSCLC. However, FDG-PET images taken earlier than 24 weeks post-SBRT presents larger variations in SUV of the irradiated region due to underlying radiation induced inflammatory changes, and is not recommended for assessing local tumor control after lung SBRT.</p><p>.....................................................</p><p><strong>Cite this article as:</strong> Shang CY, Kasper ME, Kathriarachchi V, Benda RK, Kleinman JH, Cole J, Williams TR. Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery? <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(4):020317.<br /><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0203.17" target="_blank"><strong>10.14319/ijcto.0203.17</strong></a></p>
International Journal of Cancer Therapy and Oncology
2014-08-16 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0203.17
International Journal of Cancer Therapy and Oncology; Vol 2, No 3 (2014): July - September
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/153
2014-12-13T14:36:25Z
IJCTO:REVIEW
cam 3u
"141019 2014 eng "
dc
Cancer research and therapy: Where are we today?
Sawant, Sampada; C.U. Shah College of Pharmacy, SNDT Women’s University, Juhu, Santacruz (West), Mumbai, India
Shegokar, Ranjita; Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universität Berlin, Berlin, Germany
Cancer Therapy
Cancer Therapy; Nanoparticles; Targeting Drugs; Surface Modification; Gene Therapy; Vaccines; Herbal Actives; Personalized Medicine
<p>Till date scientists are struggling to understand the complete mechanism of carcinogenesis. In future, the real time detection of cancer may help scientists to identify some of the complicated biological mechanisms. Certain special features of cancer cells enable researchers to deliver the drug or to develop the right drug therapy. These cell properties include over expression or over activity in uptake of certain nutrients e.g. folic acid and increased permeability. Listed properties might vary depending upon the type of cancer and can be fully exploited by using nanoparticles either to detect the site of cancer or to direct the drug at the affected site. Product approach like drug conjugates, complexes serves as a good platform to solve issues like solubility, toxicity, poor penetration and stability related to cancer drugs. Beside this, several drug delivery platforms are under development by researchers in academia as well as in industry to deliver therapeutic molecules and new chemical entities to the targeted site in body. Amongst them, nanotechnology both at molecular and supramolecular level is a leading platform and can help to image, detect and treat cancer. Surface modification of nanoparticles by coating or anchoring their surface with special markers, materials, peptide, proteins, antibodies or antigens add extra feature and thereby can enhance the effectiveness. These treatments can be used individually or in combined form. In this review, advances on nanotechnological platform are discussed together with some assisting techniques like magnetic field, photo or light field, sonic rays are touched upon. New biological therapies that are advancing in this direction include the antisense therapy, cell therapy, gene therapy, radiation therapy and SiRNA interfaces which are discussed in brief in this article. This article gives short overview on use of complementary and alternative medicine for treatment of cancer such as traditional Chinese medicine (TCM), Ayurveda to avoid toxic effects of synthetic drugs.</p>
International Journal of Cancer Therapy and Oncology
2014-12-22 00:00:00
application/pdf
text/html
http://www.ijcto.org/index.php/IJCTO/article/view/0204.8
International Journal of Cancer Therapy and Oncology; Vol 2, No 4 (2014): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/194
2015-03-29T11:59:33Z
IJCTO:CASE
cam 3u
"141214 2014 eng "
dc
A case of endometrial carcinoma with age related hyperkyphosis treated with definitive radiotherapy
Murthy, Arvind S; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Manur, Janaki G; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Ponni, Arul TR; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Koushik, Kirthi AS; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Alva, Ram C; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Somashekar, Mohan K; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Kannan, Ram A; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Harjani, Ritika R; Department of Radiation Oncology, M S Ramaiah Medical College, Bangalore
Radiation Oncology;Brachytherapy
Brachytherapy; Endometrial Cancer; Hyperkyphosis
Gynecologic Oncology
<p>This report describes a simple brachytherapy procedure in a patient with endometrial cancer with age related hyperkyphosis. Sixty-eight year-old postmenopausal woman with age related hyperkyphosis presented with endometrial carcinoma, and the patient was not operated on due to associated pelvic deformity. The patient received whole pelvic radiation followed by uterovaginal brachytherapy. Patient was supported with soft pillows to support her exaggerated anterior concavity during brachytherapy procedure and execution. The brachytherapy dose was 6 Gy per fraction per week for 3 weeks using image guidance. This is probably the first reported case of endometrial cancer with age related hyperkyphosis. In spite of the associated skeletal problems, a simple brachytherapy procedure is possible and provides good result. </p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/0301.6
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/194/2246
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/256
2015-03-29T11:59:33Z
IJCTO:CASE
cam 3u
"150206 2015 eng "
dc
The role of robotic partial cystectomy in a patient with metastatic primary adenocarcinoma of the bladder
James, Katherine; Department of Urology, Hertfordshire and South Bedfordshire Robotic Urological Cancer Centre, Lister Hospital, Stevenage
Vasdev, Nikhil; Department of Urology, Hertfordshire and South Bedfordshire Robotic Urological Cancer Centre, Lister Hospital, Stevenage
Adshead, James M; Department of Urology, Hertfordshire and South Bedfordshire Robotic Urological Cancer Centre, Lister Hospital, Stevenage
Urologic Oncology
Robotic Partial Cystectomy; Adenocarcinoma Bladder; Metastasis; Outcome
Urological Oncology
<p>Treatment of urachal adenocarcinoma (UA) of the urinary bladder has typically been with radical cystectomy (RC) but more conservative approaches are gaining popularity. Here we present the case of a female patient with metastatic primary bladder UA who was treated with robotic partial cystectomy (RPC) and adjuvant chemotherapy; she is alive with no evidence of disease recurrence or metastatic disease at 5 years. This case provides some of the longest follow-up after RPC to date thereby demonstrating that RPC is a safe and oncologically viable treatment for selected patients even several years after definitive treatment. Patients undergoing RPC benefit from the reduced morbidity associated with this less radical treatment whilst enjoying similarly successful oncological outcomes to RC. </p>
International Journal of Cancer Therapy and Oncology
Nil
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/0301.20
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/333
2015-03-29T12:04:13Z
IJCTO:EDITORIAL
cam 3u
"150329 2015 eng "
dc
Journal of Proton Therapy: Call for Papers
Proton Therapy, Journal of
<p><strong><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #0000ff;">Journal of Proton Therapy (JPT) </span></span></span></span></span></span></span></span></strong></strong>is an international open access, peer-reviewed journal, which publishes original research, technical reports, reviews, case reports, editorials, and other materials on proton therapy with focus on radiation oncology, medical physics, medical dosimetry, and radiation therapy.</p><ul><li>No article processing/submission fee</li><li>No publication fee</li><li>Peer-review completion within 3-6 weeks</li><li>Immediate publication after the completion of final author proofread</li><li>DOI assignment for each published article</li><li>Free access to published articles for all readers without any access barriers or subscription</li></ul><p>The views and opinions expressed in articles are those of the author/s and do not necessarily reflect the policies of the Journal of Proton Therapy.</p><p><strong>Authors are encouraged to submit articles for publication in the inaugural issue of the <em><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #0000ff;">Journal of Proton Therapy </span></span></span></span></span></span></span></span></strong></span></span></span></span></span></span></span></strong></em></strong>by <a href="http://www.protonjournal.org/index.php/jpt/about/submissions#onlineSubmissions" target="_blank">online</a> or email to <em><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #0000ff;">editor@protonjournal.com</span></span></span></span></span></span></span></span></strong></span></span></span></span></span></span></span></strong></em></p><p>For more information, please visit <em><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #0000ff;"><br /><a href="http://www.protonjournal.com/" target="_blank">www. protonjournal.com</a><br /><em><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #0000ff;"><a href="http://www.protonjournal.org/" target="_blank">www. protonjournal.org </a><br /></span></span></span></span></span></span></span></span></strong></span></span></span></span></span></span></span></strong></em> <br /></span></span></span></span></span></span></span></span></strong></span></span></span></span></span></span></span></strong></em></p><p><strong>**************************************</strong></p><table class="announcements"><tbody><tr class="title"><td class="title"><h4><strong>Journal of Proton Therapy Welcomes <a href="http://www.protonjournal.org/index.php/jpt/pages/view/editorialboard" target="_blank">Editorial Board</a> Members</strong></h4></td><td class="more"> </td></tr><tr class="description"><td class="description"><p><strong>Chee-Wai Cheng, PhD</strong><strong><br /> </strong>Dr. Cheng is the Director of Proton Medical Physics at the University Hospitals as well as Professor of Clinical Radiation Oncology at the Case Western Reserve University, Cleveland, Ohio, USA.</p><p><strong>Carlos Vargas, MD</strong><br />Dr. Vargas is a Radiation Oncologist at the Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona. </p><p><strong>Luca Cozzi, PhD</strong><strong><br /> </strong>Dr. Cozzi is a Clinical Research Scientist at the Department of Radiotherapy and Radiosurgery at Humanitas Cancer Center, Milan, Italy.</p><p><strong>Ted Ling, MD</strong><strong><br /> </strong>Dr. Ling is a Resident Physician at the Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda, California, USA.</p><p><strong>Haibo Lin, PhD</strong><br /> Dr. Lin is a Medical Physicist at the Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</p><p><strong>Xiaodong Zhang, PhD</strong><br /> Dr. Zhang is an Associate Professor at the Department of Radiation Physics - Patient Care, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.</p><p><strong>Alexei V. Trofimov, PhD </strong><strong><br /> </strong>Dr. Trofimov is a Radiation Physicist at the Department of Radiation Oncology, Massachusetts General Hospital (MGH) as well as Assistant Professor of Radiation Oncology at Harvard Medical School, Boston, Massachusetts, USA.</p><p><strong>Minesh Mehta, MD</strong><strong><br /> </strong>Dr. Mehta is the Medical Director at the Maryland Proton Treatment Center as well as Professor at the Department of Radiation Oncology, University of Maryland, Baltimore, Maryland, USA.</p><p><strong>Terence Sio, MD, MS</strong><strong><br /> </strong>Dr. Sio is a Resident Physician at the Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.</p><p><strong>Bijan Arjomandy, PhD</strong><strong><br /> </strong>Dr. Arjomandy is a Lead Senior Proton Medical Physicist at the McLaren Proton Therapy Center, Flint, Michigan, USA.</p><p><strong>Gino Lim, PhD</strong><strong><br /> </strong>Dr. Lim is the Department Chair and Associate Professor at the Department of Industrial Engineering, University of Houston, Houston, Texas, USA.</p><p><strong>Wayne D. Newhauser, PhD</strong><br /> Dr. Newhauser is the Professor and Director of Medical Physics and Health Physics at Louisiana State University, Baton Rouge, Louisiana, USA.</p><p><strong>Shikui Tang, PhD</strong><br /> Dr. Tang is a Medical Physicist at ProCure Proton Therapy Center, Somerset, New Jersey, USA.</p><p><strong>David Mansur, MD<br /> </strong>Dr. Mansur is a Division Chief at Radiation Oncology, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.</p><p><strong>Barbara Rombi, MD<br /> </strong>Dr. Rombi is an Attending Physician at Proton Therapy Center, S. Chiara Hospital, Trento, Italy.</p><p><strong>Cole Kreofsky, MD<br /> </strong>Dr. Kreofsky is a Resident Physician at the Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.</p><p><strong>Lane Rosen, MD<br /></strong>Dr. Rosen is a Radiation Oncologist at the Department of Radiation Oncology, Willis-Knighton Cancer Center, Shreveport, Louisiana, USA.</p><p><strong>Charles Bloch, PhD</strong><br />Dr. Bloch is an Associate Professor at the Department of Radiation Oncology, University of Washington, Seattle, WA, USA.</p><p><strong>Wei Liu, PhD</strong><br />Dr. Liu is an Assistant Professor of Radiation Oncology at Mayo Clinic, Phoenix, Arizona, USA.</p></td></tr></tbody></table><p><strong><br /></strong></p><p><em><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><strong><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #000000; font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 14px;"><span style="font-family: Cambria,'Hoefler Text','Liberation Serif',Times,'Times New Roman',serif; font-size: 12px;"><span style="color: #0000ff;"><br /></span></span></span></span></span></span></span></span></strong></span></span></span></span></span></span></span></strong></em></p>
International Journal of Cancer Therapy and Oncology
2015-03-29 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/jpt
International Journal of Cancer Therapy and Oncology; Vol 3, No 1 (2015): January - March
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/219
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
cam 3u
"150602 2015 eng "
dc
A prospective study of OAR volume variations between two different treatment planning systems in radiotherapy
Kulkarni, Bhudevi Soubhagya; Department of Radiation Oncology, Basav tarak indo American cancer hospital and research centre, Hyderabad
Dutt Sharma, Sunil; Department of Radiological Physics & Advisory Division, Bhabha Atomic Research Centre,
CTCRS, Anushaktinagar, Mumbai
Hansen, Vibeka; Joint department of Physics, Royal Marsden NHS Trust and The Institute of Cancer Research, Sutton
Sresty, NVN; Department of Radiation Oncology, Basav tarak indo American cancer hospital and research centre, Hyderabad
M, Suneetha; Department of Radiation Oncology, Basav tarak indo American cancer hospital and research centre, Hyderabad
Kandan, Mani; Department of Radiation Oncology, NRI hospital, Guntur
D, Chandrashekhar; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad
Talluri, Anil; Department of Radiation Oncology, Basav tarak indo American cancer hospital and research centre, Hyderabad
Kumar, Alok; Department of Physics, Jawaharlal Nehru Technological University, Hyderabad
Ahmed, Shabbir; Department of Radiation Oncology, Basav tarak indo American cancer hospital and research centre, Hyderabad
Radiation Oncology; Medical Physics
Organ at Risk; Volume Variations; Treatment Planning Systems; Digital Imaging and Communication Transfer
Radiation Oncology; Medical Physics
<p><strong>Purpose:</strong> It has been seen that there is a clinically significant variation in the volume calculated across different planning systems for the same digital imaging and communication (DICOM) contours.<span style="font-size: 10px;">The purpose of this study is to investigate the difference in volumes of organs at risk when the structure sets were exported from the Eclipse ((Palo Alto, USA Version 10.0) to XIO CMS (Electa, Crawley, UK Version 4.40.00) treatment planning system (TPS) and identify how the differences occur.</span></p><p> </p><p><strong>Methods: </strong>We prospectively analyzed the volumes of organs at risk from computerized tomography (CT) data of 54 patients. Head and neck and brain tumors were taken for this study and contoured on Eclipse treatment planning system (TPS) after importing images from CT. These contoured images were then exported using radiotherapy DICOM transfer facility to XIO CMS planning system and compared the contoured volumes with Eclipse TPS structured volumes. <strong></strong></p><p><strong>Results: </strong>Our analysis showed that the differences in calculated volumes of the contours for the patients between the two planning systems can be large. Mixed results are shown for different organs with the absolute volume difference ranging from -0.25 cc to 319.73 cc. These results clearly shown that the two TPS interprets the contours differently when calculating the volume, and there is a closer match with the theoretical calculated volumes with XIO CMS calculated volumes. <strong></strong></p><p><strong>Conclusion:</strong> Observed discrepancies were consistent between the two planning systems. This impact of contouring variability could play a role on plan quality metrics which is used as criteria for clinical trial protocol compliance.</p>
International Journal of Cancer Therapy and Oncology
NIL
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.6
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/219/2391
http://www.ijcto.org/index.php/IJCTO/article/download/219/2392
http://www.ijcto.org/index.php/IJCTO/article/download/219/2393
http://www.ijcto.org/index.php/IJCTO/article/download/219/3099
http://www.ijcto.org/index.php/IJCTO/article/download/219/3100
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/361
2016-01-03T12:17:48Z
IJCTO:ORIGINAL
cam 3u
"150811 2015 eng "
dc
Role of laparoscopic surgery in cancer of stomach: Our early experience
Chrungoo, Rajinder; Department of Surgery, ASCOMS Jammu, Jammu And Kashmir (J&K)
Mala, Tariq; Department of Surgery, ASCOMS Jammu, Jammu And Kashmir (J&K)
Gupta, Rahul; Department of Surgery, Government Medical College, Jammu
Kachroo, Shadi; Department of Surgery, Government Medical College, Jammu
Chrungoo, Inakshi; Department of Medicine & Surgery, Government Medical College, Jammu
Malla, Shahid; Department of Medicine & Surgery, Government Medical College, Jammu
Surgery
Diagnostic Laparoscopy; Laparoscopic Gastrojejunostomy; Laparoscopic Gastrectomy; Unresectable Tumors; Palliation; Laparoscopic Biopsy
<p><strong>Purpose:</strong> To study the clinical outcome and scope of laparoscopic management in patients of cancer stomach. <strong></strong></p><p><strong>Methods: </strong>This is a prospective study of our first 25 patients of cancer stomach managed laparoscopically. Following procedures were undertaken: 1) Gastric resection in resectable cases; 2) Palliative bypass; 3) Tumor/ nodal/ peritoneal/ any other/ biopsy in cases of unresectable tumors. <strong></strong></p><p><strong>Results: </strong>Growth was resectable in 10 (40%) patients, and unresectable in 15 (60%) patients. Diagnostic laparoscopy had sensitivity of 100%, while other modalities of investigation were not totally useful in 1/3 to ½ of cases. Laparoscopic gastrojejunostomy was done in 5 (20%) patients, laparoscopy assisted distal partial gastrectomy was performed in 8 (32%) patients while totally laparoscopic gastrectomy was possible in 1 (4%) patient. Long term follow up was observed. <strong></strong></p><p><strong>Conclusion</strong>: In cancer stomach laparoscopy is a safe, effective, and cost effective means of directing appropriate therapy especially in patients requiring diagnostic, staging and palliative procedures.</p>
International Journal of Cancer Therapy and Oncology
none
2015-09-25 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.33.20
International Journal of Cancer Therapy and Oncology; Vol 3, No 3 (2015): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/361/3363
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/424
2016-01-03T12:17:09Z
IJCTO:CONF
cam 3u
"151011 2015 eng "
dc
Antineoplastic mechanisms of Iodine in cancers that take up Iodine
Aceves, Carmen; Instituto de Neurobiología, Universidad Nacional Autónoma de México
Anguiano, Brenda; Instituto de Neurobiología, Universidad Nacional Autónoma de México
<p><strong>Purpose:</strong> In addition to being a component of thyroid hormone (TH), iodine can be an antioxidant as well as an antiproliferative and differentiation agent that helps to maintain the integrity of several organs with the ability to take up iodine.</p><p><strong>Methods and Results</strong>: Studies from our laboratory shown that in preclinical (cell culture, induced animal cancer and xenographs) and clinical studies (mammary cancer protocol), molecular iodine (I<sub>2</sub>) supplementation exerts suppressive effects on implantation, development, and progression of cancer neoplasias. These effects can be mediated by a variety of mechanisms and pathways, including direct actions, in which the oxidized iodine modulates the immune/tumor response and through iodolipid formation and the activation of peroxisome proliferator-activated receptors type gamma (PPARγ) triggering apoptotic and/or differentiation pathways.</p><p><strong>Conclusion:</strong> The absence of side effects and the easy availability and handling of I<sub>2</sub> have allowed the establishment of clinical protocols to utilize I<sub>2</sub> supplementation as an adjuvant in therapies against cancers that take up iodine.</p><p>-----------------------------------------</p><p><strong>Cite this article as: </strong>Aceves C, Anguiano B. Antineoplastic mechanisms of Iodine in cancers that take up Iodine. Int J Cancer Ther Oncol 2015; 3(4):3401.</p><p class="C-Email">[This abstract was presented at the BIT’s 8<sup>th</sup> Annual World Cancer Congress, which was held from May 15-17, 2015 in Beijing, China.]</p>
International Journal of Cancer Therapy and Oncology
This work was partially supported by grants PAPIIT-UNAM 200813 and 202513 and CONACYT 176911.
2015-12-30 00:00:00
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.01
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/472
2016-01-03T12:17:08Z
IJCTO:ORIGINAL
cam 3u
"151201 2015 eng "
dc
Investigating dosimetric effect of rotational setup errors in IMPT planning of synchronous bilateral lung cancer
Rana, Suresh; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
Zhang, Yongbin; Department of Medical Physics, Scripps Proton Therapy Center, San Diego, California
Larson, Gary; Department of Radiation Oncology, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
Vargas, Carlos; Radiation Oncology, Proton Collaborative Group (PCG), Warrenville, Illinois
Dunn, Megan; Radiation Oncology, Proton Collaborative Group (PCG), Warrenville, Illinois
Zheng, Yuanshui; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, Oklahoma
Medical Physics
Proton Therapy; Rotational Setup Error; IMPT; Bilateral Lung Cancer
<p><strong>Purpose:</strong> The purpose of this study is to evaluate the dosimetric effect of rotational setup errors on the synchronous bi-lateral lung cancer plans generated by the intensity modulated proton therapy (IMPT) technique.</p><p><strong>Methods:</strong> The original IMPT plans were generated in for the left planning target volume (PTV) and right PTV of the left lung and right lung, respectively. Each plan was generated using two beams (lateral and posterior-anterior) with an isocenter placed at the center of the corresponding PTV. The IMPT plans were optimized for a total dose of 74 Gy[RBE] prescribed to each PTV with 2 Gy(RBE) per fraction. Original plans were recalculated by introducing simulated rotational errors. For each PTV, 18 rotational plans (±1⁰, ±2⁰, and ±3⁰) for each of the yaw, roll, and pitch rotations were generated. <strong></strong></p><p><strong>Results:</strong> Rotational errors caused the reduction in the clinical target volume (CTV) and PTV coverage in new rotational IMPT plans when compared to the original IMPT lung plans. The CTV D99 was reduced by up to 13.3%, 9.1%, and 5.9% for the yaw (+3⁰), roll (-3⁰), and pitch (+3⁰), respectively. The PTV D95 was reduced by up to 8.7%, 7.3%, and 4.6% for the yaw (+3⁰), roll (-3⁰), and pitch (+3⁰), respectively. The PTV V100 showed the highest deviation with a reduction of dose coverage by up to 40.1%, 31.8%, and 33.9% for the yaw (-3⁰), roll (-3⁰), and pitch (+3⁰) respectively. <strong></strong></p><p><strong>Conclusion:</strong> The rotational setup errors with magnitude of ≥2⁰ can produce a significant loss of dose coverage to the target volume in the IMPT of a synchronous bi-lateral lung cancer. The yaw had the most severe impact on the dosimetric results when compared to other two rotational errors (roll and pitch).</p>
International Journal of Cancer Therapy and Oncology
2015-12-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.34.14
International Journal of Cancer Therapy and Oncology; Vol 3, No 4 (2015): October - December
en
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/419
2016-07-16T17:03:00Z
IJCTO:CASE
cam 3u
"160206 2016 eng "
dc
Ductal carcinoma In-Situ in turner syndrome patient undergoing hormone replacement therapy: A case report
Bawa, Rashmi; Department of Surgery, Pine Health Services, Maine
Matemavi, Praise; Department of Surgery, New York Presbyterian Queens Hospital/Weill Cornell Medical College, New York
Maizlin, Ilan; Department of Surgery, New York Presbyterian Queens Hospital/Weill Cornell Medical College, New York
Sung, Kap-Jae; Department of Surgery, New York Presbyterian Queens Hospital/Weill Cornell Medical College, New York
Surgical Oncology
Turner Syndrome, Ductal Carcinoma In-Situ, DCIS, Hormone Replacement Therapy, HRT, Estrogen Replacement Therapy, Breast Cancer
Breast Cancer
Turner’s syndrome is a rare congenital disease which affects about 1 in every 2500-3000 live-born females. This happens due to chromosomal abnormalities in a phenotypic female, causing increased gonadotropin concentrations and low concentrations of estrogens from infancy. As a result, hormone replacement therapy is started in most adolescent Turner syndrome patients to initiate and sustain sexual maturation. Accordingly, most Turner’s syndrome patients undergo several decades of estrogen replacement therapy, from puberty to post-menopausal age. The highly publicized findings of the Women’s Health Initiative have called into question the appropriateness of hormone replacement therapy in adolescents with Turner’s syndrome. Those concerns were mostly theoretical extrapolations, as few prospective studies of cancer occurrence in women with Turner syndrome have been reported. Consequently, several recent publications have challenged those extrapolations, based on the assertion that the levels of hormone replacement in Turner syndrome patients are well below the physiologic levels observed in normal menstruating women, as well as the fact that these women are significantly younger than those studied by the Women’s Health Initiative. In discord to those reports, we present a case of ductal carcinoma in-situ in a 40-year-old Turner patient, who had undergone over two decades of combined hormone replacement therapy. The patient underwent an elective excisional biopsy for a palpable mass, with histopathology revealing a complex fibroadenoma with a nidus of ductal carcinoma in-situ. The lesion was noted to be estrogen receptor positive and progesterone receptor negative, with heavy staining for HER-2/Neu receptor. The patient was treated with tamoxifen. While a rare case, it is imperative for the astute clinician to keep in mind the consequences of long-term hormone replacement therapy in Turner’s syndrome patients in order to avoid missed diagnosis of breast cancer for optimum management of these patients.
International Journal of Cancer Therapy and Oncology
2016-03-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.41.13
International Journal of Cancer Therapy and Oncology; Vol 4, No 1 (2016): January - March
en
http://www.ijcto.org/index.php/IJCTO/article/download/419/3826
http://www.ijcto.org/index.php/IJCTO/article/download/419/3827
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/492
2016-07-16T06:19:04Z
IJCTO:CASE
cam 3u
"160621 2016 eng "
dc
An Extremely Rare and Unusual Case of Retroperitoneal and Pelvic Metastasis from Squamous Cell Carcinoma of Vallecula
Purkayastha, Abhishek; Department of Radiation Oncology
Army Hospital Research and Referral,
DhaulaKuan, Delhi Cantt-110010
Delhi, India
Sharma, Neelam; Department of Radiation Oncology
Army Hospital Research and Referral,
DhaulaKuan, Delhi Cantt-110010
Delhi, India
Suhag, Virender; Department of Radiation Oncology
Army Hospital Research and Referral,
DhaulaKuan, Delhi Cantt-110010
Delhi, India
Radiation Oncology
Metastasis, Pelvic Lymph Nodes, Retroperitoneum, Squamous Cell Carcinoma, Vallecula
Head and neck cancer; metastasis
<p>We report an extremely rare and unusual case of retroperitoneal and pelvic metastasis from primary squamous cell carcinoma of vallecula. Generally carcinoma oropharynx metastasizes to lungs, liver and bone while retroperitoneal and pelvic metastasis is rarely heard of. To the best of our knowledge this case is one of the scantly reported cases ever of this kind in the world. A 60-year-old male presented with dysphagia and hoarseness of voice of four month duration. Computed tomography (CT) scan face and neck showed growth right vallecula. Biopsy of lesion showed squamous cell carcinoma. Metastatic work up was negative. He received definitive chemo-radiation. Patient during follow up presented with dyspepsia, abdominal discomfort and weight loss. Whole body positron emission tomography (WB PET) scan revealed retroperitoneal and pelvic lymph node deposits which were confirmed as metastasis of squamous cell carcinoma by CT guided fine needle aspiration cytology (FNAC). Patient was exhibited palliative chemotherapy but his general condition deteriorated and he finally succumbed to his metastatic illness. This case is being reported to highlight its extreme rarity, the diagnostic and therapeutic challenges it presented and its overall dismal prognosis.</p>
International Journal of Cancer Therapy and Oncology
Nil
2016-06-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.42.10
International Journal of Cancer Therapy and Oncology; Vol 4, No 2 (2016): April - June
en
http://www.ijcto.org/index.php/IJCTO/article/download/492/4096
http://www.ijcto.org/index.php/IJCTO/article/download/492/4097
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/502
2016-09-18T08:59:14Z
IJCTO:REVIEW
cam 3u
"160807 2016 eng "
dc
The role of CDK inhibitors in breast cancer therapy
Huszno, Joanna; Clinical and Experimental Oncology Department, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice
Medical Oncology
CDK inhibitors, Palbociclib, Abemaciclib, Ribociclib, Breast cancer
Targeted therapies
<p>Cyclin D1 and cyclin-dependent protein kinases CDK4/6 are part of RB-pathway which plays a very important role in the regulation of cell cycle progression and cell death. d-type cyclins associate with cdk4 and 6 to phosphorylate the Rb protein. Hyperphosphorylation of Rb promotes the release of the E2F family of transcription factors that then promotes entry into S phase through activation of key target genes. CDK inhibitors are proteins that suppress CDK-cyclin protein kinase activity in the G1 phase of the cell cycle and promote G1 arrest in response to environmental or intracellular signals. A literature search of these topics was performed through PubMed. Results from preclinical and early-stage clinical trials support the efficiency of CDK inhibitors such palbociclib, abemaciclib and ribociclib for the treatment of human cancers - including breast cancer. The first-in-class CDK4/6 inhibitor, which significantly extended PFS in combination with endocrine therapy in the first and subsequent lines of treatment for steroid receptor -positive, HER2-negative advanced breast cancer is Palbociclib. Other inhibitors (abemaciclib, ribociclib) are still in clinical trials and are a very promising group of drugs.<strong></strong></p>
International Journal of Cancer Therapy and Oncology
2016-07-13 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.43.4
International Journal of Cancer Therapy and Oncology; Vol 4, No 3 (2016): July - September
en
http://www.ijcto.org/index.php/IJCTO/article/download/502/4161
http://www.ijcto.org/index.php/IJCTO/article/download/502/4278
http://www.ijcto.org/index.php/IJCTO/article/download/502/4279
http://www.ijcto.org/index.php/IJCTO/article/download/502/4280
http://www.ijcto.org/index.php/IJCTO/article/download/502/4281
http://www.ijcto.org/index.php/IJCTO/article/download/502/4282
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
oai:ojs.ijcto.org:article/558
2017-02-12T15:24:27Z
IJCTO:ORIGINAL
cam 3u
"161228 2016 eng "
dc
Role of preoperative 18-FDG- PET/CT in early-stage breast cancer upstaging and modification of treatment
Tewari, Anshu; Department of Nuclear medicine and PET/CT, Amrita Institute of Medical Sciences and Research Centre, Kochi
Sundaram, Shanmuga Palaniswamy; Department of Nuclear medicine and PET/CT, Amrita Institute of Medical Sciences and Research Centre, Kochi
Subramanyam, Padma; Department of Nuclear medicine and PET/CT, Amrita Institute of Medical Sciences and Research Centre, Kochi
Nuclear medicine
Breast cancer, Initial staging, PET/CT, Upstaging, Treatment modification
PET/CT
<p>Purpose: The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer.</p><p>Methods: A total of 72 consecutive patients (age: range 24-78 years, mean 51 years), with newly diagnosed operable breast cancer (Infiltrating Ductal carcinoma: Lobular carcinoma: Others - 49:15:8) with tumor size 10-65 mm were examined preoperatively. All patients underwent conventional assessment imaging modalities like mammography, breast/axillary ultrasound and PET/CT.</p><p>Results: PET/CT identified a primary tumor in all but two patients. PET/CT solely detected unsuspected distant metastases (bones, lung, brain etc) in 9 patients and new primary cancers (endometrium and lung) in another two patients, as well as 11 cases of extra-axillary lymph node involvement. In 6 patients, extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 9% (6/70) and ultimately a modification of planned treatment in 12% (9/70) of patients. PET/CT evaluation led 5 patients of stage II A to stage IV, 3 patients of stage II B to stage IV and 1 patient to Stage IIIB which further modified treatment plan from an adjuvant to a metastatic approach.</p><p>Conclusion: PET/CT is a valuable tool to provide information on extra-axillary lymph node involvement, distant metastases and other occult primary cancers. Preoperative <sup>18</sup>F fluorodeoxyglucose PET/CT has a substantial impact on initial staging and on clinical management in patients with early-stage breast cancer.</p>
International Journal of Cancer Therapy and Oncology
NA
2016-10-30 00:00:00
application/pdf
http://www.ijcto.org/index.php/IJCTO/article/view/ijcto.44.13
International Journal of Cancer Therapy and Oncology; Vol 4, No 4 (2016): October - December
en
http://www.ijcto.org/index.php/IJCTO/article/download/558/4512
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
38989c63fd21cc5870e27efc0e35a90f